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Cardiac pump performance is highly dynamic and the rhythmic contraction and 
relaxation during a single heart beat is produced by myofilaments composed of highly ordered 
thin and thick filaments arranged in sarcomeres within each cardiac myocyte.  The thin filament, 
molecular switch protein cardiac troponin I (cTnI) toggles between actin and the Ca2+-binding 
subunit, troponin C (cTnC) to regulate muscle contraction.  Cellular signaling via the protein 
kinase C (PKC) pathway, modulates contractile function and phosphorylates cTnI on serines 
(Ser)23/24, Ser43/45, and threonine (Thr)144. While the functional effects of cTnISer23/24 
phosphorylation are well characterized, the role of cTnISer43/45 remains controversial.  
During cardiac dysfunction, cTnISer43/45 phosphorylation increases, but it is unclear 
whether this phosphorylation improves or reduces function. Gene transfer into intact cardiac 
myocytes is used in the present study to examine the functional role of cTnISer43/45 and 
reconcile divergent in vitro and in vivo responses.  Phospho-null (Ala) substitution at 
cTnISer43/45 diminished myocyte shortening amplitude and myofilament Ca2+ sensitivity of 
tension, indicating Ala substitution is not functionally conservative at this site.  However, 
cTnISer43/45 phospho-mimetic (Asp) substitutions produced the anticipated decrease in basal 
contractile function and myofilament Ca2+ sensitivity 2 days after gene transfer into myocytes.  
Moreover, cTnISer43Asp and cTnISer45Asp individually modulated function.   
Interestingly, the slowed shortening and re-lengthening rates returned toward control 
values after more extensive sarcomeric cTnI replacement at day 4. Further studies demonstrated 








reticulum and increased sarcomeric protein phosphorylation.  Overall, these adaptations are 
proposed to communicate and fine-tune the modulatory effects of cTnISer43/45 phosphorylation 
and/or phospho-mimetic substitution.  This communication was further examined with Asp 
substitutions at cTnI Ser23/24 and Ser43/45 (e.g. cTnIAspQuad).  Studies with cTnIAspQuad 
showed Ser23/24 and Ser43/45 modulate function through separate mechanisms, Ser23/24 
enhances the functional response to Ser43/45,  and cTnIAspQuad induces a different adaptive 
signaling response than cTnISer43/45Asp. Overall, the present experiments identify 
cTnISer43/45 phosphorylation as a modulatory brake in the heart, which is fine-tuned by 
adaptive signaling. This modulatory brake is predicted to play an important role during sustained 






























Regulation of cardiac performance 
The heart is a muscular organ, designed to pump blood to peripheral tissues for delivery 
of oxygen and nutrients and removal of waste [1] . Mammalian hearts have 4 chambers 
composed of 2 atria and 2 ventricles, and the ventricles are separated from the atria and large 
arteries by valves to maintain unidirectional blood flow [1, 2]. Blood moves through the heart via 
rhythmic contraction and relaxation of each chamber, with the larger ventricular chambers 
responsible for blood delivery to the arteries.  Rhythmic pumping of the ventricles is separated 
into two phases known as systole (contraction) and diastole (relaxation), and individual cardiac 
myocytes are responsible for this rhythmic pumping action (Fig. 1.1A).  A single electrical 
stimulus (e. g. an action potential) is sufficient to initiate cardiac depolarization and contraction 
of each chamber throughout the heart because myocytes are arranged as a  functional syncytium 
to rapidly spread depolarization from cell to cell [1, 2]. Following pressure development and the 
ejection of blood into the vasculature, myocytes repolarize, and pressure returns to resting levels 
as each chamber in the heart relaxes.  During this relaxation phase, valves located between the 
atria and ventricles open, and the ventricles fill with blood in preparation for the next cardiac 
cycle [1, 2].  
Cardiac contraction is elegantly regulated by internal and external elements to match 
blood flow with the metabolic demands of peripheral organs. The amount of blood pumped from 
the ventricles into large arteries, such as the aorta, during a cardiac cycle is measured as stroke 
volume and the amount of blood pumped per minute is measured as cardiac output (CO).  The 
load on the heart prior to contraction (preload) or the load experienced during contraction 
(afterload) can intrinsically regulate CO, as described by the Frank-Starling mechanism [1, 2]. 
External factors, including neurohormones, also work to regulate cardiac pump function over 
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longer periods of time [1, 2]. This neurohormonal input produces post-translational 
modifications of many cellular proteins including proteins located in the myofilaments, which 
are ultimately responsible for generating contraction and relaxation. Phosphorylation of these 
myofilament proteins modulates alterations in cardiac contractility and relaxation [3, 4] [5].  
Under physiological conditions, the internal and external factors work seamlessly to maintain 
cardiac performance.  However, current therapies provide palliative care and, other than 
transplantation, there are no treatments capable of completely restoring cardiac function in 
patients with heart failure.  Thus, end-stage heart failure is irreversible, and both neurohormonal 
modulation and inherent cardiac contractility and/or relaxation are compromised in these patients 
[6].  In the future, development of viable heart failure therapies will require improved insights 
into myofilament function and its modulation.  
Cellular events in the cardiac cycle 
Multiple electrical and mechanical events in each cardiac myocyte and the functional 
syncytium between myocytes are fundamentally responsible for the cardiac cycle [7]. The first 
set of events in the cardiac cycle result from electrical changes in the myocyte membrane (e.g. 
sarcolemma) known as an action potential, which is composed of membrane depolarization and 
repolarization produced by Na+, K+ and Ca2+ currents.  The action potential rapidly spreads from 
cell to cell via gap junctions present at the end to end contacts, which electrically couple rod 
shaped myocytes to each other [1, 2]. During the action potential, opening of voltage-gated Ca2+ 
channels located in specialized sarcolemmal invaginations, or  t-tubules, initiates the amplified 
release of Ca2+ from stores located within the adjacent sarcoplasmic reticulum (SR). Ryanodine 
receptors located within the SR are responsible for this amplified Ca2+ release.  Collectively, the 
voltage-gated and SR release of Ca2+ via ryanodine receptors into the cytosol is known as Ca2+-
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induced Ca2+ release or CICR [8, 9].  The resulting rise in cellular Ca2+ is responsible for 
excitation-contraction (E-C) coupling (e.g. linking electrical to mechanical events) [8].   
Specifically, the elevated levels of Ca2+ result in binding of this cation to troponin in the 
myofilament, which initiates the mechanical events necessary for pressure development and the 
ejection of blood into large arteries by each cardiac ventricle.  The myocyte sarcolemma then 
repolarizes, and pressure development returns to baseline levels as cytosolic Ca2+ is pumped 
back into the (SR) and/or out of the myocyte [10] [2, 7].  
The contractile unit and the biophysics of contraction 
Myofilaments within cardiac myocytes contain organized bundles of sarcomeres to 
translate the Ca2+ signal or transient into mechanical pressure or force (Fig.1.1B) [7, 11]. 
Sarcomeres are the basic functional unit of striated muscle, and each sarcomere is composed of a 
highly ordered and overlapping arrangement of thick and thin filaments [7]. The backbone of the 
thick filament is composed of parallel bundles of myosin (e.g. cross-bridge), each consisting of 
two myosin heavy chains (MHC) and four light chains (Fig.1.1C)[12].  An ATPase within the 
globular head region of the MHC hydrolyzes adenosine triphosphate (ATP) to produce adenosine 
diphosphate (ADP) and inorganic phosphate (Pi), which provides the energy necessary for the 
molecular motor function of each myosin [7, 13, 14].  Myosin light chains (MLC) modulate the 
stiffness of  the S1 heavy chain region in myosin containing the globular head and lever arm 
(Fig. 1.1C) [15]. Cardiac myosin binding protein C (cMyBP-C) is also located in the thick 
filament and appears to play both structural and regulatory roles, although its exact function 
remains controversial (Fig. 1.1C) [16, 17]. Both MLC and cMyBP-C regulate MHC movement 
and proximity to the thin filament to prevent interactions between the thick and thin filament 
when Ca2+ levels are low [15, 18, 19]. 
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  The backbone of the thin filament is formed by an -helical coiled coil of polymerized 
actin, which reversibly interacts with the myosin cross-bridge during each contraction (Fig. 
1.1C) [3, 9]. The thin filament also contains regulatory proteins such as tropomyosin (Tm), 
which is arranged along actin in a -helical coiled-coil (Fig. 1.1C).  Tm is believed to sterically 
block actomyosin interactions in the absence of Ca2+ and rotate across the actin filament to allow 
the cross-bridge to attach to actin, generating force or pressure during the cellular Ca2+ transient 
[20].  Troponin (Tn) is another regulatory protein designed to coordinate Tm positioning and 
cross-bridge access to actin.  Tn is a heterotrimeric protein consisting of cardiac troponin C 
(cTnC), cardiac troponin T (cTnT), and cardiac troponin I (cTnI) (Fig.1.2A). TnC binds Ca2+ and 
is the subunit responsible for initiating contraction during the Ca2+ transient, while cTnT links Tn 
to Tm and assists in Tm positioning on actin [3, 9]. The final subunit is the inhibitory protein 
cTnI, which acts as a molecular switch protein within the Tn complex by binding to actin in the 
absence of Ca2+ and then dissociating from actin and binding more tightly to cTnC in the 
presence of Ca2+ (Fig.1.2B).   In the myocardium, cTnI also plays an important role in opening 
the Ca2+ binding domain located in an amino-terminal hydrophobic patch of cTnC (Fig.1.2A) 
[21]. Overall, the Ca2+-induced conformational changes in Tn are critical for the generation and 
decay of force produced by the rhythmic interactions between actin and myosin [3, 9].  
The force generated by the interaction between actin and myosin is currently explained 
by a 3 state model of thin filament activation, which has largely replaced the on-off mechanism 
described in the original Hill model (Fig. 1.2C) [22, 23].  An advantage of the 3-state model is 
the incorporation of both Ca2+-binding to cTnC and cooperative activation by neighboring, 
strong-binding cross-bridges to explain force generation in the myofilament [14, 22]. In this 
model, Tm oscillates between 3 states, and the cellular environment determines the state most 
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Tm occupies at a given point in time.  In the absence of Ca2+, Tm primarily occupies the 
“blocked” position on the thin filament, and in this position, the myosin cross-bridge is unable to 
interact with actin (Fig.1.2C).  As Ca2+ binds to TnC, Tm increasingly occupies an intermediate 
position on the actin filament known as a “closed” state, which allows weak, non-force 
generating cross-bridge binding to actin (Fig.1.2C) [14].  When Tm occupies the third "open" 
state, a cross-bridge forms strong, force-generating interactions with actin (Fig.1.2C) [14].  
Currently, Tm is proposed to transition back to the intermediate "closed" state followed by the 
"blocked" state as the SR Ca2+ pump (SERCA2A) and sarcolemmal Na+/Ca2+ exchanger reduce 
cytosolic Ca2+ levels and cause Ca2+ to dissociate from cTnC in the repolarized myocyte [10].   
At the same time these transitions develop in the thin filament, the hydrolysis of ATP into 
ADP and Pi by MHC provides the energy needed for force development [14].  The release of Pi 
is tightly coupled to the cross-bridge power-stroke, which generates force (pressure) when length 
remains constant under isometric conditions or produces thin filament sliding by the cross-bridge 
when the sarcomere shortens under isotonic conditions. After the power-stroke, the strong, force-
generating cross-bridge attachment to actin is only relieved when ADP dissociates and is 
replaced by ATP [14].  
In addition to the individual contributions of the thick and thin filaments, there is an 
important allosteric component to force generation.  The Tm transition from “blocked” to 
“closed” and "closed" to "open" states are cooperative processes whereby the transition of one 
functional unit, composed of 7 actins, 1 Tm and 1 Tn, increases the probability neighboring 
functional units will transition to the same state (Fig.1.2C) [3]. For example, strong cross-bridge 
binding to a thin filament functional unit in the “open” state increases the likelihood an adjacent 
cross-bridge will bind to actin and generate force without the need for an additional increase in 
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Ca2+ bound to cTnC (Fig.1.2C) [3, 14]. Ultimately, strong, force-generating interactions between 
actin and myosin are responsible for the generation of pressure and the thin filament sliding 
needed to eject blood from the ventricle into the large arteries during the systolic phase of each 
cardiac cycle.   
The current model of muscle contraction outlined above demonstrates the significant 
progress made in understanding the molecular events responsible for force generation. However, 
significant gaps remain in our understanding of the conformational changes and interactions 
among sarcolemmal, Ca2+ cycling and myofilament proteins responsible for cardiac contraction 
and relaxation.  For example, pressure development during systole depends on the rate-limiting 
release of Ca2+ from ryanodine receptors in the SR under most conditions, and yet two or more 
rate-limiting steps often contribute to relaxation rate [24] [8, 10].  While some components 
contributing to pressure decay are known, there is only a vague understanding about the precise 
contribution of each event over time.  Currently, the initial phase of relaxation is most often 
attributed to Ca2+ dissociation from cTnC, while a second  phase depends heavily on the kinetics 
of SR Ca2+ re-uptake and/or Ca2+ extrusion from myocytes [10].  However, recent evidence 
suggests cross-bridge detachment from the thin filament also influences the later phase(s) of 
relaxation in myocytes [24]. To gain insight into this complex, multi-phasic process, further 
work is necessary to define the contribution of each process over a range of physiological 
conditions.  
Phosphorylation of cTnI and modulation of contractile function by cTnISer23/24 
Post-translational modifications, such as phosphorylation, work to fine tune cardiac 
contraction and relaxation.  A range of approaches are used to examine the role phosphorylation 
of individual thick and thin filament proteins plays in modulating contractile performance, 
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including work on cTnI.  Biochemical work identified 6 kinase-targeted residues in cTnI 
including Ser23/24 in the cardiac-specific N-terminal domain, Ser43/45 in the HI(1) -helix at 
the beginning of the IT arm, Ser78 in the I-T Arm, and Thr144 in the inhibitory peptide domain 
(IP) (Fig. 1.2A) [25, 26]. Additional candidate phosphorylation sites within cTnI continue to be 
identified using improved mass spectroscopy approaches, including recent work identifying 14 
cTnI phosphorylation sites [27].  With the identification of new phosphorylation sites in cTnI, 
the kinases targeting each residue and the functional role modulated by phosphorylation often 
remain controversial.  Conceptual insights into these issues are needed because alterations in 
phosphorylation of several sites within cTnI are associated with cardiac dysfunction and the 
progression to end-stage heart failure in both animal models and human patients [28, 29] [27] 
[30, 31].  
Perhaps the most studied phosphorylation site in cTnI is Ser23/24, located in the cardiac-
specific N-terminus of cTnI (Fig.1.2A).  The first kinase found to phosphorylate cTnI was 
protein kinase A (PKA), a member of the AGC family of Ser/Thr protein kinases, which targets 
cTnISer23/24. Sympathetic stimulation of -adrenergic receptors ( -AR) in cardiac myocytes 
activates adenylyl cyclase (AC) to increase cellular cyclic-AMP (cAMP), which in turn activates 
PKA [32] [5, 33, 34]. Basal cTnI Ser23/24 phosphorylation is detected in both normal human 
tissue and in animal models [35-37]. PKA phosphorylation at cTnISer24 occurs first, and this 
site is thought to be constitutively phosphorylated in cardiac myocytes [38, 39]. Additionally, 
phosphorylation of both Ser23 and Ser24 is required to modulate cTnI function [40, 41]. 
Phosphorylation of cTnISer23/24 de-sensitizes the myofilament to Ca2+ in both in vitro and 
cellular studies, and this desensitization results in the accelerated Ca2+ release from cTnC [42-
46].  In agreement with this mechanism, expression of cTnI containing a phospho-null Ala 
9 
 
substitution at Ser23/24 in isolated rat myocytes, eliminates the accelerated relaxation response 
to the -AR agonist, isoproterenol [43].  Moreover, phospho-mimetic Asp substitutions on 
cTnISer23/24 reduced myofilament Ca2+ sensitivity of tension and accelerated re-lengthening 
rate in intact myocytes without changing peak tension [43].    
A number of genetic mouse models also have been generated to examine the modulatory 
role of cTnISer23/24 phosphorylation in the whole heart. Complete replacement of endogenous 
cTnI using a knock-out followed by knock-in of cTnI containing Ala substitutions at Ser23/24 
(Ala2nb) eliminated the ability of PKA activation to decrease myofilament Ca2+ sensitivity (Table 
1.1) [47].  In transgenic (tg) mouse models, >95% replacement of endogenous cTnI with  
phospho-mimetic cTnISer23/24Asp (cTnIPP) decreased myofilament Ca2+-sensitivity of tension 
in permeabilized cells, accelerated re-lengthening rates in intact myocytes, and increased in vivo 
cardiac relaxation rates (dP/dtmin) compared to non-transgenic controls (Table 1.1) [43, 48, 49]. 
Taken together, the in vitro and in vivo approaches uniformly demonstrated cTnISer23/24 
phosphorylation reduces myofilament Ca2+ sensitivity and increases relaxation rate by 
accelerating Ca2+ release from cTnC [42, 43, 48]. In keeping with the observations in animal 
models, reduced cTnISer23/24 phosphorylation develops in end-stage heart failure and is 
associated with the expected increase in myofilament Ca2+ sensitivity and slowing of relaxation 
[27] [31] [29].  
Influence of PKC-mediated cTnI phosphorylation on contractile function 
Protein kinase C (PKC) is a second member of the AGC kinase family which 
phosphorylates cTnI[26] [50, 51]. Multiple neurohormones activate PKCs through G-protein 
coupled receptors (GPCR) including catecholamine stimulation of -adrenergic receptors ( -
AR), endothelin (ET-1) activation of ETA receptors, and angiotensin II (AngII) activation of 
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AT1A receptors [52] [53, 54]. Twelve PKC isoforms have been identified and divided into 3 
families based on cofactors required for kinase activation [55]. Classical PKCs , I, II, and ) 
require both Ca2+ and lipid co-factors, such as diacylglycerol (DAG), in the cell or synthetic 
phorbol esters, such as phorbol 12-myristate 13-acetate (PMA), for activation [50, 55].  
Activation of novel class PKC isoforms ( , , , and  is Ca2+ independent but requires lipid co-
factors. In contrast, atypical PKCs ( , /  are often activated through protein-protein interactions 
mediated via a Phox and/or Bem 1 domain [55]. PKC , PKC , PKC , PKC , and PKC  are 
expressed in the adult mammalian cardiac myocytes [56-58].  
 Early in vitro work showed PKC phosphorylates 3 clusters of residues within TnI, and 
PKC , PKC , and PKC  each phosphorylate Ser43/45 and Thr144, while PKC preferentially 
phosphorylates Ser23/24 [59-61].  Novel class PKC isoforms ( , ) are postulated to 
phosphorylate cTnI in vivo, based on their anticipated distribution within myocytes.  However, 
the role PKC-mediated cTnI phosphorylation plays in modulating cardiac function remains 
controversial. A focal point for this controversy is the contribution of cTnISer43/45 
phosphorylation, due to conflicting results obtained from in vitro and in vivo models [49, 62] [47, 
51, 63, 64]. Determining the functional role modulated by cTnISer43/45 phosphorylation is 
critical because there is evidence linking increased PKC activity and downstream cTnI 
phosphorylation to contractile dysfunction [56, 65]. In agreement with this idea, phosphorylation 
of cTnISer43/45 is negligible in normal human and animal hearts [30, 35-37]. In contrast, PKC 
expression and activity increase and cTnISer43/45 phosphorylation is augmented in human end-
stage heart failure [27, 29-31, 56, 65, 66]. 
A substantial body of in vitro analyses predicts PKC-dependent cTnI phosphorylation at 
Ser43/45 will reduce cardiac function [67] [45, 51, 63, 68]. PKC-phosphorylated cTnI 
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diminished myofilament Ca2+-sensitivity and maximum actomyosin ATPase activity in both 
reconstituted thin filaments and cardiac myofibrils [45, 51, 63].  Myofibrillar ATPase activity 
often, but not always, predicts a similar change in loaded cross-bridge cycling rate during the 
ejection of blood from the ventricle.  Phospho-null Ala substitutions at cTnISer43/45 or 
pharmacological inhibition of PKC mitigates the reduction in maximum actomyosin ATPase 
activity [51] [45].  Interestingly, the phosphorylation-induced decrease in myofilament Ca2+ 
sensitivity also is present after reconstitution with cTnISer43/45Ala, although investigators have 
repeatedly failed to comment on this phenotypic change [64] [45]. Conversely, replacement of 
cTnISer45, cTnISer43/45, and cTnISer43/45Thr144 with phospho-mimetic Glu reduces 
maximum actomyosin ATPase activity and myosin S1-binding to the thin filament in 
reconstituted preparations [67].  Exchange of endogenous cTnI with a recombinant 
cTnISer43/45Glu in permeabilized, papillary muscle bundles reduces myofilament Ca2+ 
sensitivity of tension, consistent with the results obtained using biochemical approaches [68].  In 
addition, this construct also reduces maximum Ca2+-activated tension, maximum thin filament 
sliding speed and cooperative Ca2+-mediated activation of sliding speed (e.g. Hill n) [68]. 
Although the results of one study are interpreted to indicate PKC phosphorylation of cTnIThr144 
increases myofilament Ca2+ sensitivity, the majority of in vitro approaches suggest PKC-
mediated cTnI phosphorylation reduces Ca2+ sensitivity [69] [45, 51, 63, 68]. Overall, the 
examination of cTnISer43/45 indicates phosphorylation of this cluster uniformly reduces 
MgATPase activity and myofilament Ca2+ sensitivity [68] [45, 51, 63, 67]. Based on chemical 
shift analysis by NMR, cTnISer43/45 phosphorylation is predicted to modulate myofilament 
Ca2+ sensitivity by destabilizing a C-terminal helix in cTnC [70]. More recently, Glu 
replacement at cTnISer45 disrupted a critical interaction between this residue and the amino (N)-
12 
 
lobe of cTnC.  This disruption is anticipated to  decrease opening of the hydrophobic patch 
containing the regulatory Ca2+ binding site on this lobe of cTnC and also result in diminished 
myofilament Ca2+ sensitivity [71].  The separate effects of cTnISer43 and cTnISer45 on 
myofilament function have not been thoroughly explored using these types of in vitro approaches 
or in more complex model systems. One goal of this dissertation is to determine if cTnISer43 
and cTnISer45 independently adjust contraction of individual myocytes.  
As with cTnISer23/24, the development of several genetic animal models further 
examined the modulatory role of PKC-mediated cTnI phosphorylation in fine-tuning cardiac 
pump function. One mouse model utilized a knock-out/knock-in approach to replace 
cTnISer23/24, cTnISer43/45, and cTnIThr144 with Ala (Ala 5nb) (Table 1.1) [64]. Under basal 
conditions, Ala replacement of all 5 PKC-targeted cTnI residues diminished myofilament Ca2+ 
sensitivity in permeabilized myocytes compared to wild-type controls, although this change was 
not identified or discussed in the published study  [64].  As expected, treatment of heart tissue 
with the PKC agonists  ET-1 and PMA did not change maximum actomyosin ATPase activity in 
myofibrils isolated from Ala5nb mice [47]. Conversely, ET-1 and PMA treatment slowed re-
lengthening in intact wild-type myocytes and increased myofilament Ca2+ sensitivity of 
actomyosin ATPase activity and cellular isometric tension compared to Ala5nb myocytes [47, 64]. 
Based on these results, the authors concluded  cTnISer43/45/Thr144 phosphorylation increases 
myofilament Ca2+-sensitivity, which is directly opposite of the change predicted from the 
majority of  biochemical/biophysical studies [64] [45, 68] [47]. The authors suggested the 
increased myofilament Ca2+ sensitivity and slowed re-lengthening produced by PKC activation 
of control myocytes may result from myosin light chain kinase (MLCK) activation and the 
downstream phosphorylation of myosin light chain 2 (MLC2), also known as the regulatory light 
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chain (RLC) [47].  Although overall RLC phosphorylation was not different between 
myofilaments from wild-type and Ala5nb mice, the ability of MLCK to increase Ca2+ sensitivity 
is significantly attenuated in Ala5nb myofilaments [47].  This finding indicates adaptive changes 
in the Ala5nb model may confound the direct influence of phosphorylation on contractile 
function. In addition, the prominent reduction in myofilament Ca2+ sensitivity observed in Ala5nb 
mice suggests amino acid substitutions of cTnISer43/45 may influence the conformation of the 
Tn core and produce significant changes in basal cardiac function [64].  Although in vivo cardiac 
function has not been measured in the Ala5nb mouse, the development of a dilated 
cardiomyopathy in this model supports this idea [64].   
In a separate tg model, ~50% of endogenous cTnI was replaced by cTnISer43/45Ala 
(Table 1.1) [72]. In cTnISer43/45Ala mice, basal cardiac function did not differ from  non-tg 
controls, although Ca2+-activated maximum actomyosin ATPase activity and isometric tension 
generation were significantly reduced compared to control preparations [72-74]. Interestingly, 
cTnISer43/45Ala expression increased overall cTnI phosphorylation and reduced cTnT 
phosphorylation.  These results suggested adaptations could maintain overall function and/or 
mask functional changes induced by cTnISer43/45Ala and provided an explanation for the 
discrepancies between in vitro studies and the results observed with the Ala5nb mouse. 
Experiments performed in chapter 2 of this dissertation address the role of Ala substitutions at 
cTnISer43/45 on basal myofilament function in intact and permeabilized cardiac myocytes 
(Ch.2).  
Animal models expressing a cTnI with phospho-mimetic replacement of the PKC-
targeted clusters have also been developed to further examine the role of PKC-mediated cTnI 
phosphorylation in modulating cardiac pump function. In one tg mouse model, all 5 PKC-
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targeted residues in cTnI are replaced with aspartic acid (Asp; cTnIAllP) to mimic the negative 
charge introduced by phosphorylation (Table 1.1) [49]. Maximum Ca2+-activated actomyosin 
ATPase activity, myofilament Ca2+ sensitivity, and isometric tension generation were each 
reduced in myofibrils and myocytes from this mouse compared to non-transgenic mice [75] [49]. 
These observations are consistent with the in vitro studies discussed earlier in this section and 
predict the presence of diminished cardiac function in cTnIAllP mice.  Specifically, these mice 
were anticipated to show diminished peak pressure and accelerated relaxation [49]. However, 
hemodynamic measurements of cTnIAllP cardiac function revealed no change in ventricular 
pressure or relaxation rate (dP/dtmin).  Instead, only the rate of pressure development (dP/dtmax) 
slowed in cTnIAllP mice compared to non-transgenics [49]. The inconsistency between in vitro 
and in vivo outcomes in this mouse model make data interpretation difficult and highlight the 
need for an additional model to study the functional effects of PKC-mediated cTnI 
phosphorylation on cardiac performance.  
In another tg mouse model, ≈7% of endogenous cTnI was replaced by a cTnI with 
phosphomimetic Glu substitutions at cTnISer43/45 and cTnIThr144 (cTnIPKC-P) to examine the 
modulatory roles of PKC-specific residues (Table 1.1) [62]. This minimal level of cTnIPKC-P 
expression unexpectedly diminished isometric force production in fibers isolated from tg mice. 
However, there were no changes in myofilament Ca2+ sensitivity in cTnIPKC-P fibers compared to 
wild-type controls.  Based on these findings, diminished pressure development was anticipated in 
cTnIPKC-P hearts, and indeed, a slowed rate of contraction (-d /dtmax) and reduced peak pressure 
development were observed in isolated whole hearts from cTnIPKC-P mice [62]. However, 
relaxation rates also were slowed in both fiber bundles and isolated hearts [62]. Collectively, the 
role cTnISer43/45 phosphorylation plays in modulating function remain ambiguous based on the 
15 
 
inconsistencies between in vivo models expressing phospho-null or phospho-mimetic cTnI 
substitutions along with the unexpected in vivo phenotypes which in vitro studies failed to 
predict. Therefore, a cellular approach may be an appropriate model to evaluate the role 
cTnISer43/45 phosphorylation plays in fine-tuning cardiac performance. The work described in 
this dissertation utilizes isolated cardiac myocytes to define the functional influence of 
phosphorylation at one or both residues within cTnISer43/45 using phospho-mimetic Asp 
substitutions (Ch.3). Isolated cardiac myocytes have been shown to be a viable model to bridge 
earlier work in biochemical systems with more complex in vivo models [76] [7, 43, 77]. 
Isolated cardiac myocytes also could be an effective approach for addressing functional 
cross-talk between phosphorylated residues within cTnI, such as cTnISer23/24 and 
cTnISer43/45. While many of the animal models evaluating the functional impact of cTnI 
phosphorylation by PKC have addressed multi-residue phosphorylation, the functional 
relationship between cTnISer23/24 and cTnISer43/45 remain to be directly addressed in in vitro 
or in vivo models. The close physical proximity of these cTnI clusters and the potential ability of 
both clusters to reduce myofilament Ca2+ sensitivity provide further rationale for  investigating 
the relationship between these PKC-targeted residues (Fig. 1.2A) [25, 26, 43, 46, 60, 68].  
The relationship between cTnISer23/24 and cTnISer43/45 has been indirectly examined 
by comparing cardiac function in cTnIAllP to cTnIPP mice as well as comparing cTnIAla5nb to 
cTnIAla2nb mice (Table 1.1)[47, 49, 64]. For example, the ability of PKC agonists ET-1 and 
PMA to reduce maximum actomyosin ATPase activity and isometric tension is absent in 
myofilaments from Ala5nb but is more pronounced in Ala2nb mice compared to wild-type controls 
[47]. Conversely, reduced myofilament Ca2+ sensitivity of tension is observed in both cTnIPP and 
cTnIAllP myofilaments, and yet cardiac relaxation rate (dP/dtmin) is accelerated only in the cTnIPP 
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mouse hearts [49]. In both sets of mice, the results are consistent with communication between 
cTnISer23/24 and cTnISer43/45, which influences cardiac performance.  The results from the 
cTnIAla2nb mice suggest cTnISer23/24 phosphorylation could dampen the functional influence of 
PKC-mediated cTnISer43/45 phosphorylation [47].  In contrast, cTnISer43/45 phosphorylation 
appears to suppress the actions of cTnISer23/24 based on the comparison of cTnIAllP to cTnIPP 
mice [49]. The functional relationship between cTnISer23/24 and cTnISer43/45 is explored in 
chapter 4 (Ch.4).  An important goal of this work is to differentiate between direct versus 
potential adaptive functional influences in isolated myocytes after gene transfer of cTnI 
containing phospho-mimetic substitutions at these 4 residues.   
Alterations in cTnI phosphorylation identified in failing hearts highlights the importance 
of understanding the physiological effects of each PKC-targeted cTnI residue, both alone and in 
combination. Moreover, divergent phosphorylation patterns at cTnISer43/45 and cTnISer23/24 
are observed in many cardiac injury models, and several studies indicate PKC expression and 
activation are increased during periods of cardiac dysfunction [27] [56, 65] [29-31]. 
Phosphorylation of cTnISer23/24 is significantly reduced in tissue from end-stage heart failure 
patients diagnosed with either ischemic cardiomyopathy (ICM) or dilated cardiomyopathy 
(DCM) [27]. Conversely, diminished Ca2+-activated maximum force production and increased 
sliding speed are linked to augmented classical PKC expression in tissue from failing hearts and 
could be restored to non-failing values following myofilament de-phosphorylation with protein 
phosphatase 2A (PP2A) [65].  The detected phosphorylation pattern of cTnISer43/45 also 
appears to be more complex during heart failure.  Phosphorylation at cTnISer43 increases in both 
ICM and DCM while increased cTnISer45 phosphorylation appeared to be unique to DCM [27] . 
These observations are consistent with the diminished Ca2+-activated force production observed 
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in failing human heart tissue [65]. The alterations in phosphorylation at specific cTnI residues 
also appear to be time and disease dependent. Phosphorylation at cTnISer23/24 increased while 
phosphorylation at cTnISer43 was unchanged in patients with hypertrophy and an absence of 
change in systolic function. In contrast, cTnISer43 phosphorylation was reduced in patients with 
left ventricular dilation and diminished ejection fraction [66]. Collectively, these studies provide 
strong evidence of an association between cTnISer43 or cTnISer45 phosphorylation and 
pathological alterations in cardiac contraction.  Due to the complex cTnISer43/45 
phosphorylation patterns detected across multiple disease states and time points, it is unclear 
whether PKC phosphorylation of Ser43/45 in cTnI contributes to physiological modulation of 
cardiac performance and/or to the progression of heart failure.  
Hypothesis and aims 
Work presented in this dissertation tests the hypothesis that cTnISer43/Ser45 
phosphorylation decreases cardiomyocyte contractile performance. Additionally, functional 
cross-talk between multiple PKC-phosphorylated residues in cTnI is predicted to be present and 
contribute to modulatory changes in myocyte contractile performance.  These hypotheses are 
tested in 2 separate aims.  The individual versus combined modulatory role of cTnISer43 and/or 
cTnISer45 on myocyte contractile function is evaluated under basal conditions and in response to 
PKC activation in the first aim (Ch. 2 and Ch. 3). A second aim is designed to test whether 
phosphorylation at cTnISer23/24 impacts the effect of cTnISer43/45 on cardiomyocyte 
contraction and relaxation (Ch. 4). Work in this dissertation is performed on isolated myocytes 
expressing phospho-null (Ala) or phospho-mimetic (Asp) substitutions at one or both residues in 
cTnISer43/45 (e.g. cTnISer43/45Ala) (Fig. 1.3A).  After verifying expression and incorporation 
of each construct, both direct versus indirect, adaptive influences on function are measured using 
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sarcomere shortening measurements, isometric tension development, and Ca2+ cycling in intact 
myocytes (Figs.1.3B-D). Primary measures of contractile function in the shortening assay 
include peak shortening amplitude, shortening rate and the time to peak (TTP) shortening, while 
relaxation is evaluated from the re-lengthening rate, times to 50% and 75% re-lengthening 
(TTR50% and TTR75%, respectively), and resting length (Fig. 1.3D).Western blot also is utilized to 
detect changes in sarcomeric and Ca2+ handling protein phosphorylation following phospho-null 
or phospho-mimetic construct expression (Fig. 1.3A).  
Experiments in chapter 2 address the influence of cTnISer43/45 on basal contractile 
performance and in response to PKC activation by ET-1. Under basal conditions, Ala is 
predicted to be a functionally conservative substitution for cTnISer43/45 since Ala replacement 
at cTnISer23/24 does not influence basal myocyte contractile performance [43, 78]. However, 
the reduced myofilament Ca2+-sensitivity of isometric tension apparent in previous in vitro and 
in vivo studies with cTnISer43/45Ala suggest both residue size and polarity at cTnISer43/45 are 
critical for maintaining basal function [45, 47, 64]. Though a reduction in myofilament Ca2+ 
sensitivity could develop, most measures of cellular shortening are not expected to differ 
significantly from controls. Expression and sarcomere replacement with cTnISer43/45Ala also is 
predicted to reduce the response to ET-1 activation of PKC in intact myocytes, since 
cTnISer43/45Ala mitigates the response to the -adrenergic PKC agonist phenylephrine in 
myofibrils from transgenic mice [73]. In the event the ET-1 response is similar between controls 
and cTnISer43/45Ala-expressing myocytes, the results would suggest specific agonists activate 
different PKC isoforms, which may target other cTnI residues and/or additional 
myofilament/Ca2+ cycling protein targets.  
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Studies performed in chapter 3 are designed to evaluate the influence of cTnISer43/45 
phosphorylation on sarcomere shortening and isometric tension development in isolated 
myocytes. In these experiments, phospho-mimetic Asp is substituted for cTnISer43/45 via 
adenoviral gene transfer (Fig. 1.3A); this substitution is predicted to diminish peak shortening 
amplitude, reduce maximum isometric tension development and decrease myofilament Ca2+ 
sensitivity based on majority of previous in vitro and in vivo work (Fig 1.3D) [49, 62, 63, 52, 67, 
68, 75]. However, the variable influence of cTnISer43/45 phospho-mimetic substitutions on 
contractile function in the literature indicates experiments are needed to differentiate between the 
direct versus adaptive, indirect influence on contractile function [51, 68, 79, 80]. An additional 
component of this chapter tests whether cTnISer43 and cTnISer45 work independently to 
modulate myocyte contractile function. Expression of cTnISer43Asp or cTnISer45Asp may not 
individually modulate sarcomere shortening and isometric tension because, like cTnISer23/24 
phosphorylation, replacement at both residues may be required to produce a functional response 
[40]. In the event cTnISer43 and cTnISer45 function independently, work will focus on 
identifying whether these residues perform similar actions within the myocyte and/or they 
influence separate mechanisms to alter function. 
  The influence of functional cross-talk between cTnISer23/24 and cTnISer43/45 
phosphorylation will be investigated in chapter 4. Previous work evaluating the influence of 
multi-site cTnI phosphorylation is limited to communication between all 5 PKC-targeted 
residues, cTnISer23/24 and Thr144, or cTnISer43/45 and Thr144 [47, 49, 62, 64, 75]. Work 
from the cTnIAllP mouse indirectly suggests cTnISer43/45 has a dominant influence on function 
over Ser23/24 [49, 75]. Therefore, a phospho-mimetic cTnI containing Asp substitutions at 
cTnISer23/24 and cTnISer43/45 (cTnIAspQuad) is introduced into isolated rat myocytes via 
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adenoviral-mediated gene transfer (Fig. 1.3A) and is expected to reduce myocyte contractile 
function and diminish myofilament Ca2+ sensitivity of tension (Fig. 1.3D). An acceleration of 
myocyte re-lengthening rate is anticipated in the event cTnISer23/24 influences function 
separately from cTnISer43/45 [40, 43, 45, 46, 68]. Conversely, it is possible Asp replacement at 
both cTnISer23/24 and cTnISer43/45 may abrogate the functional effects of each cluster and 
there may be no net influence on all measures of contractile function.  Isolated cardiac myocytes 
are expected to be an effective model for evaluating the direct impact of cTnISer23/24 and 
cTnISer43/45 on function and determining whether these clusters influence comparable or 
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Table 1.1. In vitro and in vivo characteristics of cTnI phospho-null and phospho-mimetic mouse 
models. Available information concerning the mouse model, amount and location of replacement, age, 
pathological indicators, permeabilized preparations, intact preparations, and whole organ measurements. 
MRI = Magnetic Resonance Imaging. Phos = phosphorylation. pCa50 = Change in myofilament Ca2+ 
sensitivity. NC = No change,   = decreased,  = increased. 
 
Adopted from Previs et. al. 2012 Science.
The Sarcomere
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Fig. 1.1  Cellular components underlying cardiac contraction.   A.  Confocal image of an adult
cardiac myocyte immunostained for troponin I (TnI; green) and FLAG  (red).  The striated pattern
highlighted in the box is produced by the sarcomere.  B.  Illustration of a single sarcomere containing
overlapping arrays of thick and thin filaments.  A sarcomere is defined as the region between 2 z-lines.  
Thin filaments are absent in the bare area formed around the central region (M-line), and cardiac myosin 
binding protein C (cMyBP-C) is distributed within the C-zone of each sarcomere.  C.  Illustration of a 
magnified section of the sarcomere highlighted in B.  Individual proteins within the thin and thick filaments 
are shown in this illustration.  The thick filament is composed of myosin, myosin light chain 1 (e.g. essential
light chain; ELC) and 2 (regulatory light chain; RLC) plus cMyBP-C.  Actin forms the coiled-coil backbone
of the thin filament.  Tropomyosin (Tm) and heterotrimeric troponin (troponin C, troponin I, and troponin T) 


































Fig. 1.2. Cardiac troponin I in the myofilament. A. Structural model of the Tn core containing 
cTnI (green), cTnC (blue), and cTnT (magenta). The locations of the 5 PKC-targeted phosphorylation 
sites within cTnI are noted. Important points of interaction between cTnI and the additional Tn 
subunits are also highlighted. B. A cartoon illustrating the conformation change that occurs within cTnI in 
the presence or absence of Ca2+ C. Cartoon depiction of the 3 state model. The transition from “blocked” 
to “closed” is mediated by Ca2+ binding to troponin. The myofilament further transitions to an open, force 
generating state following the interactions with strongly-bound cross-bridges. 
Adopted from Takeda et. al. 2003 Nature.
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Fig. 1.3 Approaches to evaluate expression and contractile function in myocytes expressing cTnI with 
phospho-null or phospho-mimetic substitutions in PKC-targeted residues. A.  The cTnI constructs with 
substitutions are introduced into isolated adult rat cardiac myocytes via recombinant adenoviral-mediated 
gene transfer.  B.  Expression and replacement of endogenous cTnI with the cTnI constructs and 
phosphorylation of specific residues within myofilament proteins are detected by Western blot analysis.  C.  
Sarcomeric localization of the individual constructs is detected using dual immunohistochemical labeling 
for cTnI and FLAG-tagged cTnI.  D.  Contractile function responses are determined by measuring isometric tension
(upper panel) in detergent-permeabilized myocytes over a range of Ca2+ concentrations (pCa = -log [Ca2+]).  The 
Ca2+-activated tension curves are analyzed to determine maximum tension (Po) and myofilament Ca
2+  sensitivity 
(pCa50= Ca
2+ required for 50% tension generation).  The arrows in this illustration indicate decreases in Po and in
pCa50 values for myocytes shown in the blue curve versus the orange curve.  In a second approach, sarcomere 
shortening is measured in intact cardiac myocytes (lower panel).  A representative trace demonstrates the 
contractile function measurements analyzed using this approach, including resting length, peak shortening 
amplitude, the rates of shortening and re-lengthening, time to peak (TTP; not labeled), and the times to 50% and 75% 
re-lengthening (TTR50% and TTR75%, respectively).  For measurements of the cellular Ca
2+ transient, the same approach 
is utilized to measure shortening except myocytes are loaded with cell permeable Fura-2AM dye and Ca2+ transients
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Phosphorylation of cardiac troponin I serines 43/45 (cTnISer43/45) by protein kinase C 
(PKC) is associated with cardiac dysfunction and yet there is disagreement about the role this 
cluster plays in modulating contractile performance. The present study evaluates the impact 
of phospho-null Ala substitutions at cTnISer43/45 (cTnISer43/45Ala) on contractile 
performance in intact myocytes.  Viral-based gene transfer of cardiac troponin I (cTnI) or 
cTnISer43/45Ala resulted in time-dependent increases in expression, with 70-80% of 
endogenous cTnI replaced within 4 days. Western analysis of intact and permeabilized 
myocytes along with immunohistochemistry showed each exogenous cTnI was incorporated 
into the sarcomere of myocytes.  In contractile function studies, there were no differences in 
shortening and re-lengthening for cTnI and cTnISer43/45Ala-expressing myocytes 2 days 
after gene transfer.  However, more extensive replacement with cTnISer43/45Ala after 4 
days diminished peak shortening amplitude and accelerated re-lengthening measured as the 
time to 50% re-lengthening (TTR50%).   A decrease in myofilament Ca2+ sensitivity of tension 
also was observed in permeabilized myocytes expressing cTnISer43/45Ala and was 
consistent with accelerated re-lengthening observed in intact myocytes under basal 
conditions.  Phosphorylation of cTnISer23/24 and the Ca2+ transient were not changed in 
these myocytes.   These results demonstrate extensive sarcomere expression of 
cTnISer43/45Ala directly modulated myofilament function under basal conditions.  In further 
work, the accelerated re-lengthening observed in control or cTnI-expressing myocytes treated 
with the PKC agonist, endothelin-1 (ET, 10nM), was slowed in myocytes expressing 
cTnISer43/45Ala. This outcome may indicate cTnISer43/45 is targeted for phosphorylation 




Thin filament cardiac troponin (cTn) interacts with tropomyosin and actin to regulate 
actomyosin interactions in response to changes in calcium during cardiac systole and diastole [7, 
20].  Cardiac troponin I (cTnI) acts as a molecular rheostat within the Tn complex by strongly 
interacting with actin in the absence of Ca2+ and then toggling to interact with troponin C (cTnC) 
as Ca2+ levels increase [2].  Multiple kinases phosphorylate TnI and often modulate myofilament 
Ca2+ sensitivity.  In biochemical studies, protein kinase C (PKC), a serine/threonine kinase, 
phosphorylated the cardiac isoform of troponin I (cTnI) at three residue clusters: serines 23/24 
(Ser23/24), serines 43/45 (Ser43/45), and threonine 144 (Thr144), based on the rat sequence 
[26].  Phosphorylation of cTnISer43/45 is of interest because heart failure is associated with 
increased phosphorylation of the analogous Ser41 and Ser43 residues in human cTnI [27] [65].  
Increased cTnISer43 and/or cTnISer45 phosphorylation in myocardium also develops with 
cardiac dysfunction caused by pressure overload in rats [29, 30].  In addition, transient increases 
in cTnI Ser43 phosphorylation are observed in a mouse model of myocardial infarction [31].   
Experimental work with PKC-phosphorylated cTnI indicates phosphorylation at these 
residues decreases myofilament Ca2+ sensitivity and peak contractile function.   Biochemical 
studies indicate moderate TnI phosphorylation by PKC  decreases myofilament Ca2+ sensitivity 
and peak actomyosin ATPase [45, 51, 60].  Further phosphorylation by this isozyme significantly 
reduces maximum ATPase activity and dampens the Hill coefficient (nH).   Extraction and 
replacement with cTnI containing phospho-mimetic Glu at cTnISer43/45 produces a similar 
decrease in Ca2+ sensitivity and peak isometric force  as well as peak sliding velocity [68, 81]. In 
a transgenic (tg) mouse model, replacement of wild-type cTnI with phospho-mimetic Asp 
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residues at all 3 PKC-targeted clusters produced a similar shift in peak actomyosin ATPase 
activity[49]. These changes are consistent with the slowed rate of contraction measured in vivo. 
In contrast to this work, studies with phospho-null cTnISer43/45Ala substitutions have 
generated different ideas about the role played by this cluster in modulating myofilament 
function.   In keeping with phosphorylation and phospho-mimetic studies, replacement of wild-
type cTnI with phospho-null Ala substitutions at Ser43/45 blunted the Ca2+ sensitivity shift of 
actomyosin ATPase activity during moderate cTnI-specific phosphorylation by PKC  [61]. 
However, cTnISer43/45Ala also appeared to decrease maximum ATPase and Ca2+ sensitivity 
compared to cTnI under basal conditions.      
The myofilament functional response associated with cTnISer43/45Ala expression could 
significantly influence organ-level function.  However, cardiac performance is not detectably 
different between wild-type littermates and a transgenic (tg) mouse model expressing about 50% 
of total cTnI as cTnISer43/45Ala [82]. Further analysis of cellular function in this model 
indicated there are changes in myofilament function compared to controls [72] [73]. 
Myofilament Ca2+ sensitivity also appeared to decrease relative to wild-type cTnI in a separate 
knock-in mouse expressing cTnI with Ala substitutions in all 3 PKC-targeted clusters  [64].  
Other indices of contractile shortening and the Ca2+ transient remained similar to controls.     
Results from these earlier studies in mouse models indicate this construct may significantly 
impact myofilament function, although it is unclear whether the functional response is caused by 
a direct or adaptive change with cTnISer43/45Ala expression.  While Ala substitutions for Ser 
are favored as a phospho-null substitution due to similarities between these residues, it remains 
unclear whether Ser43/45Ala is a functionally conservative substitution in cTnI.   In the present 
study, recombinant adenoviral-mediated gene transfer of cTnISer43/45Ala is used to evaluate the 
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impact of this substitution mutant on contractile function in isolated myocytes. Experiments also 

























Mutagenesis strategy and adenoviral constructs  
Full-length wild-type rat cTnI cDNA [83] was used to substitute serines 43 and 45 with 
alanines and produce a phospho-null cTnISer43/45Ala using the QuikChange site-directed 
mutagenesis  kit (Invitrogen) [78].  The mutagenesis primers were 5’-
gtctaagatcgccgccgccagaaaacttcag-3’ (sense; mutated residues are shown in bold/underlined) and 
5’ctgaagttttctggcggcggcgatcttagac-3’ (anti-sense), which removed a BglII site from cTnI. The 
cDNA for cTnISer43/45Ala with and without a carboxy-terminal FLAG-tag were then sub-
cloned into the pDC315 shuttle vector [84]. Recombinant adenoviral vectors for each cDNA 
were created by homologous recombination of the shuttle vector with pBHGlox E1,3Cre in 
HEK293 cells. High titer, recombinant adenovirus was generated and the titer was determined by 
plaque assay [85].    
Myocyte isolation and gene transfer  
Myocytes were isolated from adult, female Sprague-Dawley rats (200g) as previously 
described in detail [85]. All animal procedures were approved and performed following the 
guidelines outlined by the University Committee on the Use and Care of Animals at the 
University of Michigan. Briefly, hearts removed from heparinized rats were perfused on a Baker 
perfusion apparatus and digested with collagenase and hyaluronidase.  Isolated, Ca2+-tolerant 
myocytes were plated onto laminin-coated coverslips and cultured in DMEM supplemented with 
5% FBS, penicillin (50 U/ml), and streptomycin (50 g/ml: P/S) at 37°C in a 5% CO2 incubator 
for 2 hrs. Recombinant adenovirus containing cTnI (±FLAG) or cTnISer43/45Ala (±FLAG) was 
diluted in serum-free media and added to myocytes.  One hr later, additional serum-free M199 
media supplemented with P/S was added to each well. Media was changed the next day, and then 
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every other day thereafter for non-paced myocytes.  Other coverslips were transferred into a 
stimulation chamber and paced at 0.2Hz with media changed every 12 hours.   
 Western blot analysis 
 The levels of expression and myofilament replacement for each cTnI substitution 
mutant, myofilament stoichiometry, and cTnI phosphorylation of Ser23/24 were determined via 
Western blot.  Sarcomeric proteins were separated by SDS-PAGE on a 12% acrylamide gel then 
transferred onto PVDF membranes [86].  Membranes were blocked with 5% milk or albumin 
and then probed with primary antibody (Ab), followed by conjugated secondary antibodies 
(Abs).  Primary Abs included an anti-troponin I monoclonal Ab (mAb; 1:4000, MAB1691, 
Millipore), anti-phospho-cTnI Ser23/24 polyclonal Ab (pAb; 1:1000, Cell Signaling), and anti-
troponin T mAb (1:500, Fitzgerald).  Secondary Abs included Alexa-Fluor 680-conjugated goat 
anti-mouse (GAM; 1:25,000, Invitrogen), horseradish peroxidase (HRP)-conjugated GAM 
(1:2000, GAM-HRP, Cell Signaling), and HRP-conjugated goat anti-rabbit (GAR) (1:2000, 
GAR-HRP, Cell Signaling) Abs.  Alexa Fluor-conjugated Ab was detected using an Odyssey 
infrared imaging system, while a BioRad imaging system detected HRP-conjugated Ab using 
enhanced chemiluminescence (ECL, Pierce).  Quantity One software (BioRad) was used for 
quantitative analysis of expression.  Expression of cTnI, Tm or cTnT were normalized to a silver 
(Ag)-stained band on the gel or Sypro-stained band on the blot (cTnI only), and phosphorylation 
of Ser23/24 was normalized to cTnI.  
Immunofluorescence 
 Cellular localization was determined with cTnIFLAG and cTnISer43/45AlaFLAG using 
indirect immunohistochemistry, as previously described [85].  Localization of each construct was 
compared to non-treated controls or cTnIFLAG-expressing myocytes.  Briefly, myocytes were 
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fixed in paraformaldehyde, treated with NH4Cl4 to minimize excess aldehydes, and then blocked 
in phosphate buffered saline (PBS) containing 20% normal goat serum (NGS) plus 0.5% Triton 
X-100.  TnI immunostaining was performed with the anti-troponin I mAb described in the 
Western protocol (1:500), washed and blocked again prior to incubation in secondary GAM Ab 
conjugated to Texas Red (TR) (1:500, Sigma). After blocking with GAM IgG overnight and 
GAM IgG Fab fragments for 1 hr, FLAG-tagged cTnI was detected using anti-FLAG mAb 
(1:500, Invitrogen) and secondary GAM Ab conjugated to fluorescein isothiocyanate (FITC; 
1:500, Invitrogen).  Cells were imaged with a Fluoview 500 laser scanning confocal microscope 
(Olympus) and images were de-convoluted with Autoquant X (Media Cybernetics).  
Phosphorylation detected by radiolabeling in intact myocytes 
  Myofilament proteins in intact myocytes were labeled with [32P]orthophosphate in 
M199 media containing calyculin A (Cal A; 10 nM), as described previously [78].  Radiolabeled 
proteins were separated with 12% SDS-PAGE.  Then, gels were exposed to a phosphorimage 
cassette to detect myofilament protein phosphorylation.   
Sarcomere shortening and calcium transient measurements  
Myocytes were paced at 0.2 Hz starting 24 hrs after isolation and then paced for up to 4 
days after gene transfer.   Resting sarcomere length, peak shortening amplitude (% baseline), 
time to peak (TTP) shortening, and times to 25%, 50%, and 75% re-lengthening (TTR25%, 
TTR50%, and TTR75%) were measured on signal-averaged traces collected with a CCD-camera 
(Ionoptix).  Coverslips with myocytes were perfused in a 37ºC chamber.  For some experiments, 
signal-averaged Ca2+-transient and sarcomere shortening measurements were recorded in 
myocytes loaded with Fura-2AM, as described in detail earlier [86]. Resting and peak Ca2+ 
ratios, the rate of Ca2+ rise and decay within the myocyte, and the times to 25%, 50% and 75% 
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Ca2+-transient decay (TTD25%, TTD50%, TTD75%) were measured 4 days after gene-transfer for 
these studies.  
Isometric force measurements 
 Isometric force was measured in myocytes 4 days after gene transfer, as described earlier 
[87, 88]. Briefly, one end of a myocyte was mounted to a motor (Model 315C, Aurora Scientific) 
and the other end to a force transducer (model 403A, Aurora Scientific) with a resonance 
frequency of 1.1MHz on the stage of a Nikon TS-i Eclipse microscope.  Myocytes attached to 
the force transducer and length controller were incubated in ice-cold high relaxing solution (HR; 
pH 7.0) composed of pCa (-log [Ca2+]) 9.0, 10 mM EGTA, 20 mM Imidazole, 1 mM free Mg2+, 
4 mM free ATP, 14.5 mM creatine phosphate and sufficient KCl to bring the ionic strength to 
180 mM at 15oC.  Myocytes were permeabilized in HR containing 0.1% Triton X-100 and 
sarcomere length was set to 2.0 m. Active isometric tension at each pCa was determined using 
the slack method, with pCa concentrations ranging from 9.0 to 4.5 [87].  Ion concentrations for 
each pCa were calculated using MATLAB, as described earlier [89].  Tension was measured in 
low EGTA-containing relaxing (pCa 9.0) and activating (pCa 4.5) solutions after every two 
measurements in sub-maximal calcium solutions [87].  Each pCa solution was buffered to pH 7.0 
at 15oC and contained Ca2+ ranging from 10-9 to 10-4.5 M, 20 mM Imidizole, 7 mM EGTA, 1 mM 
free Mg2+, 4 mM free ATP, 14.5 mM creatine phosphate along with sufficient KCl to bring the 
ionic strength to 180 mM.    The tension-pCa curve for each group was fitted using the 
Marquardt-Levenburg nonlinear, least squares algorithm for the Hill equation, where P is the 
fractional tension, K is the midpoint or –log [Ca2+] producing 50% peak tension (pCa50) and nH is 




Statistical analysis  
Results are expressed as mean ± SEM.  Myocyte contractile function was analyzed using 
an unpaired Student’s t-test for data collected 2 days after gene transfer.  Protein expression and 
contractile function measured 4 days after gene was analyzed using a one-way analysis of 
variance (ANOVA) and post-hoc Newman-Keuls tests.  Statistical significance was set at p< 





















The initial experiments evaluated sarcomere expression and endogenous cTnI replacement 
with FLAG-tagged versions of cTnI and cTnISer43/45Ala 2 and 4 days after gene transfer.  
Sarcomere incorporation of cTnISer43/45AlaFLAG and cTnIFLAG was comparable over this 
time interval.  A second important component of this study evaluated whether Ala acts as a 
neutral amino acid substitution for cTnISer43/45, meaning Ala is functionally conservative and 
has no impact on contractile function in myocytes.  The results show this substitution produces 
direct, functional changes in contractile performance following extensive cTnISer43/45Ala 
replacement without generating adaptive responses within the myocyte.   
Expression and sarcomeric replacement with cTnI substitution mutants.   
The initial work focused on analyzing expression and sarcomere replacement of 
endogenous cTnI with cTnISer43/45Ala. Western analysis showed both cTnIFLAG and 
cTnISer43/45AlaFLAG replaced endogenous cTnI over time, with 35-45% replacement after 2 
days and 70-80% by day 4 (Figs. 2.1A-C). In myocytes expressing cTnI and cTnISer43/45Ala, 
protein expression was normalized to a band on the silver-stained gel or Sypro-stained blot, 
which indicated replacement with either cTnI construct did not change total cTnI expression 
(Fig. 2.1D).  The expression level of other thin filament proteins such as tropomyosin (Tm, Fig. 
2.1B) and troponin T (TnT; results not shown) also showed preservation of stoichiometry in 
myocytes expressing FLAG-tagged cTnI and cTnISer43/45Ala.  These results are consistent with 
sarcomeric cTnI replacement and maintenance of thin filament stoichiometry reported in earlier 
studies [43, 49, 90, 91]. 
Biochemical studies and indirect immunohistochemistry indicated both constructs are 
incorporated into the sarcomere.  Similar levels of non- and FLAG-tagged cTnI and 
37 
 
cTnISer43/45Ala expression were detected by Western analysis in intact and detergent 
permeabilized myocytes (Fig. 2.2A).  Confocal image analysis of immunostained myocytes 
provided further proof these exogenous cTnIs were incorporated into sarcomeres (Fig. 2.2B).   
The striated staining observed with anti-FLAG Ab overlapped with the sarcomere pattern 
detected with anti-TnI Ab in myocytes expressing cTnIFLAG or cTnISer43/45AlaFLAG (Fig. 
2.2B).     
 Influence of cTnISer43/45Ala on basal contractile performance.   
In the next set of studies, sarcomere shortening and re-lengthening in intact myocytes was 
measured to evaluate the impact of cTnISer43/45Ala expression on contractile function.  There 
were no significant differences in the mechanics and kinetics of shortening and re-lengthening 
between myocytes expressing cTnI versus cTnISer43/45Ala 2 days after gene transfer (Fig. 
2.3A).  Resting sarcomere length, shortening and re-lengthening rate, and time to peak 
shortening (TTP) also were similar in myocytes expressing cTnI or cTnISer43/45Ala compared 
to non-treated controls 4 days after gene transfer (Fig. 2.3B).  However, peak shortening 
amplitude was significantly decreased in myocytes expressing cTnISer43/45Ala compared to 
controls (Fig. 2.3B).   In addition, the time to 50% re-lengthening (TTR50%) was significantly 
accelerated in cTnISer43/45Ala-expressing myocytes compared to myocytes expressing cTnI.  
These results indicate more extensive replacement of endogenous cTnI with cTnISer43/45Ala 
diminished shortening amplitude and accelerated re-lengthening 4 days after gene transfer.   
Isometric tension measurements were performed to determine whether cTnISer43/45Ala 
directly influences myocyte contractile function.  Analysis of the pCa50 derived from the 
tension/pCa relationship indicated cTnISer43/45Ala produced a significant decrease in 
myofilament Ca2+ sensitivity of tension (Fig. 2.3C).  However, similar peak tension values were 
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observed in control, cTnI- and cTnISer43/45Ala-expressing myocytes (controls: 3.48mN±0.51, 
n=10; cTnI: 5.00mN±0.54, n =11; cTnISer43/45Ala: 3.20mN±0.67, n=6). The accelerated re-
lengthening in intact myocytes and rightward shift in Ca2+-activated tension indicate 
cTnISer43/45Ala decreases myofilament Ca2+ sensitivity.  However, the reduction in shortening 
amplitude without peak tension changes may result from adaptive changes within the myocyte.   
 Compensatory adaptations in cardiac myocytes expressing cTnISer43/45Ala. 
 The cellular Ca2+ transient was measured in Fura-2AM-loaded myocytes to determine 
whether direct or adaptive changes contributed to the diminished shortening amplitude in 
myocytes.   In agreement with the earlier results, shortening amplitude in Fura-2AM-loaded 
myocytes remained significantly lower and TTR50% was accelerated in cTnISer43/45Ala-
expressing myocytes relative to cTnI-expressing myocytes (Fig. 2.3; results not shown).  Basal 
and peak Ca2+ ratios were not significantly different between myocytes expressing cTnI versus 
cTnISer43/45Ala (Fig. 2.4).   There was a trend toward accelerated TTD values in Fura-loaded 
myocytes expressing cTnISer43/45Ala, although this change was not statistically different from 
controls (Fig. 2.4).    
The potential for myofilament adaptations to differentially impact peak shortening versus 
tension was evaluated in the next group of studies.  There were no detected differences in 32P 
incorporation into proteins when comparing radiolabeled control and cTnISer43/45Ala-
expressing myocytes (Fig. 2.5A).  Additional work with a cTnISer23/24 specific phospho-Ab 
showed phospho-cTnISer23/24/total cTnI ratios tended to increase in cTnISer43/45Ala-
expressing myocytes but were not significantly different from controls (Fig. 2.5B-C).  The 
absence of change in the Ca2+ transient and myofilament phosphorylation suggest this cTnI 
substitution mutant directly influences cross-bridge cycling rate, but not peak tension. 
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The effects of cTnISer43/45Ala on the contractile response to endothelin-1.   
Introduction of a phospho-null cTnI into the myofilament, such as cTnISer43/45Ala, is 
often used to determine whether specific residue(s) are targeted by kinases such as PKC.  Thus, 
the ability of the endogenous PKC-activating neurohormone, endothelin-1 (ET), to modulate 
contractile function was compared in cTnI- and cTnISer43/45Ala-expressing myocytes.  In 
earlier work, cTnI phosphorylation by ET preserved re-lengthening rate [78].  Studies with a 
cTnISer23/24Ala phospho-null indicated this cluster contributed to re-lengthening rate after 60 
min of ET (10 nM) treatment but had little influence during an acute 15 min treatment with ET. 
In the present studies, ET increased shortening amplitude and accelerated the shortening rate in 
all 3 groups of myocytes, in keeping with the earlier work (Fig. 2.6).  There was a trend for re-
lengthening rate to be slower in cTnISer43/45Ala-expressing myocytes compared to myocytes 
expressing cTnI or cTnIFLAG, although this difference was not statistically significant (Fig. 
2.6).  However, myocytes expressing cTnISer43/45Ala developed a significant increase in the 
time to 75% re-lengthening (TTR75%) compared to control or cTnIFLAG-expressing myocytes.  
This slowed re-lengthening also was matched by a trend toward an accelerated time to peak 
shortening (TTP) with cTnISer43/45Ala, although the ET-induced change in TTP was not 
statistically different from controls.  Taken together, these results suggest the cTnISer43/45 
cluster helps to preserve re-lengthening rate during the ET response.  ET activation of PKC 
presumably phosphorylates this cluster to maintain re-lengthening rate, which is absent from 







The goals of the present study were to determine whether cTnISer43/45Ala is a functionally 
conservative substitution and to identify whether this residue cluster contributes to functional 
responses to the PKC agonist, ET.  Ala substitution for Ser at 43/45 in cTnI is expected to be 
functionally conservative and not diminish the myocyte contractile function response to PKC.  
This substitution mutant has no detectable influence on intact myocyte shortening when it 
replaced less than 50% of endogenous cTnI 2 days after gene transfer (Figs. 2.1, 2.3).  However, 
more extensive sarcomere incorporation of cTnISer43/45Ala by day 4 decreased myofilament 
Ca2+ sensitivity and accelerated re-lengthening, in addition to reducing myocyte shortening 
amplitude under basal conditions (Figs. 2.1-2.3).  Collectively, this work demonstrates Ser 
residues at cTnI43/45 contribute to basal contractile function in the myofilament.  In addition, 
high cTnISer43/45Ala levels slowed re-lengthening in response to the PKC agonist ET compared 
to controls (Fig. 2.6).  These later results are consistent with Ala substitutions at cTnISer43/45 
acting as phospho-null residues during the agonist response and support the idea this cluster 
contributes to PKC agonist-induced modulation of contractile function.  
The functional changes caused by extensive replacement with cTnISer43/45Ala may be 
due to the polar attributes of Ser compared to Ala.  In the x-ray crystal structures for the Tn core 
domain, both cTnISer43 and cTnISer45 reside in an -helical region at the start of the I-T arm 
and are in close proximity to the N-lobe of cardiac troponin C (cTnC) [25]. Kobayashi and 
colleagues suggested cTnISer45 interacts with Glu10 in cTnC and cTnISer45 phosphorylation 
would disrupt this interaction [71]. Introduction of a less polar Ala at this site and at cTnISer43 
also could modify interactions between cTnI and cTnC and lead to the decreased Ca2+ sensitivity 
predicted to result from phosphorylation.  The shift in myofilament Ca2+ sensitivity of tension 
41 
 
and the accelerated TTR50% in intact myocytes (Fig. 2.3B) are consistent with this interpretation.  
My findings also indicate cTnISer43/45Ala may be a useful tool to investigate cTnI residues 
leading into the amino-terminus of the I-T arm (aa 33-45).  This region has the potential to 
interact with multiple domains within cTnI and cTnC, as it traverses the region between the 
amino- and carboxyl- globular TnC domains.   
The results showing a reduction in myofilament Ca2+ sensitivity with cTnISer43/45Ala 
expression are predicted to accelerate relaxation in intact myocytes.  Indeed re-lengthening was 
accelerated in myocytes, although this acceleration was detected midway through re-lengthening 
(Fig. 2.3B).  Diminished myofilament Ca2+ sensitivity also was evident in a cTnIAla5nb mouse 
model expressing cTnI with Ala substitutions at Ser23/24, Ser43/45 and Thr144 [47, 64]. In 
addition, there  was a trend toward reduced myofilament Ca2+ sensitivity in a transgenic mouse 
expressing cTnISer43/45Ala, although the change was not statistically significant [74].  While 
cTnISer43/45Ala replaced about 50% of endogenous cTnI in the transgenic model, expression of 
cTnI-Ala5 on a null background left no endogenous cTnI in these hearts.  Changes in re-
lengthening and Ca2+ sensitivity were detected with more extensive cTnISer43/45Ala 
replacement at day 4 in this study (Fig. 2.3B).  These results, together with findings in mouse 
models suggest extensive cTnISer43/45Ala replacement is required to shift myofilament Ca2+ 
sensitivity.    
Based on earlier work, it was unclear whether peak isometric tension would change in 
myocytes expressing cTnISer43/45Ala compared to controls.  No changes in peak tension are 
observed in the current work, although decreased peak tension is observed in fiber bundles from 
transgenic hearts expressing cTnISer43/45Ala compared to non-transgenic controls [82]. This 
difference is not likely explained by the level of cTnISer43/45Ala expression, as 70-80% 
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replacement is achieved in the present study, which exceeds the ~50% replacement in tg 
myocytes (Fig. 2.1) [82].  Instead, the dissimilar outcomes may be explained by elevated cTnI 
and troponin T (TnT) phosphorylation in the transgenic fiber bundles [72, 74].  There are no 
detectable changes in myofilament phosphorylation compared to control levels in the present 
study (Fig. 2.5).  The reductions in peak tension and sliding velocity observed with a phospho-
mimetic cTnISer43/45Glu during in vitro studies also are consistent with diminished peak 
tension caused by adaptive Tn phosphorylation in the transgenic mouse model [68] [82].  In 
addition, the lack of change in peak tension and myofilament phosphorylation detected in 
myocytes from the cTnIAla5nb mouse are similar to results in the present study (Figs. 2.3, 2.5) 
[47, 64].    
In contrast to peak tension, extensive replacement with cTnISer43/45Ala is associated 
with diminished shortening amplitude in myocytes in the present study (Fig. 2.3).  Changes in 
the amplitude and re-lengthening rate are not observed in myocytes from the cTnIAla5nb mouse 
[47, 64].  The divergent outcomes between the current work and the cTnIAla5nb may be due to 
different experimental conditions, such as pacing frequency, temperature and/or animal model.   
Alternatively, there may be other adaptive differences between the 2 studies, such as changes in 
the Ca2+ transient.  Similar Ca2+ transients are observed in cTnISer43/45Ala and cTnI-expressing 
myocytes for the current study, and it is unclear whether myocytes expressing cTnIAla5nb 
develop differences in the basal Ca2+ transient (Fig. 2.4)[47, 64].  However, cTnISer43/45Ala 
also reduced unloaded peak actomyosin ATPase activity by 50% in biochemical studies [45].  
The later results suggest the Ala substitution may significantly impact unloaded or lightly-loaded 
myofilament cross-bridge cycling.   
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A final component of this study compared the contractile response to the PKC agonist, 
ET in cTnISer43/45Ala and controls.  As anticipated, ET enhanced peak shortening in myocytes 
expressing cTnI or cTnISer43/45Ala (Fig. 2.6).  Earlier work established cellular alkalosis 
produces this enhanced peak shortening response to ET [86, 92].  In contrast, ET accelerated re-
lengthening in controls, as measured by TTR75%, while cTnISer43/45Ala slowed this re-
lengthening response (Fig. 2.6) [86].  This result is consistent with cTnISer43/45Ala acting as a 
phospho-null for Ser43/45 during the ET response, although there are alternative explanations 
for these results.  For example, cTnISer43/45Ala-induced decrease in myofilament Ca2+ 
sensitivity under basal conditions may prevent a further shift in Ca2+ sensitivity during the ET 
response and/or modify the troponin conformation such that it is unable to respond to 
phosphorylation of other target residues.  The current work, along with results obtained in 
several earlier studies, is not able to distinguish between these possibilities [64, 73, 74].  
However, more extensive myofilament phosphorylation appeared to be required to decrease the 
actomyosin ATPase Ca2+ sensitivity in response to PKC in at least one study, which provides 
some support for these alternative possibilities [61]. 
 In conclusion, results from the present study show sarcomeric incorporation of 
cTnISer43/45Ala in myocytes decreases myofilament Ca2+ sensitivity of tension and peak 
shortening amplitude without triggering adaptive changes in the Ca2+ transient or Ser23/24 
phosphorylation within cTnI.   The slowed re-lengthening produced by cTnISer43/45Ala during 
the ET response is consistent with this construct acting as a phospho-null substitution during the 




























































































































Fig. 2.1 Expression of cTnI and cTnISer43/45Ala with and without FLAG 2 and 4 days 
after gene transfer. A. Representative Western blot illustrating cTnI expression in myocytes 2 
and 4 days after adenoviral-mediated gene transfer of cTnI, cTnIFLAG, cTnISer43/45Ala, and 
cTnISer43/45AlaFLAG into adult rat myocytes. B. Representative Western showing cTnI 
expression 4 days after gene transfer of the same recombinant viral constructs listed in A. A 
representative example of tropomyosin (Tm) also is shown in the left panel of B to demonstrate 
maintenance of thin filament stoichiometry. A silver (Ag)-stained portion of the gel is included 
in A (right panel) and B to indicate protein loading. Samples show in the left panel of B were 
separated on the same gel, and the black line between samples indicates separation by additional 
samples. C. Quantitative comparison of endogenous cTnI replacement by cTnIFLAG and 
cTnISer43/45AlaFLAG 2 and 4 days after gene transfer. Results are expressed as FLAG 
expression as a percentage of total TnI expression. D. Quantitative analysis of cTnI 
stoichiometry in myocytes 4 days after gene transfer of cTnI or cTnISer43/45Ala. TnI expression 
is normalized to expression in control myocytes. A one-way ANOVA indicated there were no 
significant differences (*p>0.05) in cTnI expression compared to controls in panel D.  
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Fig. 2.2 Analysis of sarcomere incorporation of cTnI and cTnISer43/45Ala with and 
without FLAG tags. A. A representative Western comparing cTnIFLAG, cTnISer43/45Ala, and 
cTnISer43/45AlaFLAG expression in intact (I) and detergent-permeabilized (P) myocytes 4 days 
after gene transfer. Samples shown were separated on the same gel and the black line between 
samples indicates separation by additional samples. A silver (Ag)-stained portion of the gel is 
shown to indicate protein loading in each lane. There were no detectable differences in the 
expression detected in intact and permeabilized myocytes, which provides evidence of sarcomere 
incorporation for each construct. B. Projection confocal images showing cTnI (left panel) and 
FLAG (middle panel) immunostaining along with the overlay (right panel) for control myocytes 
(top panels) and myocytes expressing cTnIFLAG (middle panels) and cTnISer43/45AlaFLAG 
(lower panel). Dual immunostaining for cTnI and FLAG were detected with TR and FITC, 
respectively, as described in the Methods section. Insets for each myocyte are shown to 
demonstrate a higher resolution striated pattern of immunostaining. These results show 





































































































































































Fig. 2.3.  Cardiac myocyte contractile function 2 and 4 days after gene transfer of cTnI 
constructs.  A. Comparison of sarcomere shortening and re-lengthening measurements in 
control myocytes and myocytes expressing cTnISer43/45Ala 2 days after gene transfer.   An 




Fig 2.3 (cont.) In addition to these measurements, the time to peak (TTP), re-lengthening 
rate, and times to 25% and 75% re-lengthening also were not different between these 2 groups.  
B.  Comparison of cardiac myocyte shortening and re-lengthening 4 days after gene transfer of 
cTnI and cTnISer43/45Ala.  Results were compared using a one-way ANOVA and Newman-
Keuls post-hoc test with p<0.05 (*) considered statistically significant from control values.  
Resting sarcomere length, shortening and re-lengthening rates and TTP were not different in 
controls and myocytes expressing cTnIFLAG or cTnISer43/45Ala.  The shortening amplitude 
decreased and there was an acceleration midway through re-lengthening (TTR50%) detected in 
myocytes expressing cTnISer43/45Ala.  C. Quantification of pCa50 in control myocytes 4 days 
after gene transfer.  Myofilament Ca2+ sensitivity was significantly reduced in cTnISer43/45Ala- 
expressing myocytes versus controls (Control 5.43±0.091, n=10, cTnI 5.43±0.088, n=11 and
cTnISer43/45Ala-expressing myocytes 4.98±0.077, n=6). Statistical differences between the 
pCa50 values were identified using one-way ANOVA and Newman-Keuls post-hoc test with 
































































Fig. 2.4 Comparison of Ca2+-transients in Fura-2AM-loaded myocytes 4 days after gene 
transfer.  Basal and peak Ca2+ levels were similar in control, cTnI-, and cTnISer43/45Ala-
expressing myocytes. The rates of Ca2+ release and decay also were similar among the 3 groups.  
There was a trend toward acceleration of Ca2+ decay, as indicated in the TTD50%, although a one- 






















































Fig. 2.5 Myofilament phosphorylation 4 days after gene transfer. A. Radiolabeling of 
proteins observed after 32P incorporation into control and cTnISer43/45Ala-expressing 
myocytes. B. Representative Western blot showing cTnISer23/24 phosphorylation (top panel), 
cTnI expression (middle panel) and a band on the Sypro-stained blot (lower panel). C. 
Quantitative comparison of cTnISer23/24 phosphorylation in myocytes expressing cTnI. Total 
cTnI was normalized to a quantified band on Sypro-stained blots. A one-way ANOVA and 
Newman-Keuls post-hoc tests showed there was no significant elevation in cTnISer23/24 















































































































Fig. 2.6 Sarcomere shortening and re-lengthening in response to the PKC agonist, 
endothelin-1 (ET, 10 nM). Experiments were performed using control myocytes and myocytes 
expressing cTnIFLAG or cTnISer43/45Ala 4 days after gene transfer. Results are expressed as a 
% change from basal during 15 minutes of ET. A one-way ANOVA analysis and post-hoc 
Neuman-Keuls tests (*p<0.05) showed significant increases in TTR75% for cTnISer43/45Ala-
expressing myocytes compared to controls. This increase indicates a slowing of relaxation in 
myocytes expressing cTnISer43/45Ala and suggests cTnISer43/45 phosphorylation may preserve 
relaxation rate during the ET response. Measurements of times to 25% and 50% re-lengthening 















PHOSPHO-MIMETIC SUBSTITUTION OF CARDIAC TROPONIN I SER43 AND 





Protein kinase C (PKC)-mediated phosphorylation of cardiac troponin I (cTnI) is 
predicted to modulate contractile function in the heart.  PKC targets multiple residues on cTnI 
including serines 43/45 (cTnISer43/45), although the specific modulatory role played by 
cTnISer43/45 phosphorylation is controversial. The goals of the present study are to bridge 
differences between in vitro and in vivo studies by determining the functional impact of 
cTnISer43/45 phosphorylation on intact myocyte function.  Specifically, contractile function in 
intact cardiac myocytes is analyzed after viral-based gene transfer to replace endogenous cTnI 
with phospho-mimetic cTnISer43Asp and/or cTnISer45Asp.  Partial replacement with 
cTnISer43Asp or cTnISer45Asp reduced peak shortening amplitude, while cTnISer45Asp also 
slowed shortening and re-lengthening rates 2 days after gene transfer.  Increased replacement of 
cTnISer43Asp and cTnISer45Asp over 4 days, along with cTnISer43/45Asp, continued to reduce 
peak shortening amplitude. Diminished myofilament Ca2+ sensitivity of tension also is observed 
at the same time point in permeabilized myocytes expressing cTnISer45Asp.  Taken together, 
these results demonstrate cTnISer43 and cTnISer45 independently modulate contractile function.  
Results from intact cells also show the cTnISer43/45 substitutions produce a different functional 
phenotype than cTnISer23/24 phosphorylation, in agreement with in vivo measurements in 
genetic animal models.  In addition, the later phase of shortening and re-lengthening are 
accelerated in myocytes with cTnISer43 and cTnISer45 substitutions at day 4 compared to day 2. 
This finding indicates the onset of an adaptive signaling response. Indeed, significant changes in 
cellular Ca2+ re-uptake and myofilament protein phosphorylation are detected and are consistent 
with the adaptive functional response, which is predicted to help fine tune the influence of PKC-
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Dynamic regulation of myofilament proteins is essential for coordinating cardiac pump 
performance during both systole and diastole. Calcium binding to the thin filament during systole 
initiates the transition of the myofilament to a pressure generating state.   The function of this 
pump is modulated by post-translational phosphorylation of many sarcomeric proteins, such as 
the thin-filament protein cardiac troponin I (cTnI) [3, 4]. Many kinases target cTnI, including the 
Ser/Thr kinase PKC, which phosphorylates 3 cTnI clusters of residues, including Ser23/24 in the 
cardiac-specific N-terminal domain, Ser43/45 in the H1(I) helix, and Thr144 in the inhibitory 
peptide (IP) region [60] [25, 26]. PKC expression and activation increases and cTnI 
phosphorylation patterns are altered in both human and animal models of cardiac dysfunction 
[27] [28-31, 56, 65].  Thus, understanding the precise functional role of each PKC-targeted 
cluster in cTnI will provide insight into their contribution and/or role during cardiac dysfunction 
and the progression to end-stage heart failure.   
Extensive work has focused on the functional impact of cTnISer23/24 phosphorylation.  
In addition to PKC, this cluster is targeted by other kinases in the AGC family, including protein 
kinase A (PKA), protein kinase G (PKG), as well as a member of the Ca2+/calmodulin-dependent 
kinase superfamily, protein kinase D (PKD) [93] [34] [33] [94] [95] [96]. Phosphorylation at 
cTnISer23/24 enhances the Ca2+ dissociation rate from the regulatory site on troponin C (TnC), 
which reduces myofilament Ca2+ sensitivity of tension and actomyosin ATPase activity [42]. In 
the heart, this shift augments cardiac relaxation rate in both in vitro and in vivo systems [49] [43, 
45, 46, 60].  Accelerated relaxation rate helps to preserve diastolic filling time, which is 
particularly important in response to sympathetic stimulation of PKA during the “fight or flight” 
response. A consistent reduction in cTnISer23/24 phosphorylation also develops in both animal 
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and human models of end-stage heart failure, which is postulated to contribute to diastolic 
dysfunction during end-stage heart failure [27] [28-31].  
In contrast, the modulatory role of cTnISer43/45 phosphorylation remains controversial. 
Several earlier studies showed PKC-mediated phosphorylation of cTnI reduced Ca2+ sensitivity 
and maximum MgATPase activity in reconstituted myofilaments , while PKC phosphorylation of 
the myofilament was associated with increased Ca2+ sensitivity in other studies [68] [47, 64, 69] 
[97, 98].  More recent studies examined the impact of cTnI with phospho-null Ala or negatively 
charged Asp/Glu phospho-mimetic substitutions on cTnISer43/45 to determine whether this 
cluster produces and increased or decreased myofilament Ca2+ sensitivity.  Substitution of 
cTnISer43/45 with phospho-mimetic Asp reduced myofilament Ca2+ sensitivity and maximum 
actomyosin ATPase activity while non-phosphorylatable alanine (Ala) attenuated these changes 
[67] [51, 60, 63].  Exchange of endogenous cTnI with a phospho-mimetic cTnISer43/45Glu also 
reduced Ca2+-sensitivity and maximum isometric tension in a permeabilized, multi-cellular 
papillary preparation. Moreover, exchange with cTnISer43/45Glu reduced maximum thin 
filament sliding speed and cooperativity (reduced Hill coefficient [nH]) without altering the Ca2+ 
sensitivity of sliding in motility assays [68].  Based on these in vitro analyses, PKC-mediated 
cTnISer43/45 phosphorylation appears to reduce contractile function, although the changes 
responsible for the divergent PKC-mediated functional responses are not completely understood.    
Further work examined the role of cTnISer43/45 and the other 2 clusters in transgenic 
(tg) mouse models to better understand the role of PKC-mediated cTnI phosphorylation in 
modulating whole heart function.  Full replacement of endogenous cTnI with cTnI containing 
phospho-mimetic Asp substitutions in all 5 PKC-targeted residues (cTnIAllP mouse) reduced 
myofilament Ca2+ sensitivity and maximum values for tension and actomyosin MgATPase 
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activity [49, 75]. These changes are predicted to reduce peak pressure or perhaps accelerate 
relaxation rates.  However, in vivo cardiac function measurements indicated only pressure 
development is slowed in the cTnIAllP mouse heart, without significant changes in peak pressure 
or relaxation rate (dP/dtmin) compared to non-transgenic controls [49].  Replacement of 
cTnISer43/45 and cTnIThr144 with phospho-mimetic Glu (cTnIPKC-P) in approximately 10% of 
the cTnI produced a much different phenotype in a second animal model.  Peak tension 
development decreased in papillary muscles isolated from these mice, without a significant 
change in myofilament Ca2+ sensitivity and/or in peak actomyosin MgATPase activity [62].  
These myofilament alterations were associated with a reduction in peak pressure and slowing of 
relaxation in isolated, perfused hearts [62].  Slowing of cardiac pressure development is the one 
shared component in both cTnIAllP and cTnIPKC-P mice, and yet the difference in the 
cTnISer23/24 substitution between these models is unable to explain the other phenotypic 
differences between these mice. Other explanations for these discrepancies, including the 
contribution of and/or role for adaptive response(s), have not been explored.  Additionally, the 
divergent functional outcomes observed using in vitro versus in vivo approaches in a mouse 
model such as the cTnIAllP mouse make it difficult to determine the direct functional role of 
cTnISer43/45. Based on the current state of understanding, a cellular model combining the 
simplicity of reconstituted myofilaments with the intact cellular environment is expected to 
provide insight into the functional impact of cTnISer43/45 phosphorylation on contractile 
function. 
In addition, it remains unclear whether cTnISer43 or cTnISer45 independently modulate 
contractile function.  Phosphorylation at both cTnISer23 and cTnISer24 is required to reduce 
myofilament Ca2+ sensitivity of force and accelerate muscle relaxation [41] [40, 46]. A single in 
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vitro study examined the role of cTnISer45 alone using a Glu substitution in reconstituted 
actomyosin complexes.  This substitution compromised the ability of Ca2+ to bind to the 
actomyosin complex and diminished Ca2+-activated MgATPase by stabilizing the “inactive” or 
“blocked” state of actin (Fig. 1.2C) [67].  There are no published studies comparing the 
individual impact of cTnISer43 and cTnISer45 on contractile function.    
Experiments in the present study are designed to determine the impact of cTnISer43/45 
phosphorylation on isolated cardiac myocyte contractile function using viral-based gene transfer 
and replacement of endogenous cTnI with cTnI containing phospho-mimetic substitutions at one 
or both of the Ser43/45 residues. This work demonstrates the direct functional response produced 
by cTnISer43/45 substitutions and also allows for testing the hypothesis cTnISer43 and 
cTnISer45 individually influence myofilament function.  Overall, the results are in agreement 
with both earlier in vitro and in vivo work, and thus bridge the gap emerging from studies in less 
versus more complex models.  The outcome of this work also demonstrates the rapid adaptive 
response developed with expression of cTnI containing Ser43/45 phospho-mimetic substitutions.  
Finally, preliminary work is shown to determine whether the increased sarcomeric protein 






Gene transfer and cardiac myocyte isolation 
 Site-directed mutagenesis (QuikChange, Invitrogen) was used to substitute aspartic acid 
(Asp) for cTnISer43 and/or cTnISer45 in full-length, wild-type cTnI cDNA (rat), as described 
previously [83, 85, 99].  The cTnI phospho-mimetic substitutions generated include: 
cTnISer43Asp, cTnISer45Asp, and cTnISer43/45Asp with and without a FLAG tag [99]. The 
primers for site-directed mutagenesis at cTnISer43 were 5’-
atgccaagaaaaagtctaagatcgatgcctccagaaaacttcagttgaag-3’ (sense: mutagenized residues are 
underlined/bolded) and 5’-cttcaactgaagttttctggaggcatcgatcctagactttttcttggcat-3’ (anti-sense), 
which introduced a Hind III site. For cTnISer45Asp, a Cla I site was introduced with a sense 
primer of 5’-gatctccgccgacagaaagcttcagttgaag-3’ and anti-sense primer of 5’-
cttcaactgaagctttctgtcggcggagatc-3’. Phospho-mimetic substitutions were introduced at both 
residues using the sense primer 5’-gccaagaaaaagtctaagatcgatgccgacagaaaacttcag-3’ and the anti-
sense primer 5’-ctgaagttttctgtcggcatcgatcttagactttttcttggc-3’, which also introduced a ClaI site.  
Recombinant adenoviruses were constructed by homologous recombination of the pDC315 
shuttle vector and pBHGLox E1,3Cre (Microbix) in HEK293 cells for each cDNA [85, 100].   
 Myocytes were isolated from adult Sprague Dawley rats (200g; female) as approved by 
and in accordance with the guidelines of the University Committee on the Use and Care of 
Animals at the University of Michigan (UCUCA). The generation of Ca2+-tolerant myocytes was 
described in detail in Ch.2 [85] [99]. After plating the myocytes on laminin-coated coverslips, 
vector-based gene transfer was used to express wild-type cTnI, cTnISer43Asp, cTnISer45Asp, or 
cTnISer43/45Asp with and without a FLAG-tag [99].  For gene transfer into myocytes, 
recombinant adenovirus was diluted in serum-free DMEM containing penicillin (50U/ml) and 
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streptomycin (50 g/ml; P/S) was added to myocytes for 1 hr [99] [85]. Then, M199 media 
supplemented with P/S was added to cells, and media was changed again 24hr later.  Thereafter, 
media was replaced every other day in quiescent myocytes maintained in 6-well plates. Media 
was replaced every 12 hrs in a subset of electrically paced cells stimulated at 0.2 Hz. 
Expression analysis:  Westerns and immunohistochemistry 
 Replacement of endogenous cTnI with FLAG-tagged wild-type cTnI or phospho-mimetic 
substitutions, maintenance of myofilament stoichiometry, and changes in myofilament 
phosphorylation were monitored by Western blot, as described earlier (Ch.2) [99]. Both 
replacement and sarcomere stoichiometry were analyzed 2 and 4 days post-gene transfer.  
Studies to assess changes in myofilament phosphorylation were performed 4 days after gene 
transfer.  For Western analysis, PVDF membranes were probed with the primary and secondary 
antibody pairs shown in Table 3.1, and then proteins were quantified and normalized as 
previously described (Ch.2)[99]. 
  
Table 3.1. Antibodies used for Western blot analysis. The left column lists the primary antibody and the 
corresponding HRP-tagged secondary antibody is listed in the right column. Goat-anti-mouse (GAM), goat-anti-
rabbit(GAR), horseradish-peroxidase (HRP).  Unless otherwise noted, antibodies were obtained from Cell Signaling 
Technology. *Site-specific phospho-cMyBP-C antibodies were a kind gift of Dr. Sadayappan [101].  
Myofilament incorporation of FLAG-tagged wild-type and substituted cTnI were 
visualized via indirect immunofluorescence using dual primary antibodies, as described in detail 
Primary Antibodies Secondary Antibodies
Total troponin I (mAb, 1:4000, MAB1691, Millipore) GAM-HRP (1:2000)
Tropomyosin (mAb, 1:1000, Sigma Aldrich) GAM-HRP (1:2000)
Phospho-cTnI Ser23/24 (pAb, 1:1000) GAR-HRP (1:2000)
Total cMyBP-C (pAb, 1:1000, Santa Cruz Biotechnology) GAR-HRP (1:2000)
Phospho-cMyBP-C Ser273 (pAb, 1:2500)* GAR-HRP (1:2000)
Phospho-cMyBP-C Ser282 (pAb, 1:2500)* GAR-HRP (1:2000)
Phospho-cMyBP-C Ser302 (pAb, 1:5000)* GAR-HRP (1:2000)
Total Phospholamban (pAb: 1:1000, Sigma Aldrich) GAR-HRP (1:2000)
Phospho-phospholamban Ser16 (pAb, 1:1000, Upstate Biologicals) GAR-HRP (1:2000)
Phospho-phospholamban Thr17 (mAb, 1:5000, Badrilla) GAM-HRP (1:2000)
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earlier (Ch.2) [85, 99]. Non-treated and cTnIFLAG-expressing cardiac myocytes served as 
negative and positive controls, respectively. Immunostaining with an anti-cardiac troponin I 
antibody (mAb, 1:500, MAB1691, Millipore) and goat-anti-mouse (GAM)-conjugated 
fluorescein isothiocyanate secondary antibody (1:500, FITC, Sigma) was used to immunostain 
and localize cTnI.  Expression and sarcomere incorporation of exogenous cTnI was examined 
using a primary antibody directed to the FLAG-tag (mAb; 1:500, Invitrogen) followed by a 
GAM secondary antibody conjugated to Texas Red (1:500, TR, Invitrogen). Projection images of 
immunostained myocytes were captured on a Fluoview 500 laser scanning confocal microscope 
(Olympus), and de-convoluted using Autoquant X software (Media Cybernetics).  
Cellular function:  sarcomere shortening, Ca
2+ 
transient and isometric tension  
 Two and 4 days after gene transfer, sarcomere shortening was measured in 0.2Hz-paced 
intact myocytes expressing cTnISer43Asp, cTnISer45Asp, or cTnISer43/45Asp and compared to 
control myocytes and myocytes expressing wild-type cTnI (Ch.2) [86, 99, 102]. Signal-averaged 
traces collected using a CCD camera system (Ionoptix) were analyzed for changes in resting 
sarcomere length, peak amplitude (% baseline), time to peak (TTP), shortening and re-
lengthening rates, time to re-lengthening25% (TTR25%), time to re-lengthening50% (TTR50%), and 
time to re-lengthening (TTR75%).  In separate studies, the Ca2+-transient and sarcomere 
shortening were recorded in a subset of chronically paced myocytes loaded with Fura-2AM 2 
and 4 days after gene transfer [86] [99, 103].  In these myocytes, resting and peak Ca2+-ratios, 
rates of Ca2+ rise and decay, and the time to decay25%, 50%, 75% (TTD25%, TTD50%, and TTD75%, 
respectively) were determined from signal-averaged traces as described earlier (Ch.2) [99] [86].  
Isometric tension was measured in myocytes 4 days after gene transfer to evaluate the 
effects of cTnISer43/45 phospho-mimetic substitution on myofilament Ca2+ sensitivity and peak 
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tension. Individual myocytes were mounted to a piezoelectric motor (Model 315C, Aurora 
Scientific) on one end and a force transducer (Model 403A, 600Hz resonance frequency, Aurora 
Scientific) on the other end, and then sarcomere length was set to either 2.0 m or 2.3 m in high 
relaxing (HR; pH 7.0) solution [87, 99]. Cells were permeabilized in (HR) solution containing 
0.1% Triton X-100 (Ch. 2), and active tension was measured over Ca2+ (pCa = -log [Ca2+]) 
ranging from pCa 9.0 to 4.5 using the slack test approach (20% of original length [Lo]) (Ch.2) 
[87-89, 99]. Resting (pCa 9.0) and maximum tension (pCa 4.5) were recorded after each pair of 
sub-maximal pCa solutions to determine total and resting tension, respectively (Ch. 2). Tension-
pCa curves were generated for control, wild-type cTnI, and cTnISer45Asp-expressing myocytes 
and fitted using the Marquardt-Levenburg non-linear, least squares algorithm for the Hill 
equation (SigmaPlot). For this algorithm, P equals the fractional tension, K is equal to the pCa50, 
and nH is the Hill coefficient in the following equation:    P = [Ca2+]nH/(KnH+[Ca2+]nH) 
Phosphorylation assays 
Myocytes cultured for 4 days after gene transfer were treated with kinase and 
phosphatase inhibitors using the agonists/inhibitors shown in Table 3.2. Inhibitors were diluted 
in M199 media and applied to cells for 10min-2hr. Cells were incubated in a 37°C water-
jacketed incubator. A second set of cells was treated with DMSO (1%) diluted in media or M199 
alone to serve as a control for the assay conditions. After inhibitor treatment, Myocytes were 
collected into ice-cold sample buffer and stored at -80ºC immediately after the incubation with 
inhibitors/agonists was completed. Myofilament proteins were separated by SDS-PAGE and 







Targeted Concentration Dilution Method Supplier 
H89 Protein Kinase A 1 M dH20 Sigma-Aldrich 
kb-NB-142-70 Protein Kinase D 10 M DMSO Tocris 
Calyculin A Protein Phosphatases 10nM Ethanol CalBiochem 
Table 3.2. Kinase and phosphatase inhibitor utilized for phosphorylation assays. Table lists the agonist or 
inhibitor used, its target, the concentration used, and the vehicle used for dilution.  
Data analysis and statistics 
 Data are presented as the mean ± SEM. Each data set is analyzed by one-way analysis of 
variance (ANOVA) followed by a Newman-Keuls post-hoc test unless otherwise noted. Results 





Myofilament expression of cTnISer43/45 phospho-mimetic substitutions  
 Gene transfer of FLAG-tagged wild-type cTnI, cTnISer43Asp, cTnISer45Asp and 
cTnISer43/45Asp increasingly replaced endogenous cTnI over time (Fig. 3.1A,B). Each 
construct replaced 35-45% of endogenous cTnI by day 2, and replacement increased to 65-85% 
by day 4, in agreement with earlier work (Fig. 3.1B) [78, 86, 99]. Total cTnI protein expression 
levels remained comparable to controls for each of the constructs (Fig. 3.1C). Western analysis 
and quantitation of tropomyosin (Tm) expression also indicated thin filament stoichiometry 
remained unchanged in myocytes expressing each of the cTnI phospho-mimetic substitutions  
(Fig. 3.1C). Immunohistochemical staining with cTnI and FLAG primary mAbs in myocytes 
expressing either FLAG-tagged wild-type cTnI or cTnISer43/45 phospho-mimetic substitutions 
show co-staining of these antibodies in a pattern consistent with sarcomere localization (Fig. 3.2) 
[99].  
Influence of cTnISer43/45 substitutions on myofilament function 
 Sarcomere shortening and re-lengthening measurements in intact myocytes determined 
phospho-mimetic cTnISer43 or cTnISer45 replacement significantly diminished peak shortening 
amplitude 2 days after gene transfer without changing resting sarcomere length (Fig. 3.3). Peak 
shortening amplitude tended to decrease in cTnISer43/45Asp-expressing myocytes, but this 
change was not yet statistically different at this time point.  Partial replacement of endogenous 
cTnI with cTnISer45Asp slowed the shortening rate and re-lengthening rate.  Both 
cTnISer43Asp and cTnISer43/45Asp also tended to slow myocyte shortening and re-
lengthening, but the reduction produced by either construct was not significantly different from 
controls at day 2 (Fig. 3.3). All other indices of sarcomeric shortening and re-lengthening also 
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remained unchanged from controls (Fig. 3.3). These results demonstrate partial myofilament 
replacement with cTnISer43Asp or cTnISer45Asp independently modulates contractile 
performance. The relatively enhanced ability of phospho-mimetic replacement at cTnISer45 to 
modulate shortening and re-lengthening rates also suggests this residue dominantly modulates 
contractile function. However, the preserved peak shortening amplitude in myocytes expressing 
cTnISer43/45Asp suggests the individual residues modulate myofilament contractile 
performance through separate mechanisms.  
 Four days after gene transfer, cTnISer43Asp, cTnISer45Asp, and cTnISer43/45Asp each 
diminished peak shortening amplitude to a similar degree as the individual cTnISer45Asp 
substitutions at day 2 (Figs. 3.3, 3.4A).  The reduced peak shortening amplitude was not 
accompanied by a change in resting sarcomere length for any of the cTnISer43/45 phospho-
mimetic constructs. In contrast to day 2, the shortening rate in myocytes expressing 
cTnISer45Asp returned to control levels while cTnISer43Asp reduced shortening rate (Fig. 3.3 
vs. Fig.3.4). Moreover, the time to peak (TTP) shortening is significantly reduced in myocytes 
expressing cTnISer43Asp or cTnISer45Asp compared to controls 4 days after gene transfer (Fig. 
3.4A). An accelerated TTP is consistent with the return of shortening rate toward control values 
in myocytes expressing cTnISer45Asp but is incongruent with the continued slowing of 
shortening produced by cTnISer43Asp expression (Fig 3.4A).  The re-lengthening rate in 
cTnISer45Asp-expressing myocytes also returned toward to control values, though the time to 
re-lengthening 50% (TTR50%) did not differ from controls (Fig. 3.4A). The functional results 
obtained 4 days after gene transfer support the conclusion cTnISer43 and cTnISer45 
independently modulate contractile function.  In addition, an acceleration of TTP in the presence 
of a slowed shortening rate, observed in myocytes expressing cTnISer43Asp, provides evidence 
65 
 
adaptations develop in isolated myocytes with increased cTnISer43/45 phospho-mimetic 
replacement. The restoration of shortening and re-lengthening rate in myocytes expressing 
cTnISer45Asp supports this hypothesis.  
Based on work in animal models expressing cTnI with phospho-mimetic replacements at 
cTnISer43/45, the shortening/re-lengthening responses observed in the present study are 
expected if cTnISer43/45 substitutions reduce myofilament Ca2+ sensitivity of tension (pCa50) 
(Fig. 3.4B) [49, 62].  Therefore, the impact of the cTnISer45Asp substitution on isometric 
tension generation in permeabilized myocytes was measured over a range of Ca2+ concentrations 
(pCa) 4-5 days after gene transfer. The cTnISer45Asp construct was selected for analysis 
because it exerted the greatest impact on peak shortening amplitude 2 days post-gene transfer 
(Fig. 3.3).  The tension-pCa relationship remained comparable among control, wild-type cTnI, 
and cTnISer45Asp-expressing myocytes at a sarcomere length of 2.0 m (Fig. 3.4B). In earlier 
work, cTnISer43/45Glu exchanged into permeabilized papillary muscles reduced pCa50 and peak 
tension, but measurements were performed at a sarcomere length of 2.3 m [68]. Thus, tension 
measurements were repeated at the same sarcomere length, and a reduction in pCa50 is observed 
at this longer length in myocytes expressing cTnISer45Asp compared to controls or myocytes 
expressing wild-type cTnI (Fig. 3.4B). In contrast to the earlier findings, peak tension remained 
comparable to controls in myocytes expressing cTnISer45Asp at either sarcomere length. Based 
on these findings, the reduction in maximum tension observed with cTnISer43/45Glu is either 
mediated via cTnISer43 and/or could depend on other differences in the experimental approach. 
However, the observed reduction in myofilament Ca2+ sensitivity in myocytes expressing 
cTnISer45Asp agrees with previous work and may contribute to the restored re-lengthening 





 cycling and myofilament phosphorylation with cTnISer43/45 substitutions  
The restored shortening rate, restored re-lengthening rate, and accelerated TTP observed at 
day 4 indicates the onset of adaptive responses as cTnISer43/45 phospho-mimetic substitutions 
increasingly replace endogenous cTnI. One cellular adaptation that can modulate cardiomyocyte 
shortening and re-lengthening is altered Ca2+ cycling. Thus, Ca2+ transients were measured in 
Fura-2AM-loaded myocytes 2 and 4 days post-gene transfer (Figs. 3.5, 3.6).  There were no 
significant changes to the basal Ca2+ transient measured in myocytes expressing any of the cTnI 
phospho-mimetics at day 2 compared to control levels (Fig. 3.5). Additionally, the contractile 
response was comparable to non-Fura-treated myocytes 2 days after gene transfer (Fig. 3.3 vs. 
Fig. 3.5). In contrast, adaptations in the Ca2+ transient are detected 4 days after gene transfer of 
the cTnI phospho-mimetic substitutions (Fig. 3.6). In these cells, the TTR50% was significantly 
faster than controls after extensive cTnISer45Asp replacement and was accompanied by a faster 
TTD50% for Ca2+ in all myocytes, including wild-type cTnI (Fig. 3.6). Additionally, basal Ca2+ 
levels increased in both wild-type cTnI and cTnISer43/45Asp-expressing myocytes 4 days after 
gene transfer. However, this increase did not impair peak Ca2+ levels in these myocytes.  In 
contrast, cTnI phospho-mimetic substitutions on one or both cTnISer43/45 residues reduced peak 
shortening, although the Ca2+ transient amplitude remained comparable to controls. No other 
alterations to Ca2+ handling were noted in these studies. Overall, cTnISer43Asp or cTnISer45Asp 
appear to directly modulate contractile function 2 days after gene transfer. The alterations in 
baseline Ca2+ and TTD50% observed after 4 days are consistent with a modest adaptive response 
in the Ca2+ cycling pathway. 
While altered Ca2+ handling could restore or maintain re-lengthening rate in myocytes 
expressing cTnISer43/45 phospho-mimetic substitutions, the adaptations contributing to the 
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restored shortening rate are unclear.  Basal shortening measurements indicate adaptive changes 
in the regulation of thin filament function could also contribute to the differences in myocyte 
contraction observed at 2 versus 4 days. Thus, representative sarcomeric proteins likely to 
contribute to the adaptive response were examined by comparing the phospho-to-total protein 
ratios detected using Western analysis in controls and myocytes expressing each of the phospho-
mimetic cTnI substitutions.  Additional phosphorylation sites within cTnI, cMyBP-C, and PLB 
were examined to assess adaptive signaling. 
 Altered phosphorylation in the un-modified, PKC-targeted Ser23/24 cTnI residues was 
determined using site-specific phospho-antibodies (Fig 3.7). In previous studies, cardiac specific 
expression of cTnISer23/24Asp reduces myofilament Ca2+ sensitivity of tension and accelerates 
in vivo dP/dtmin [43]. Indeed, elevated phosphorylation of cTnISer23/24 develops in myocytes 
expressing cTnISer43Asp or cTnISer45Asp 4 days after gene transfer compared to controls (Fig 
3.7A). Phosphorylation also tended to increase with cTnISer43/45Asp expression but did not 
reach statistical significance (Fig.3.7A). Expression of all 3 cTnISer43/45 phospho-mimetic 
substitutions also increased phosphorylation of cTnIThr144, but adaptive phosphorylation of this 
residue was not significantly increased in myocytes studied here (Fig. 3.7B). The cTnIThr144 
phospho-mimetic cTnIThr144Glu reduces the Ca2+ sensitivity of cross-bridge cycling in in vitro 
motility assays but did not alter tension generation [68]. Interestingly, cTnISer43Asp alone 
elevated cTnIThr144 phosphorylation to the greatest extent while the effects of cTnISer45Asp or 
cTnISer43/45Asp expression were not as pronounced (Fig. 3.7B).  These results demonstrate 
phospho-mimetic substitutions at Ser43 and Ser45 clearly enhance phosphorylation of other cTnI 
sites, although the communication is dependent on the substitution site. The adaptive 
cTnISer23/24 phosphorylation produced by increased cTnISer43/45 phospho-mimetic 
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replacement likely aids in maintaining myocyte re-lengthening rate but is not expected to 
modulate cellular shortening rates.  
 Additional sarcomeric modifications could also play a role in the adaptive response.  
Because of its ability to increase cross-bridge cycling rates in response to an altered 
phosphorylation state, cMyBP-C phosphorylation was examined using site-specific phospho-
antibodies individually directed to 3 well-characterized target residues within its cardiac-specific 
m-motif: pSer273, pSer282, and pSer302 (Fig. 3.8) [16, 101]. Interestingly, only phosphorylation 
at cMyBP-CpSer282 was significantly increased by expression of the 3 phospho-mimetic cTnI 
substitutions compared to controls. Phosphorylation of cMyBP-CpSer273 was highly variable in 
these same myocytes, but not statistically different from controls.  There was less variable 
phosphorylation at the cMyBP-CSer302 residue, and the phosphorylation state did not differ 
from controls in myocytes expressing cTnISer43Asp and/or cTnISer45Asp. The present results 
show the augmented cMyBP-CSer282 phosphorylation is consistent with the restored/maintained 
shortening in myocytes expressing phospho-mimetic cTnISer43/45 substitutions.  
The influences of cTnI phospho-mimetics on contractile protein phosphorylation cannot 
account for the accelerated Ca2+ decay (Fig. 3.6).  Thus, studies also examined phospholamban 
(PLB) phosphorylation, which modulates sarcoplasmic reticulum (SR) Ca2+ uptake by the 
SERCA2A pump.  PLB is targeted by multiple kinases including protein kinase A (PKA) at 
Ser16 and Ca2+/Calmodulin-dependent protein kinase C (CaMKII) at Thr17 [104] .  
Phosphorylated PLB accelerates removal of Ca2+ from the cytosol into the SR, which could 
produce the accelerated TTD50% (Fig. 3.6). PLB phosphorylation at the PKA-targeted residue 
Ser16 tended to increase in myocytes with >50% replacement by cTnISer43/45 phospho-mimetic 
substitutions, though this increase did not reach statistical significance (Fig. 3.9). However, 
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expression of these cTnI substitutions did not generate significant alterations in PLBThr17 
phosphorylation (Fig. 3.9). Based on these findings, increased replacement with cTnISer43/45 
phospho-mimetics enhances Ser16 phosphorylation on PLB, which could produce the 
accelerated Ca2+ TTD50%. Overall, enhanced phosphorylation both within cTnI as well as 
additional myofilament and Ca2+-handling proteins result from the presence of negative charges 
at cTnISer43/45.  These adaptive changes modulate cross-bridge cycling and Ca2+ cycling and 
likely contribute to the return of shortening and re-lengthening rates toward controls values in 





The present experiments demonstrate cTnISer43 and cTnISer45 independently modulate 
contractile function (Fig. 3.3-3.6).  My studies also provide evidence the two residues may work 
against each other within the same cTnI to prevent changes in function, at least at low levels of 
expression (Fig. 3.3).  In addition, the differences in function observed 2 and 4 days after gene 
transfer of cTnI with phospho-mimetic substitutions at Ser43 and/or Ser45 led me to examine the 
development of  signaling adaptations mediated via post-translational modifications of 
myofilament and Ca2+ cycling proteins (Figs.3.7-3.9).  Finally, the present set of experiments 
demonstrate the cellular analysis of cTnISer43/45 serves as a bridge for understanding both  in 
vitro and in vivo studies on cTnISer43/45 phosphorylation.   
Prior to these studies, it remained unclear whether the cTnISer43/45 cluster was similar 
to cTnISer23/24 phosphorylation, which requires phosphorylation of both residues to  produce a 
functional response [40, 41].  These  results show partial replacement of endogenous cTnI with 
either cTnISer43Asp or cTnISer45Asp is sufficient to diminish peak shortening amplitude (Figs. 
3.1-3.3).  The inability of low level cTnISer43/45Asp expression to change cell shortening 
suggests these individual residues may work to counter the actions of the other residue (Fig. 3.3). 
However, the potential for one residue to counteract the other is expression-level dependent, as 
more extensive cTnISer43/45Asp expression is capable of reducing peak shortening amplitude 
(Fig. 3.4A).  
The independent mechanisms employed by cTnISer43 and cTnISer45 in cTnI to modify 
function may result from their positioning on different faces of the H1(I) helix in the IT arm of 
cTnI, which may lead to different interactions with residues in cTnC and cTnI and/or overall 
positioning of the H1 -helix (Fig. 1.2A). Specifically, cTnISer45 is predicted to make critical 
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contacts with both the Ca2+ binding N-lobe and the structural C-lobe of TnC. My results indicate 
cTnISer45 exerts the most dramatic influence on shortening amplitude and the rates of 
shortening and re-lengthening, which may be due to interactions with both lobes of cTnC 
(Figs.1.2A, 3.3, 3.4A)[70] [71] [25]. In contrast, the positioning of cTnISer43 at the very 
beginning of the H1 -helix may influence up- or down-stream cTnI residues and have less 
direct impact on the cTnC N- or C-lobes [25].  If one or more of these predictions are correct, 
one of these Ser residues could counteract and/or attenuate the conformational change(s) 
necessary for the other residue to change contractile function when combined in the same cTnI 
(e.g. cTnISer43/45Asp).  
Multiple mechanisms are proposed to contribute to the reduction in peak shortening 
produced by phospho-mimetic substitutions at cTnISer43/45.  The rightward shift in 
myofilament Ca2+ sensitivity produced by cTnISer23/24 phosphorylation translates into an 
acceleration of cardiac relaxation in the intact myocyte or heart [43, 46] [49] [42]. While 
cTnISer43/45 phosphorylation could produce the same effect, it is not observed in the current 
studies  (Figs. 3.3, 3.4).  Recently, separate mutations within TnC differentially affected the on 
rate (e.g. affinity) and off rate (e.g. dissociation) of TnC binding to Ca2+, with a similar impact 
on myofilament Ca2+ sensitivity [105]. This idea clearly applies to the influence of cTnISer23/24 
and cTnISer43/45 phosphorylation on function.  The slowed shortening rate observed in 
myocytes expressing cTnISer43/45Asp substitutions, and the amplified influence of 
cTnISer43/45Asp substitutions on both shortening rate and peak shortening in the presence of 
Ca2+-buffering Fura-2AM support the idea these functional changes result from slowed Ca2+ 
binding to TnC (Figs. 3.3-3.6). The slowing of loaded shortening velocity in permeabilized 
preparations, and the significant slowing of in vivo pressure development observed in hearts from 
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both cTnIAllP and cTnIPKC-P mouse models provide further support for this mechanism [75] [49] 
[62].  Moreover, reductions in the  Ca2+ association constant (Ka) and actomyosin ATPase 
activity are observed in biochemical studies using cTnISer45Glu, which is predicted to result 
from the a reduced interaction with Glu10 in the N-lobe of TnC [67, 71]. Overall, the lack of 
change in maximum tension is consistent with the observed ability of cTnISer45Glu to slow Ca2+ 
binding kinetics to cTnC, without this cluster causing cTnI to interfere with maximal steady state 
Ca2+ binding to cTnC [67].   
Morimoto et al. proposed another possibile mechanism by suggesting cTnISer43/45 
phosphorylation destabilizes the interaction between cTnI and the C-lobe of TnC to diminish 
myofilament activation [106].  This group predicted destabilization limits the ability to shift 
tropomyosin (Tm) away from the cross-bridge binding site on actin [68, 106]. A NMR analysis 
of  cTnC-cTnI after cTnISer43/45 phosphorylation also indicated destabilization of the C-lobe of 
TnC [70].  However, the results indicate this possibility is unlikely to be a mechanism 
contributing to the functional response in the intact myofilament, as destabilization also should 
reduce maximum isometric tension production, which is not observed with cTnISer45Asp (Figs. 
3.4B).  Phosphorylation or phospho-mimetic substitutions at cTnISer43/45 have variously 
reduced or had no impact on maximum isometric tension production (Figs. 3.4B) [68] [62, 79, 
80]. Collectively, this differential impact of phospho-mimetic residues suggests the residue 
selected (i.e. Glu versus Asp) may affect the functional phenotype.  Alternatively, the 
preparation utilized for the experiment (papillary fibers vs. myocytes) may contribute to a 
differential impact on maximal tension [62, 68] [49] [79] [80]. However, in either case, it is 
unclear how cTnISer43/45-induced destabilization of the C-lobe could explain the observed 
functional changes.   
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The  reduced Ca2+ association to TnC also cannot easily explain the slowed re-lengthening 
rate observed in myocytes expressing cTnISer43/45 phospho-mimetics (Figs 3.3, 3.5,3.6).  
Instead, a slowing of cross-bridge detachment from the thin filament is proposed as an 
alternative mechanism, which would  contribute to the diminished peak shortening and slowing 
of re-lengthening rate observed in the present study (Figs. 3.3-3.4) [68]. The reduced binding 
affinity of S-1 myosin observed with cTnI phosphorylated at cTnISer43/45, decreases in thin 
filament sliding (Vmax) and Ca2+ senstivity of sliding produced by cTnISer43/45Glu, and slowed 
actomyosin ATPase activity over a range of tension in PKC-treated cardiac fiber bundles  are 
each consistent with prolonged cross-bridge displacement [45] [68] [74]. Hearts isolated from 
cTnIPKC-P mice develop slowed ventricular relaxation, although slowed relaxation is not evidence 
in PKCAllP mouse hearts [62] [49]. The exact mechanism responsible for slowing cross-bridge 
detachment is not known, but presumably could be mediated via changes in the stiffness of the 
cTn I-T arm (Figure 1.2A).  Previous work also established unloaded shortening velocity is not 
dependent on cross-bridge binding, and therefore, this mechanism is not expected to contribute 
to the slowed rate of shortening (Figs. 3.3, 3.4) [107] [68] [108] . Thus, the results are consistent 
with a dual role for cTnISer43/45 to reduce Ca2+ binding affinity to cTnC and slow cross-bridge 
detachment rate.   
In addition to the direct influence of cTnISer43/45 phosphomimetic expression, adaptive 
signaling in intact myocytes was examined in this set of experiments. Previously, replacement of 
endogenous cTnI with cTnISer43/45Ala in a tg mouse model increased cTnISer23/24 
phosphorylation, indicating load-dependent adaptive signaling may occur in the heart [72]. 
Compensatory signaling has not been detected in mouse models expressing cTnI with phospho-
mimetic substitutions [62] [49].  However, my results demonstrate several adaptations are 
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detected in both Ca2+ cycling and sarcomeric protein phosphorylation, which are expected to 
preserve myocyte contractile function (Figs. 3.7-3.9).  Specifically, the faster cytosolic Ca2+ 
decay and  increased PLBSer16 phosphorylation are consistent with the return of re-lengthening 
rate in myocytes expressing cTnISer45Asp toward control values on day 4 (Fig. 3.4, 3.9). In 
addition, the heightened cTnISer23/24 phosphorylation observed with Asp substitutions at 
cTnISer43 and cTnISer 45 is expected to increase Ca2+ dissociation from cTnC and work to 
restore cTnISer43/45Asp-induced slowing of re-lengthening rates back toward control values 
(Fig. 3.7) [42] [43] [40]. The present results also show augmented cMyBP-CSer282 
phosphorylation at day 4 in myocytes expressing all 3 phospho-mimetic substitutions, which is 
expected to accelerate cross-bridge cycling [16, 109, 110].  This adaptation could help restore the 
slowed shortening rate, as observed at day 4 in the current studies (Fig. 3.4). 
In preliminary work, the mechanism for the adaptive increase in cTnISer23/24 
phosphorylation is examined and this data is consistent with a contribution of the stress-activated 
kinase PKD, but not PKA (Figs. 3.10A-B).  However, further work is necessary to prove this 
point, as there was inadequate power for the statistical comparison.  Additional work also is 
needed to determine if other stress-activated kinases, such as PKC or PKG, contribute to this 
adaptive signaling response [93, 94] [111]  [112] [26, 33, 45, 95, 96, 113]. The present studies 
demonstrated phosphatase inhibition may be another contributor to the adaptive signaling 
response.  The change in phosphorylation at cTnISer23/24 (  phospho-ratio) was greater in control 
and cTnI-expressing myocytes following phosphatase inhibition with Cal A, suggesting 
phosphatase activity is already reduced by cTnISer43/45 substitution (Fig. 3.10C). As with the 
PKD study, more work is needed to achieve adequate power for statistical comparisons.  There is a 
growing recognition destabilization of the balance between kinase and phosphatase activity may 
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play a key role in the transition to cardiac dysfunction [102, 114, 115]. An important remaining 
question is whether this adaptive signaling is maintained over time and/or continues to be present 
under pathophysiological conditions associated with heart failure.  
 The adaptive changes here also could contribute to the cardiac phenotype in intact animal 
models expressing cTnI with phospho-mimetic substitutions at cTnISer43/45.  Both the Ca2+ 
cycling and cTnISer23/24 phosphorylation adaptations are expected to preserve diastolic function 
in the intact heart.  While adaptive signaling in the cTnIAllP mouse model was not detectable, these 
adaptations could account for the comparable relaxation rates (dP/dtmin) observed in cTnIAllP mouse 
hearts compared to non-transgenic controls [49]. Alternatively, the response in isolated myocytes 
measured over several days may be absent and/or different from the adaptations detected in 
hemodynamic measurements made in the cTnIAllP mice [49].  The depressed relaxation rate and 
lack of adaptations in Ca2+ handling and protein phosphorylation suggests adaptations may not 
develop with low-level expression, such as the cTnIPKC-P mouse model expressing 
cTnISer43/45GluThr144Glu [62].    
In summary, the results provide insight into the modulatory role of cTnISer43/45 
phosphorylation on cardiac myocyte contractile performance.  In contrast to cTnISer23/24, 
cTnISer43 and cTnISer45 independently modulate contraction.  Importantly, these studies, 
together with earlier work, also demonstrate cTnISer43/45 acts via a separate mechanism than 
cTnISer23/24. Overall, cTnISer43/45 acts as a molecular brake on cardiac contraction in intact 
myocytes, in keeping with the in vitro ability of this cluster to slow Ca2+ binding to TnC and 
cross-bridge dissociation from the myofilament. The adaptive Ca2+ cycling and sarcomeric 
protein phosphorylation observed here also indicates mechanisms are in place to further fine tune 
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the brake.  Finally, results from the present study also effectively bridge the gap between in vitro 
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Day 2 Day 4
Fig. 3.1 Expression of cTnISer43/45 phospho-mimetic substitutions with and without 
FLAG 2 and 4 days after gene transfer. A. Representative Western blot showing 
expression of cTnI (±FLAG), cTnISer43Asp(±FLAG), cTnISer45Asp(±FLAG), or 
cTnISer43/45Asp (±FLAG) 2 (left column) and 4 (right column) days after gene transfer. 
Blots probed for total cTnI (top panel) and total Tm (middle panel) show maintenance of 
thin filament stoichiometry. A section of silver (Ag) -stained gel illustrates protein loading 




Fig. 3.1 Expression of cTnISer43/45 phospho-mimetic substitutions with and without 
FLAG 2 and 4 days after gene transfer (cont.). B. Quantitative analysis of percent 
replacement (%) for each cTnI phospho-mimetic substitution at 2 (left section) and 4 (right 
section) days after gene transfer. Replacement is calculated from the ratio of cTnIFLAG /total 
cTnI x100 for each cTnI construct.  C. Quantitative analysis of thin filament stoichiometry 2 and 
4 days after adenoviral-mediated gene transfer. Stoichiometry was calculated from the ratio of 
total cTnI/Tropomyosin (Tm) protein expression for each cTnI substitution and normalized to the 
control ratio. Results were analyzed via one-way ANOVA with p<0.05* considered statistically 













Fig. 3.2 Sarcomeric localization of cTnI and cTnISer43/45 phospho-mimetic substitutions. 
Dual immunostaining with monoclonal antibodies determined myofilament incorporation of 
FLAG-tagged phospho-mimetic substitutions. Staining with a troponin (Tn)-specific antibody 
was detected with a secondary antibody conjugated to fluorescein isothiocyanate (FITC; left 
panels). A second primary antibody directed to FLAG was detected with a secondary antibody 
conjugated to Texas Red (TR; center panels). Overlays of the projection confocal images are 
included to show co-localization of FLAG-tagged cTnI phospho-mimetic substitutions and 
endogenous troponin I (TnI) (yellow; right panels). An insert is provided for controls, 
cTnIFLAG, and each FLAG-tagged cTnI phospho-mimetic substitution shows a magnified 
section of the myocyte to demonstrate the striated pattern of phospho-mimetic expression in the 
myofilament. Bars in each panel represent 10µm, except for the bar in the cTnISer45Asp panel 





















































































































Fig. 3.3. Basal cardiac shortening and re-lengthening 2 days after gene transfer.  
Sarcomeric shortening was measured in control myocytes and myocytes expressing wild-type 
cTnI, cTnIFLAG, cTnISer43Asp, cTnISer45Asp, and cTnISer43/45Asp. For these 
studies, measurements from myocytes expressing wild-type cTnI and cTnIFLAG were 
not significantly different and were pooled into a single group designated as 
“cTnI±FLAG”. Contractile function was evaluated using measurements of resting sarcomere length, 
peak shortening amplitude (% basal), shortening and re-lengthening rates, TTP, and  
TTR50% .  A p<0.05(*) was considered significantly different from control. p<0.05(^) 















































































































































































Fig. 3.4. Sarcomeric shortening 4 days after gene transfer of cTnISer43/45 
phospho-mimetic substitutions. A. Basal sarcomeric shortening measurements after 
increased replacement of endogenous cTnI by cTnISer43/45Asp phosphomimetics. 
Resting sarcomere length, peak shortening amplitude (% basal), shortening and re-lengthening 
rates, TTP, and TTR50% were quantified for controls and wild-type cTnI- 
expressing myocytes and compared to myocytes expressing cTnISer43Asp, 
cTnISer45Asp, and cTnISer43/45Asp. Data was analyzed with a 1-way ANOVA and post-hoc tests, as 
described in the Methods section, with * indicating p<0.05 versus control and ^ for p<0.05 compared to 




Fig. 3.4 Sarcomeric shortening 4 days after gene transfer of cTnISer43/45 phospho-mimetic 
substitutions (cont.). B. Calculated pCa50 and maximum tension measured at a sarcomere length 
of 2.0µm (left) and 2.3µm (right) in controls (2.0µm: 5.20±0.068, n=8; 2.3µm 5.31±0.072, n=12) 
and myocytes expressing either wild-type cTnI (2.0µm: 5.25±0.074, n=6; 2.3µm: 5.31±0.071, 
n=5) or cTnISer45Asp (2.0µm: 5.18±0.071, n=7; 2.3µm: 4.86±0.063, n=9)  4-5 days after gene 
transfer. Isometric force was measured over a range of Ca2+ as described in the Methods section. 
















































































































































































Fig. 3.5 Analysis of myocyte contractile function and Ca2+ handling in cTnISer43/45 
phosphomimetic expressing myocytes 2 days after gene transfer. Basal shortening measurements 
including resting sarcomere length, peak shortening amplitude, shortening and re-lengthening rate, and 
the time to 50% re-lengthening (TTR50%) were measured and analyzed in Fura-2AM- loaded myocytes as 
described in chapter 1 (Figure 1.3D). Ca 2+ transients also were simultaneously measured in these 
myocytes to determine whether there were changes in baseline Ca2+ ratio, peak change of the Ca2+ 
transient (% baseline), the rates of Ca2+ release and re-uptake, and the time to 50% decay (TTD50%).  




















































































































































































Fig. 3.6 Increased cTnISer43/45 phosphomimetic replacement accelerates Ca2+ 
decay. Basal shortening and Ca2+ transients were simultaneously measured in Fura-loaded myocytes 4 
days post-gene transfer in control, wild-type cTnI, and cTnISer43/45 phospho-mimetic-expressing 
myocytes. Measurements included resting sarcomere length and baseline Ca2+ ratio, peak shortening 
amplitude and peak Ca2+ ratio, shortening and Ca2+ release rates, re-lengthening and Ca2+ reuptake rates, 
and the time to 50% re-lengthening (TTR50%) and the time to 50% Ca2+ decay (TTD50%).  Statistical 


















































































































Fig. 3.7 Adaptive cTnI phosphorylation increases with extensive phosphomimetic 
replacement at cTnISer43/45. A. Representative immunoblot showing cTnISer23/24 
phosphorylation (top panel), total cTnI expression (middle panel), and sypro-stained  
band at 40 kDa for each blot (bottom panel) to determine total protein in each lane. The black line 
separating bands indicates additional lanes were removed between samples on the same gel. The 
quantitative comparison of phospho-cTnI/total cTnI ratios for each cTnI construct is shown in the lower 
panel (mean+SEM; n=5).  A 1-way ANOVA and post-hoc analysis (see Methods) demonstrated 
significantly elevated phosphorylation at cTnISer23/24 in myocytes expressing cTnISer43Asp and 
cTnISer45Asp (*p<0.05 versus control).  B. Representative Western blot analysis of phospho-cTnIThr144 
(top panel), total cTnI protein (middle panel), and protein band on sypro-stained blot (bottom panel). 
The quantitative analysis of phospho-cTnI/total cTnI ratios for each control and phosphomimetic sample 
is shown in the lower panel (mean   SEM, n=5-6). Results are considered significantly different from 

























































































































































Fig. 3.8 Phospho-mimetic replacement at cTnISer43/45 increases adaptive 
phosphorylation in cMyBP-C. Representative Western blot analysis evaluating 
phosphorylation at 3 well characterized residues within cMyBP-C: pSer273 (top panel), 
pSer282 (middle panel), and pSer302 (bottom panel). Site-specific phospho-antibodies 
were used to detect phosphorylation at cTnISer273, cMyBP-CSer282, and cMyBPCSer302 
(top panels). Blots were re-probed for total cMyBP-C protein (middle panels), and a sypro-stained 
portion of the blot (bottom panels) is shown to demonstrate protein loading in each lane (150 KDa 
band). Quantitative analysis of the phospho-cMyBP-C/total cMyBP-C ratio for each construct is shown 
in the panels located to the right of each representative blot (mean+SEM; n=3-6). Statistically different 


















































































Fig. 3.9 Phospho-mimetic replacement at cTnISer43/45 increases PLB 
phosphorylation 4 days after gene transfer. A. Representative Western blot (left panel) illustrating 
changes in phosphorylation at pSer16 PLB (top panel), total PLB (middle panel), and a band on the 
sypro-stained blot (40KDa band; bottom panel). Quantitative analysis of phospho-Ser16-PLB/total PLB 
ratio normalized to the control ratio (1.0) are shown in the right panel (mean+SEM; n=3). B. 
Representative Western blot (left panel) probed with a site-specific phospho-antibody for phospho-
Ser17 PLB (top panel). Blots were stripped and re-probed for total PLB protein expression (middle 
panel) and a sypro-stained band is shown to indicate protein loading (bottom panel). The phospho-
Ser17-PLB/total PLB ratio normalized to control values (1.0) is shown (mean+SEM; n= 3) for controls 


























































































































































































Fig. 3.10 Preliminary studies of adaptive sarcomeric protein phosphorylation in the 
presence of a PKD and a phosphatase inhibitor.  A. Western blot illustrating pSer23/24 cTnI 
phosphorylation (top panel) in phospho-mimetic-expressing myocytes 4 days post-gene transfer. 
Blots were re-probed for total cTnI to determine total cTnI protein levels (middle panel). A 
section of silver (Ag)-stained gel was included to demonstrate protein loading in each lane 
(bottom panel). B. Representative Western blot of cTnISer23/24 phosphorylation (top panels) in 
control, wild-type cTnI-, and phospho-mimetic-expressing myocytes treated with DMSO alone 
(left panels) or the PKD-inhibitor kb-NB-142-70 (10µm; right panels). A band of the sypro-
stained blot is included to indicate protein loading between lanes (bottom panels). The ratio of 
phospho-cTnI to total protein was calculated for each sample then normalized to the DMSO-
treated control. Initial quantitative analysis of the change in the phospho-cTnI/total protein ratio 
before and after inhibitor treatment (∆ Normalized Ratio; mean+SEM, n=3; lower panel) was 
determined in controls, and myocytes expressing wild-type or the phospho-mimetic constructs 
detected on the same membrane.  Statistical analysis indicated there are no significant 
differences compared to control values (p>0.05).  C. Representative Western blot showing 
phospho-cTnISer23/24 (upper panels) and total protein (lower panels) before (M199; left panels) 
and after treatment with a PP1/PP2A inhibitor (10 nM Cal A; right panels) for controls and 
myocytes expressing wild-type cTnI, cTnISer43Asp, cTnISer45Asp, or cTnISer43/45Asp 4 days 
after gene transfer.  Initial quantitative analysis of preliminary data is shown in the lowest panel.  
The change in phosphorylation is expressed as the difference (∆) between phospho-
cTnISer23/24/Total protein before and after Cal A treatment.  Statistical analysis indicated there 
































Altered phosphorylation of PKC-targeted cTnISer23/24 and cTnISer43/45 residues is 
associated with cardiac dysfunction.  In earlier work, expression of cTnISer43/45Asp augmented 
cTnISer23/24 phosphorylation, which suggests cross-talk between these clusters may contribute 
to differences reported in the earlier work.  The cross-talk idea is now further explored by 
functionally comparing viral-mediated gene transfer of cTnISer43/45Asp versus cTnI with 
Ser23/24 and Ser43/45 phospho-mimetic substitutions (cTnIAspQuad).  Epitope-tagged 
cTnIAspQuad progressively replaced endogenous cTnI over time, in agreement with earlier cTnI 
gene transfer studies.  Two days after gene transfer, partial replacement with cTnIAspQuad 
diminished  peak shortening amplitude and slowed shortening and re-lengthening rates, while 
faster time to peak (TTP) and time to 50% re-lengthening (TTR50%) intervals developed 
compared to cTnI-expressing controls.  In contrast, there were no significant changes in function 
with comparable cTnISer43/45Asp expression. By 4 days post-gene transfer, >80% replacement 
with cTnIAspQuad or cTnISer43/45Asp each reduced shortening amplitude, while TTR50% 
continued to be faster in myocytes expressing cTnIAspQuad . However, TTP, shortening and re-
lengthening rates no longer differed between controls and cTnIAspQuad-expressing myocytes.  
These results indicate cTnISer43/45 exerts a dominant influence to reduce peak shortening and 
slow shortening and re-lengthening rates.  The cTnISer23/24 cluster appears to enhance the 
impact of cTnISer43/45 on peak shortening, and likely contributes to the faster TTR50%.  The 
restoration of TTP and shortening rates observed by day 4 suggest compensatory adaptations 
contribute to the functional response with cTnIAspQuad. Indeed, adaptive increases in the 
phosphorylation of cTnI and other myofilament proteins are observed with cTnIAspQuad 
expression. Collectively, these results support the idea cTnISer43/45 phosphorylation directly 
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and adaptively modulate contractile function, with the direct influence working as a brake to 





Human heart failure is characterized by diminished pressure generation, slowed rates of 
pressure development and/or decay, and increased myofilament Ca2+ sensitivity of tension or 
pressure.  Increased protein kinase C (PKC) expression and activation are linked to these 
functional deficits in human and animal models end-stage heart failure [30, 56, 65].  In addition, 
cardiac troponin I (cTnI) is a significant myofilament protein target for PKC phosphorylation 
[26, 59, 60].  PKC can target both cTnISer23/24 and cTnISer43/45 for phosphorylation, and both 
clusters modulate cardiac contractile function [43, 46, 51, 68].   
However, the functional influence of cTnISer43/45 alone and in combination with 
cTnISer23/24 remains controversial [47, 49].  Evidence from biophysical studies indicates 
phospho-mimetic substitutions at cTnISer43/45 and another PKC target, cTnIThr144, are 
necessary to maximally reduce myofilament tension and sliding speed [116] [67, 68].   These 
studies did not address the combinatorial effects of cTnISer23/24 and cTnISer43/45 
phosphorylation. In contrast, in vivo analysis using phospho-mimetic substitutions in 
cTnISer23/24 alone and in combination with cTnISer43/45 and cTnIThr144 indicated the 
Ser43/45 and/or Thr144 sites exert a dominant influence on function, which obscures the 
influence of cTnISer23/24 on cardiac pump performance[49] [62]. However, the dominant 
cluster responsible for modulating cardiac function remains unclear [47] [49]. The different 
outcomes observed using reconstituted myofilaments compared to in vivo cardiac function 
measurements in animal models indicate experiments are needed to define the functional 
consequences of cTnISer23/24 and cTnISer43/45 phosphorylation in a cellular model to bridge 
the gap between the earlier in vivo and in vitro studies.   
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Alterations in the phosphorylation state of cTnISer23/24 and cTnISer43/45 are also 
linked to cardiac dysfunction, with reduced cTnI Ser23/24 and enhanced Ser43/45 
phosphorylation reported during end-stage heart failure [27] [28-31, 65].  In contrast, 
phosphorylation of both clusters is enhanced in a rodent model of spontaneous hypertension [30].  
The association between elevated cTnISer43/45 phosphorylation and heart failure led to the idea 
Ser43/45 phosphorylation may contribute to cardiac dysfunction [30].  Earlier work also 
indicated cTnISer43/45 influences cTnISer23/24 phosphorylation state (Ch. 3).  Thus, the 
reduction in cTnISer23/24 phosphorylation during heart failure may indicate cross-talk between 
these 2 clusters is compromised under pathophysiological conditions and/or could further 
contribute to cardiac dysfunction.  Experiments are needed to evaluate the contributions of cTnI 
Ser43/45 alone and in combination with Ser23/24 as a first step toward understanding the role 
these clusters play in the development of cardiac dysfunction.  A longer term goal of this work is 
to determine whether these changes in cTnI phosphorylation are a key contributor to dysfunction 
and the progressive transition towards end-stage heart failure [27]. 
 The present study tests the hypothesis cTnI Ser43/45 has a dominant influence on 
modulating contractile function by reducing function alone and in combination with Ser23/24. 
This idea is tested by comparing the functional impact of cTnISer43/45Asp to a cTnI containing 
Asp substitutions at Ser23/24 and Ser43/45 (cTnIAspQuad).   For these studies, viral-based gene 
transfer into isolated cardiac myocytes is used to replace endogenous cTnI, and then myocytes 
are monitored for expression, sarcomere incorporation and contractile function.  These results 
demonstrate cTnI Ser43/45 produces a dominant reduction in myocyte shortening, although 
Ser23/24 also plays a subtle but complex role in modulating function.  The present studies also 
demonstrate cTnIAspQuad activates adaptive signaling in intact myocytes, although the signaling 
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differs from the adaptive responses observed with cTnISer43/45Asp alone. In agreement with 
earlier work, the present results also bridge the gap between in vitro and in vivo work and are 

























Gene transfer into isolated cardiac myocytes  
 Site-directed mutagenesis is used to replace cTnISer23/24 and cTnISer43/45 with 
negatively charged aspartic acid (Asp) in full-length, wild-type cTnI cDNA (rat) (QuikChange; 
Invitrogen) [83, 85, 99]. The cTnIAspQuad construct is produced with and without a FLAG-tag 
using the following primers: cTnISer23/24Asp 5’-
ctgctcctgtccgacgtcgcgatgatgccaactaccgagcctatg-3’ (sense, mutated residues are 
bolded/underlined) and 5’-cataggctcggtagttggcatcatcgcgacgtcggacaggagcag-3’ (anti-sense). 
cTnISer43/45Asp 5’aaagtctaagatcgatgccgacagaaagcttcagttgaagactctg-3’ (sense) and 5’-
cagagtcttcaactgaagctttctgtcggcatcgatcttagacttt-3’ (anti-sense). Each cDNA was cloned into a 
pDC315 shuttle vector. Recombinant adenovirus used for gene transfer is produced by 
homologous recombination of the adenoviral backbone pBHGLox E1, 3Cre (Microbix) and the 
pDC315 shuttle vector in HEK293 cells [85, 100].  
Ca2+-tolerant adult rat myocytes (Sprague-Dawley female rats; 200g) are isolated using 
the protocol described earlier (Ch. 2) [85, 99].  Experiments with rats are carried out according to 
guidelines developed by the University Committee for the Use and Care of Animals (UCUCA) at 
the University of Michigan [85, 99]. Recombinant adenovirus with wild-type cTnI (±FLAG), 
cTnISer43/45Asp or cTnIAspQuad (±FLAG) is diluted in serum-free media and incubated with 
Ca2+-tolerant myocytes plated onto laminin-coated coverslips as previously described [85] [99]. 
Myocytes treated with DMEM+P/S without adenovirus serve as controls. Following isolation 
and gene transfer, cells are cultured in M199+P/S. Coverslips used for functional measurements 
are transferred to a stimulation chamber and paced at 0.2Hz 24hr after gene transfer, and media 
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is replaced every 12 hr. Media on non-stimulated cells is changed 24hr post-gene transfer and 
then every other day for up to 7 days.  
Expression analysis: Western blotting and immunohistochemistry 
 Western blot analysis is used to monitor replacement of endogenous cTnI with FLAG-
tagged wild-type cTnI or cTnIAspQuad, maintenance of myofilament stoichiometry, and protein 
phosphorylation as previously described (Ch. 2 and Ch. 3) [99].   Similar comparisons are 
performed for cTnISer43/45Asp in chapter 3.  Replacement and stoichiometry are monitored at 
days 2 and 4 while analysis of protein phosphorylation is measured at day 4 as previously 
described (Ch. 2 and Ch. 3).  For each Western blot, proteins are separated on a 12% SDS 
polyacrylamide gel and electrophoretically transferred to PVDF membranes, which are then 
probed with the primary and secondary antibody pairs described in Table 4.1. Quantification and 
normalization of bands from the Western blot are carried out as previously described (Ch. 2 and 
Ch. 3) [99].  
 
 
Table 4.1. Primary and secondary antibodies used for Western blot analysis. Primary (right column) and HRP-
linked secondary (left column) antibodies are described. The antibody and dilution used are listed. The source of the 
antibody is also noted. Goat-anti-mouse (GAM), goat-anti-rabbit (GAR), horseradish-peroxidase (HRP). Antibodies 
were purchased from Cell Signaling Technology unless otherwise noted. *Site-specific cMyBP-C phospho-
antibodies were a kind gift of Dr. Sadayappan [101]. 
Indirect immunofluorescence with dual monoclonal antibodies is used to confirm 
localization of FLAG-tagged cTnI constructs into the myofilament, as described in earlier work 
Primary Antibodies Secondary Antibodies
Total troponin I (mAb, 1:4000, MAB1691, Millipore) GAM-HRP (1:2000)
Tropomyosin (mAb, 1:1000, Sigma Aldrich) GAM-HRP (1:2000)
Phospho-cTnI Ser23/24 (pAb, 1:1000) GAR-HRP (1:2000)
Total cMyBP-C (pAb, 1:1000, Santa Cruz Biotechnology) GAR-HRP (1:2000)
Phospho-cMyBP-C Ser273 (pAb, 1:2500)* GAR-HRP (1:2000)
Phospho-cMyBP-C Ser282 (pAb, 1:2500)* GAR-HRP (1:2000)
Phospho-cMyBP-C Ser302 (pAb, 1:5000)* GAR-HRP (1:2000)
Total Phospholamban (pAb: 1:1000, Sigma Aldrich) GAR-HRP (1:2000)
Phospho-phospholamban Ser16 (pAb, 1:1000, Upstate Biologicals) GAR-HRP (1:2000)
Phospho-phospholamban Thr17 (mAb, 1:5000, Badrilla) GAM-HRP (1:2000)
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(Ch. 2 and Ch. 3) [99]. Detergent- permeabilized myocytes are stained with a troponin-I specific 
monoclonal antibody (mAb, 1:500, MAB1691, Millipore) and a secondary antibody conjugated 
to fluorescein isothiocyanate  (FITC, 1:500, Invitrogen) to detect total TnI.  A FLAG-specific 
mAb (1:500, Invitrogen) and a secondary antibody conjugated to Texas Red (TR, 1:500, Sigma) 
are used to detect exogenous cTnI. Projection images of immunostained myocytes are obtained 
using a Fluoview 500 laser scanning confocal microscope (Olympus) and de-convoluted using 
Auto quant X software (Media Cybernetics).  
Cellular function: sarcomeric shortening and Ca
2+
 transient measurements 
 Basal cell shortening measurements are performed in electronically paced myocytes in a 
heated (37ºC) perfusion chamber 2 and 4 days after gene transfer. Resting sarcomere length, 
peak shortening amplitude (% baseline), time to peak (TTP), shortening rate, re-lengthening rate, 
time to 25% re-lengthening (TTR25%), time to 50% re-lengthening (TTR50%), and time to 75% re-
lengthening (TTR75%) are calculated from signal-averaged traces measured with a video-based 
CCD camera system (Ionoptix) as previously described (Ch. 2 and Ch. 3) [99].  
 Ca2+ transients and sarcomere shortening are simultaneously measured in Fura-2AM-
loaded, electronically stimulated myocytes with the same CCD-camera system used for basal 
shortening measurements (Ch. 2 and Ch. 3) [99]. The basal Ca2+ ratio, peak Ca2+ ratios, the rates 
of Ca2+ rise and decay, the time to 25% decay  (TTD25%), the time to 50% decay (TTD50%), and 
the time to 75% decay (TTD75%), are calculated from signal-averaged traces 4 days after gene 






Data analysis and statistics 
 All data are presented as the mean±SEM. Statistical significance was set to p<0.05 (*). 
Unless otherwise noted, data are analyzed using a one-way analysis of variance (ANOVA) and 





cTnIAspQuad increasingly replaces endogenous cTnI in the myofilament 
Structural studies demonstrated the cTnIAspQuad (±FLAG) construct is expressed and 
replaces endogenous cTnI in the sarcomere of intact myocytes. The FLAG-tagged cTnIAspQuad 
replaced < 50% endogenous cTnI 2 days after gene transfer, matching the replacement achieved 
by cTnIFLAG.  Increasing temporal expression also developed for both cTnIFLAG and 
cTnIAspQuadFLAG, with >80% replacement observed by day 4 (Figs. 4.1A,B).  These results are 
comparable to the expression pattern obtained for cTnISer43/45AspFLAG in earlier work (Figs. 
3.1A,B; Figs. 4.1A,B).  Western analysis of tropomyosin (Tm) expression indicated the temporal 
increase in cTnIAspQuad expression did not alter myofilament stoichiometry compared to controls 
(Fig. 4.1C). Expression of cTnIFLAG and cTnIAspQuadFLAG also produced the striated 
immunostaining pattern indicative of sarcomeric localization in myocytes (Fig. 4.2). These 
expression and immunostaining results demonstrate cTnIAspQuad (±FLAG) replacement of 
endogenous cTnI is comparable to work with other cTnI constructs (Ch.2 and Ch.3).  
Myocyte contractile performance with cTnIAspQuad expression 
Partial replacement of endogenous cTnI with <50% cTnIAspQuad 2 days after gene 
transfer significantly reduced peak shortening amplitude and slowed shortening rate without 
altering resting sarcomere length in intact myocytes (Fig 4.3). This limited replacement with 
cTnIAspQuad also resulted in a faster time to peak shortening (TTP) and time to 50% re-
lengthening (TTR50%).  In contrast, these measured intervals remained comparable between 
controls and myocytes expressing cTnISer43/45Asp (Fig. 4.3). As previously observed, the 
shortening amplitude in cTnISer43/45Asp-expressing myocytes also remained similar to control 
values at day 2 (Figs. 3.3, 4.3).  Based on these results, the presence of cTnISer23/24 
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phosphorylation or phospho-mimetic substitution may cause sufficient conformational changes 
in cTnI to enhance the ability of low amounts of negative charge located at cTnISer43/45 (e.g. 
phosphorylation or phospho-mimetic substitution) in the same cTnI to negatively modulate 
function.   
The reduction in peak shortening amplitude and accelerated TTR50% observed in 
myocytes expressing cTnIAspQuad continued to be detected with more extensive cTnIAspQuad 
expression at day 4 (Fig. 4.4). Interestingly, the faster TTP and slowed shortening rates observed 
2 days after cTnIAspQuad gene transfer were no longer significantly different from controls, 
although the shortening rate remained slower than the rate in myocytes expressing cTnIFLAG.  
The restoration of TTP with cTnIAspQuad is worth noting, as this result is opposite from the 
changes in TTP observed in myocytes expressing cTnISer43Asp and cTnISer45Asp 2 and 4 days 
after gene transfer (Figs. 3.3, 3.4, 4.3, 4.4). More extensive replacement with cTnISer43/45Asp 
on day 4 also reduced peak shortening amplitude and slowed shortening rate compared to 
controls, although TTP and TTR50% remained unchanged from the control values (Fig. 4.4).  A 
final observation in this set of experiments was the slightly reduced resting sarcomere length 
detected with cTnIFLAG 4 days post-gene transfer, although shortening amplitude and/or the 
rates of shortening and re-lengthening were not impaired compared to non-treated controls.  
Overall, the functional studies performed 2 and 4 days after gene transfer demonstrated the 
presence of negative charge at cTnISer43/45 produces a dominant influence to reduce contractile 
function, while cTnISer23/24 is likely responsible for the faster TTR50% observed with 
cTnIAspQuad.  This later conclusion is consistent with the known ability of Ser23/24 
phosphorylation to increase the Ca2+ dissociation rate from troponin and indicates this cluster 
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independently influences function when both cTnISer23/24 and cTnISer43/45 are 
phosphorylated on a single cTnI [42].        
cTnIAspQuad generates adaptive responses 
The return of TTP and shortening rate toward control values suggests adaptive responses 
contribute to the functional differences on days 2 versus 4 in myocytes expressing cTnIAspQuad.  
Alterations in Ca2+ cycling could restore the TTP and/or shortening rate in cTnIAspQuad-
expressing myocytes back toward control values. Thus, Ca2+ transients and sarcomeric 
shortening were measured simultaneously in Fura-2AM loaded controls, and myocytes 
expressing wild-type cTnI, cTnISer43/45Asp, or cTnIAspQuad 4 days after gene transfer (Fig.4.5).  
In these experiments, there were no significant differences detected in peak shortening amplitude 
or in the release and decay rates of the Ca2+ transient among these groups of myocytes (Fig. 4.5).  
However, cTnIAspQuad expression diminished peak shortening amplitude and slowed both 
shortening and re-lengthening rates under these conditions.  The impact of cTnISer43/45Asp on 
shortening amplitude and the rates of shortening and re-lengthening were comparable to earlier 
observations, although the previously observed increase in TTD50% was not detected here (Fig. 
3.6 vs. Fig. 4.5).  In these studies, cTnIAspQuad also reduced peak shortening and slowed the rates 
of shortening and re-lengthening significantly more than cTnISer43/45Asp. The enhanced 
impact of cTnIAspQuad versus cTnISer43/45Asp observed in this set of experiments supports the 
idea phosphorylation and/or negatively charged cTnISer23/24 enhances the ability of 
cTnISer43/45 to modulate contractile function.   Fura-2-mediated Ca2+ buffering may explain the 
more dramatic ability of cTnIAspQuad to reduce contractile function and minimize the influence 
of this construct on TTR50% in the current experiments.     
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While alterations in the Ca2+ transient are not detected, it remains possible there are 
adaptations in the phosphorylation level of individual Ca2+ cycling proteins, such as 
phospholamban (PLB).  Thus, PLB phosphorylation at Ser16 and Thr17 is measured in parallel 
studies (Table 4.1, Fig. 4.6). In contrast to the tendency for cTnISer43/45Asp to enhance Ser16 
phosphorylation, a set of initial experiments indicated cTnIAspQuad tended to reduce Thr17 
phosphorylation on PLB (Fig. 3.9 vs. Fig. 4.6).  This reduction is not significantly different, 
although additional experiments are needed for a comparison with adequate statistical power 
(Fig. 4.6). Currently, the results with PLB phosphorylation levels are consistent with the lack of 
change in the cellular Ca2+ transient.  The variability of data observed here also indicates an 
observed change in PLB phosphorylation may be transient and/or may depend on the long-term 
presence of cTnISer23/24 and cTnISer43/45 phosphorylation on the same cTnI and in a majority 
of cTnI proteins within the myofilament.  Based on these findings, the restoration of shortening 
rate and TTP observed 4 days after gene transfer is likely mediated by another mechanism (Fig. 
4.4).  
Previously, sarcomeric protein phosphorylation correlated with the adaptive changes in 
shortening and re-lengthening rate produced in myocytes expressing cTnISer43Asp and/or 
Ser45Asp (Figs. 3.4, 3.7, 3.8).  Increased phosphorylation of a third PKC-targeted site on cTnI, 
Thr144, and cMyBP-C phosphorylation could modulate cross-bridge cycling rates, which could 
in turn lead to the adaptive changes in TTP and shortening rate [109, 110, 116] [59]. Therefore, 
site-specific phospho-antibodies were used to evaluate phosphorylation of both cTnIThr144 and 
cMyBP-C by Western analysis (Table 4.1, Fig. 4.7). Indeed, significantly enhanced cTnIThr144 
phosphorylation was detected in myocytes expressing cTnIAspQuad 4 days after gene transfer 
(Fig. 4.7). Earlier work demonstrated a phospho-mimetic Glu substitution for Thr144 reduced 
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the Ca2+ sensitivity of thin filament sliding speed [68].  This reduction could contribute to the 
slowing of TTP back toward control levels in the 4 day myocytes expressing cTnIAspQuad, but 
does not explain the faster shortening rate adaptation [68]. 
Further analysis also demonstrated enhanced phosphorylation of the cardiac-specific m-
motif of cMyBP-C (Table 4.1, Fig 4.7). Both Ser273 and Ser282 in cMyBP-C were substantially 
phosphorylated in myocytes expressing cTnIAspQuad compared to cTnI-expressing controls while 
there were no detected changes in the Ser302 phosphorylation level (Fig 4.7). Cross-bridge 
cycling rates increase when cMyBP-C is phosphorylated in this m-motif, and the increased 
phosphorylation of Ser273 and Ser282 is consistent with phosphorylated cMyBP-C working to 
return the slowed shortening observed with cTnIAspQuad observed at day 2 back toward control 
levels at day 4 (Figs. 4.3,4.4) [109, 110].  Taken together, the elevated phosphorylation level of 
cTnIThr144 and cMyBP-C Ser273 and Ser282 indicate myofilament expression of a phospho-
mimetic substitution at Ser23/24 and Ser43/45 on the same cTnI protein stimulates adaptive 














The current studies demonstrate PKC-targeted Ser43/45 cluster in cTnI produces a 
dominant reduction in contractile function, while cTnISer23/24 modulates function via a separate 
mechanism.  In addition, there is evidence phospho-mimetic substitutions at Ser43/45 and 
Ser23/24 on the same cTnI communicate to influence cellular contractile function.   This 
conclusion is based on the potentiated functional effect produced by cTnISer23/24Asp in 
combination with cTnISer43/45Asp, and the reduced shortening amplitude produced 2 days after 
gene transfer of cTnIAspQuad. However, more extensive cTnISer43/45Asp expression is required 
to achieve the same change in function (Figs. 3.4, 4.3). In agreement with earlier work on 
cTnISer43/45Asp, adaptive changes in myofilament protein phosphorylation also develop with 
extensive expression of cTnIAspQuad.   However, the specific adaptations are unique to 
cTnIAspQuad expression. 
  The current structural model of cTn can be used to predict a mechanism for the 
intensified effects of cTnISer43/45 within cTnIAspQuad (Fig. 1.2A) [25]. Phosphorylation or 
phospho-mimetic substitutions at Ser23/24 in cTnI is predicted to stabilize the cardiac-specific 
N-terminal domain of the protein [117] [118]. Conversely, cTnISer43 and cTnISer45 are located 
in the H1(I) -helix in the more rigid, highly conserved I-T arm, and the phosphorylation or 
phospho-mimetic substitutions at these sites may rotate this helix away from the N-lobe of cTnC 
and/or change the rigidity of the I-T arm (Fig.1.2A) [25, 70, 71, 119]. The addition of phospho-
mimetic substitutions at cTnISer23/24 to form cTnIAspQuad may further reposition the rotated I-T 
arm and accentuate the functional impact of cTnISer43/45Asp (Figs. 3.4, 4.4) [25, 70, 71, 117-
119]. Conformational differences also are expected to produce separate functional responses. 
Specifically, cTnISer43/45 phosphorylation is proposed to slow Ca2+ association or binding to 
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cTnC and/or delay cross-bridge detachment from the myofilament [67, 105] [68]. The observed 
reduction in peak shortening and slowing of shortening rate in Fura-2-loaded myocytes 
expressing cTnIAspQuad could result from slower kinetics for Ca2+ binding to cTnC, while a 
reduction in cross-bridge detachment rates would slow re-lengthening rate.  In contrast, 
phosphorylation of cTnISer23/24 enhances Ca2+ dissociation from cTnC, which should 
accelerate relaxation [42]. The presence of slowed re-lengthening rate in the presence but not the 
absence of Fura-2AM is probably related to Ca2+ buffering by Fura-2AM in these myocytes 
[103].  This buffering would mask the faster Ca2+ dissociation from cTnC by cTnISer23/24 
phosphorylation and accentuate the slowing of cross-bridge detachment and/or cTnC Ca2+ 
binding produced by cTnISer43/45Asp substitutions.   The more dramatic functional influences 
of cTnIAspQuad on shortening and re-lengthening rate and peak shortening amplitude observed in 
Fura-2AM-loaded myocytes is expected if cTnISer23/24 and cTnISer43/45 work through the 
proposed mechanisms (Fig.4.5).  Previously, phospho-mimetic replacement of all 5 PKC-
targeted cTnI residues (cTnIAllP) was predicted to reduce Ca2+ accessibility to the hydrophobic 
patch more than cTnISer23/24Asp alone [49 248]. The cTnIAspQuad construct should similarly 
reduce Ca2+ accessibility more than cTnISer43/45Asp. However, the slowing of re-lengthening 
rate observed in Fura-2AM-loaded myocytes expressing cTnIAspQuad suggests cTnISer43/45 
substitutions also reduce cross-bridge detachment rate. 
Expression of cTnIAspQuad is predicted to produce a similar change in function as 
cTnISer43/45Asp, based on earlier experiments showing cTnISer43/45Asp expression 
augmented cTnISer23/24 phosphorylation (Fig. 3.7). However, these 2 constructs have different 
influences on peak shortening amplitude, TTP, and TTR50% at both 2 and 4 days after gene 
transfer, which indicates different mechanism(s) may be involved in producing the functional 
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response (Figs. 4.3, 4.4). In myocytes expressing cTnIAspQuad, both clusters are modified on the 
same cTnI while adaptive cTnISer23/24 phosphorylation occurred more stochastically along the 
myofilament with cTnISer43/45Asp expression (Ch. 3). Studies with cTnIAspQuad also indicate 
cTnISer23/24 promotes the functional impact of cTnISer43/45 when present within the same 
cTnI. Moreover, modification of these 2 phosphorylation sites within the same cTnI allows 
Ser23/24 to independently produce the well-known acceleration of cellular re-lengthening, which 
was measured here as TTR50% (Figs. 4.3, 4.4) [43, 46]. In contrast, adaptive cTnI Ser23/24 
phosphorylation observed with cTnISer43/45Asp expression failed to change TTR50% or other 
indicators of re-lengthening rate (Fig.4.4). Thus, these differences in contractile function could 
result from conformational differences in the thin filament when modified Ser23/24 is present on 
the same versus different cTnI as Ser43/45 phospho-mimetic substitutions or phosphorylation.  
Alternatively, the functional difference could be explained by the presence of 
phosphorylation turnover at cTnI Ser23/24 for myocytes expressing cTnISer43/45Asp compared 
to the absence of turnover at this site in myocytes expressing cTnIAspQuad.  In previous studies, 
PKC activation of downstream kinase and phosphatase activity accelerated phosphorylation 
turnover at Ser23/24 and on other proteins [102, 114].  Accelerated turnover of phosphorylation 
on end-targets such as Ser23/24 proved to be highly sensitive to cellular environment and 
influenced the functional response.  Thus, this mechanism also may explain the current 
contractile function response better than a change in the magnitude of phosphorylation [120, 
121].  If Ser23/24 phosphorylation turnover is responsible for functional differences, the absence 
of turnover at cTnI Ser23/24 could influence the slower phase of re-lengthening rate in myocytes 
expressing cTnIAspQuad and have no detected impact with more rapid phosphorylation turnover 
in myocytes expressing cTnISer43/45Asp.  There is little evidence to indicate whether 
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phosphorylation on the same/different cTnI or phosphorylation turnover are responsible for the 
functional differences attributed to Ser23/24 in cTnISer43/45Asp- versus cTnIAspQuad-
expressing myocytes. Clearly, further experiments are necessary to distinguish between these 
two possible explanations for the different functional impact observed with cTnISer43/45Asp 
versus cTnIAspQuad.       
 In addition to directly modifying contractile function, the restoration of shortening rate 
and TTP toward control values on day 4 demonstrates adaptive signaling develops in myocytes 
expressing cTnIAspQuad (Figs. 4.6, 4.7). Phosphorylation of the m-motif in cMyBP-C increases 
cross-bridge cycling rate, and the enhanced cMyBP-C phosphorylation detected with 
cTnIAspQuad expression could contribute toward the restoration of shortening rate observed in my 
studies (Fig. 4.4)[109, 110]. The functional impact of elevated cTnIThr144 phosphorylation is 
more controversial.  Increased phosphorylation of Thr144 in cTnI reduced Ca2+-activated 
actomyosin ATPase activity, which indicates the adaptive phosphorylation at this residue may 
diminish cross-bridge cycling and return TTP toward control values [59, 116].  However, it 
appears counterintuitive for adaptive phosphorylation to further slow cross-bridge cycling if 
cTnISer43/45 directly decreases cross-bridge detachment rate [68]. Phosphorylation of Thr144 in 
cTnI also is proposed to destabilize Ca2+ binding to the N-domain of cTnC and may add to the 
ability of Ser23/24 to enhance Ca2+ dissociation from cTnC [49]. If so, enhanced cTnIThr144 
phosphorylation may slow TTP but also work as a secondary mechanism to preserve relaxation 
when cTnISer23/24 modulation is no longer available in cTnIAspQuad-expressing myocytes.  
Overall, these increases in cTnI and cMyBP-C phosphorylation are consistent with the functional 
adaptations, although further studies are needed to prove the extent each residue contributes to 
the adaptive response.  
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Interestingly, the adaptive signaling response observed with cTnIAspQuad is unique 
compared to adaptations previously observed with cTnI Ser43 and/or Ser45 Asp substitutions 
(Figs. 3.6-3.9, 4.5-4.7).  For example, no differences in the Ca2+ transient are detected between 
controls and myocytes expressing cTnIAspQuad, while a faster decay of the Ca2+ transient 
develops in myocytes expressing Asp substitutions at cTnISer43 and/or cTnISer45 compared to 
controls (Figs. 3.6, 3.9, 4.5). Phosphorylation of the Ca2+ cycling protein PLB at Ser16 remained 
unchanged and Thr17 phosphorylation tended to decrease in myocytes expressing cTnIAspQuad, 
although some additional experiments are needed to achieve adequate statistical power for this 
comparison (Fig. 4.6).  In contrast, cTnISer43 and cTnISer45Asp increased PLB Ser16 
phosphorylation compared to controls (Fig. 3.9).  In addition, cTnIAspQuad expression also caused 
extensive increases in cTnIThr144, cMyBP-CSer273, and cMyBP-CSer282 phosphorylation 
while cTnISer43/45Asp expression only influenced cMyBP-CSer282 phosphorylation (Figs. 3.7, 
3.8, 4.7A, 4.7B).  These differences in the adaptive responses are consistent with the possibility 
cTnISer23/24 and cTnISer43/45 modifications on the same cTnI produce a conformational 
difference compared to cTnISer43/45 alone.  Conformational-induced structural changes in the 
thin filament could differentially modify the access of kinases and/or phosphatases to specific 
sites within myofilament proteins, such as cTnI and cMyBP-C, as well as Ca2+ cycling proteins, 
such as PLB, to produce the unique adaptations observed with cTnIAspQuad.     
Based on the current findings, phosphorylation of Ser43/45 with and without Ser23/24 in 
cTnI also is predicted to play a physiologically important role in the myofilament by acting as a 
brake.  This brake may be a modulatory signal to counteract increases in sympathetic drive over 
longer periods and/or with chronic stress.  For example, increased -AR activation increases 
cardiac contractility and heart rate [32] [1, 122].  While sympathetic stimulation and downstream 
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-AR signaling are expected to maintain cardiac function over brief time periods, persistent 
elevations in sympathetic activity may be energetically unfavorable.  This type of sustained 
stress also is expected to result in sympathetic activation of -adrenergic receptors ( -ARs) 
and/or produce changes in other neurohormones such as endothelin (ET) or the renin-
angiotensin-aldosterone system [54, 123] [55].  Adult cardiac myocytes express -AR, ET 
receptors (ETR) and angiotensin II receptors (ATR), and each of these neurohormones activates 
PKC in myocytes [54] [53, 55]. Thus, the initial neurohormonal activation of PKC in cardiac 
myocytes may act as a brake in response to longer term or sustained sympathetic activation 
and/or other environmental stressors. The detection of cTnISer23/24, but not cTnISer43/45 
phosphorylation in cTnI under physiological conditions in human and animal models is 
consistent with this idea [30, 35-37].  Moreover, this idea agrees with earlier predictions 
cTnISer43/45 phosphorylation reduces cross-bridge cycling to preserve ATP stores in the heart 
[64] [47].   
The additional phosphorylation of cTnISer23/24 could be a sign of a compensatory state 
of cardiac dysfunction if cTnISer43/45 phosphorylation acts as a modulatory brake within the 
myofilament.  Based on my results, the added presence of cTnISer23/24 phosphorylation is 
anticipated to enhance the ability of cTnISer43/45 to act as a systolic brake while preserving 
relaxation (Figs.4.3-4.4). Consistent with this idea, enhanced phosphorylation of both 
cTnISer23/24 and cTnISer43/45 is observed in a rat model of spontaneous hypertension [30]. 
Heightened sympathetic drive also could be a contributing factor in the development of 
phosphorylation at both Ser23/24 and Ser43/45 in cTnI.   Indeed, augmented sympathetic drive is 
an early-stage marker of the compensated state of cardiac dysfunction [124] [5].  The adaptive 
phosphorylation of Thr144 in cTnI and residues in the m-motif of cMyBP-C observed here may 
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work to further fine tune cardiac performance during the early stages of heart failure (Figs. 4.6, 
4.7).   
Over time, the sustained activation of the cTnISer43/45 modulatory brake on 
myofilament function could be a critical element contributing to systolic and diastolic 
dysfunction and/or the transition to end-stage heart failure. Down-regulation of -AR signaling 
and/or deterioration in compensatory signaling pathways may result in the diminished 
cTnISer23/24 phosphorylation observed in end-stage heart failure [27, 29]. Previous studies 
indicate Ser43/45 phosphorylation in cTnI is present as the heart transitions from compensatory 
to decompensatory heart failure and persists in end-stage heart failure [27]  [30, 31].  Increased 
phosphatase activity and reduced cMyBP-C phosphorylation also develop with decompensated 
heart failure [125] [126] [127-129]. These changes indicate the adaptive signaling observed in 
the present study, is diminished in the later stages of heart failure. At this point, cTnISer43/45 
phosphorylation likely contributes directly to dysfunction.  
In summary, the present group of experiments demonstrates the dominance of 
cTnISer43/45 and a functional role for cross-talk between Ser23/24 and Ser43/45 within the 
same cTnI. The cTnISer43/45 cluster is predicted to work as a modulatory brake on contractile 
function.  Conformational changes within cTnI are postulated to produce the enhanced functional 
response observed with cTnIAspQuad compared to cTnISer43/45Asp. Compensatory signaling 
also is detected in myocytes expressing cTnIAspQuad, although this response differed from 
cTnISer43/45Asp alone.  Overall, adaptive signaling is thought to temper the modulatory brake 
of cTnISer43/45, and heart failure my result when similar adaptive signaling responses are 
absent. 
 





















































































Fig. 4.1 cTnIAspQuadFLAG increasingly replaces endogenous cTnI in the myofilament over time. 
A. Representative Western blot of cTnI(±FLAG) and cTnIAspQuad(±FLAG) expression 2 (left panel) and 
4 (right panel) days after gene transfer.  A troponin I-specific Ab detected both endogenous and FLAG-
tagged cTnI constructs (upper panels, Table 4.1). Tropomyosin levels were measured to determine if 
cTnIAspQuad expression alters myofilament stoichiometry (middle panels). A section of silver (Ag)-
stained gel is included to demonstrate protein loading in each lane (lower panels). All samples were run 
on the same gel, and the black line indicates a separation between these lanes by additional samples. B.  
Quantitative analysis showing cTnIAspQuad replacement of endogenous cTnI 2 (left side) and 4 (right 
side) days post-gene transfer. Replacement is calculated from the ratio of FLAG-tagged/total cTnI  
protein detected and is expressed as the percentage of endogenous cTnI replaced by each construct.  C. 
The ratio of total cTnI/Tm protein was calculated for control, cTnIFLAG, or cTnIAspQuadFLAG-
expressing myocytes. The normalized protein ratios were quantified 2 (left panel) and 4 (right panel) 
days after gene transfer. There were no statistical differences in expression compared controls in B and 





Fig. 4.2 cTnIAspQuad localizes to the sarcomere.  Permeabilized myocytes from each sample 
group were stained with monoclonal antibodies specific for TnI and FLAG to monitor both 
endogenous and exogenous cTnI localization. Projection confocal images of cTnIFLAG and 
cTnIAspQuadFLAG-expressing myocytes exhibited a striated pattern when probed with a TnI 
1°Ab and a FITC-conjugated 2°Ab (left column). Myocytes stained with a FLAG-specific 1°Ab 
and a Texas Red-conjugated 1°Ab (middle column) showed cTnIFLAG and cTnIAspQuadFLAG 
produced the same striated patterning. Overlays of these images showed co-localization of the 
two antibodies, confirming myofilament incorporation of the phospho-mimetic cTnI. A 
magnified section of each myocyte inserted into each panel illustrates the striated patterning 















































































































Fig. 4.3 Analysis of basal shortening and re-lengthening in control, cTnIFLAG, 
cTnISer43/45Asp, and cTnIAspQuad-expressing myocytes 2 days after gene transfer. Signal-
averaged traces of contractile shortening and re-lengthening were recorded in individual 
myocytes 2 days after gene transfer. Then, resting sarcomere length, peak shortening amplitude, 
shortening rate, time to peak (TTP), re-lengthening rate, and the time to 50% re-lengthening 
(TTR50%) were determined for each trace. A p<0.05 was considered to be statistically significant, 
where * indicates a difference from controls and ^ indicates a difference from cTnIFLAG-








































































































Fig. 4.4 Extensive replacement of endogenous cTnI with cTnIAspQuad modulates contractile 
function.   Signal averaged traces of basal shortening and re-lengthening were measured in each group 
of myocytes 4 days after gene transfer, as described in Fig. 4.3. The quantitative analysis of resting 
length, peak shortening amplitude, shortening and re-lengthening rates along with the time to peak 
(TTP) and time to re-lengthening 50% (TTR50%) are shown, and there were no changes in other 
measures of shortening or re-lengthening. Statistical differences (p<0.05) from controls (*) or 




















































































































































































Fig. 4.5 Contractile function and Ca2+ transients in control, cTnI, cTnISer43/45Asp and 
cTnIAspQuad-expressing, Fura-2AM-loaded myocytes 4 days after gene transfer. Basal 
shortening and Ca2+ transients were simultaneously measured in Fura-2AM-loaded myocytes in 
each group 4 days after gene transfer. Signal-averaged traces were analyzed for resting length, 
peak shortening amplitude, shortening rate, re-lengthening rate, and the time to 50% re-
lengthening (TTR50%) along with the corresponding analysis of the Ca2+ transient. The Ca2+ 
transient measurements included the basal and peak Ca2+ ratios, rate of Ca2+ release, rate of Ca2+ 
decay, and time to 50% Ca2+ decay (TTD50%). *p<0.05 indicates statistically different from 
controls, ^p<0.05 indicates statistically different from cTnI, and #<0.05 indicates statistically 



































































Fig. 4.6 Phospholamban phosphorylation in control, cTnI, and cTnIAspQuad-expressing 
myocytes 4 days after gene transfer. Representative Western blot analysis of phospholamban 
(PLB) phosphorylation at PLBSer16 (upper panel) and PLBThr17 (lower panel) using site-
specific phospho-antibodies (upper blots) compared to total PLB expression (lower blots). Black 
lines between lanes indicate groups were separated by additional samples run on the same gel. 
The phospho-PLB/total PLB protein ratio is quantified for each residue (right panels). The 
current data indicates no statistical differences compared to control values (*p>0.05) for either 

























































































































































Fig. 4.7 Myofilament protein phosphorylation in control, cTnI, and cTnIAspQuad-expressing 
myocytes 4 days after gene transfer. A. Representative Western blot analysis of cTnIThr144 
phosphorylation in myocytes 4 days after gene transfer (left panel). A site-specific phospho-
antibody is used to detect cTnIThr144 phosphorylation in control, wild-type cTnI, and 
cTnIAspQuad-expressing myocytes (upper blot). Total cTnI protein levels were also monitored 
(lower blot). The normalized phospho-cTnIThr144/total cTnI ratios are shown for each sample 
(right panel; mean SEM, n=5-6), and statistical differences (p<0.05) from control are indicated 
by *. B. Representative Western blot showing site-specific phospho-antibody detection of 
cMyBP-CpSer273 (upper panels), cMyBP-CpSer282 (middle panels), and cMyBP-CpSer302 
(lower panels). Total cMyBP-C protein levels are shown in the lower rows of each panel. The 
black line between lanes indicates additional samples separated the lanes shown on the same gel 
for Westerns shown in A and B. The normalized phospho/total protein ratios were quantified for 
























 Phosphorylation of cardiac troponin I (cTnI) plays an important role in modulating 
myocardial contractile performance [3, 6]. Moreover, alterations in protein kinase C (PKC) 
activation and downstream cTnI phosphorylation are linked to cardiac dysfunction [27] [56, 65] 
[28-31].  Thus, understanding the role(s) of each cTnI residue targeted by PKC and the 
functional interplay between residues are important issues in the modulation of contractile 
function by cTnI under physiological and pathophysiological conditions. Multiple in vitro and in 
vivo studies attempted to address these questions. However, the results are complex, and 
different approaches gave rise to divergent interpretations.  Currently, there is a lack of 
consensus about the role played by PKC-targeted cTnISer43/45 phosphorylation in the 
myocardium.   
Experiments in this dissertation addressed the role PKC-mediated cTnISer43/45 
phosphorylation plays and the influence cTnISer23/24 and cTnISer43/45 communication has in 
modulating contractile function in isolated adult rat cardiac myocytes.  The first aim in this study 
was to determine whether cTnISer43/45 acts as a modulatory brake on contractile function.  
These studies were performed using gene transfer of phospho-null (Ala) or phospho-mimetic 
(Asp) substitutions at cTnISer43 and/or cTnISer45 into adult myocytes. Overall, results from this 
work demonstrated cTnISer43/45 reduces the amplitude and rate of myocyte shortening (Ch. 2 
and Ch. 3).  In addition, Ser43 and Ser45 in cTnI independently reduced contractile function, and 
results from this work were consistent with each residue working via separate mechanisms 
within the myofilament (Ch. 3). 
Expression of cTnISer43/45 substitutions in myocytes also produced adaptive changes in 
function.  Thus, the idea adaptive signaling within the myofilament contributes to the overall 
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functional response was tested in a second aim of this dissertation (Ch.3 and Ch.4).  These 
adaptive changes produced a functional response comparable to results obtained in intact animal 
models.  Thus, extensive cTnISer43/45Asp expression levels produced dynamic signaling 
modulation across the myofilament. To better understand adaptive signaling, experiments then 
focused on the relationship between Ser23/24 and Ser43/45 in cTnI, which are both targets for 
PKC.   Phospho-mimetic cTnISer43/45 expression increased cTnISer23/24 phosphorylation, and 
yet the impact of this cTnI substitution produced a different functional response than cTnI 
containing Asp substitutions at all 4 residues (e.g. cTnIAspQuad; Ch. 3 vs. Ch. 4).  Results from 
this study indicate myofilament function is sensitive to the distribution and/or turnover of 
adaptive phosphorylation (Ch. 4).  In summary, results from the present study provided insight 
into the direct role of cTnISer43/45 and the dynamic adaptive responses contributing to cTnI 
modulation of contractile function.  Moreover, this work showed the cellular approach used here 
is an important bridge for resolving controversies arising from earlier myofilament and genetic 
animal model studies.  
SIGNIFICANT FINDINGS 
Chemical properties of substitutions at cTnISer43/45 influence contractile function  
The functional modulatory role of cTnISer43/45 phosphorylation is examined in the 
present group of studies by expressing phospho-null cTnISer43/45Ala and phospho-mimetic 
cTnISer43/45Asp substitutions in adult cardiac myocytes (Chs.2-4).  Both substitutions are 
expressed and incorporated into the sarcomere of myocytes after gene transfer to a comparable 
extent as cTnI.  The Ala substitution is functionally conservative at other sites, including 
Ser23/24 in cTnI, and not anticipated to change contractile function compared to controls [43, 
78].  In contrast, expression of cTnISer43/45Asp should mimic phosphorylation at this site and 
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reduce contractile function.  Indeed, comparable contractile function is observed in controls and 
in myocytes with <50% cTnISer43/45Ala replacement of endogenous cTnI. These results are in 
keeping with the lack of change in cardiac function observed in a transgenic (tg) 
cTnISer43/45Ala mouse model with ≈50% replacement of endogenous cTnI (Table 1.1)[72].  
However, myofilament Ca2+ sensitivity of tension in permeabilized myocytes and peak 
shortening amplitude in intact myocytes decreased while the later stages of re-lengthening 
became faster (e.g. TTR50%) with more extensive cTnISer43/45Ala expression.  These findings 
could result if hydrogen bonding by hydroxyl groups present in Ser is lost when Ala, which 
contains a less polar methyl side chain, replaces this residue.  The cTnISer45 residue is predicted 
to interact with cTnC Glu10 via this type of weak ionic interaction, and the functional alterations 
observed with cTnISer43/45Ala could result from disruption of this interaction [71].  The 
dramatic rightward shift in myofilament Ca2+ sensitivity of tension observed in the knock-
out/knock-in cTnIAla5nb mice, with complete replacement of endogenous cTnI, further reinforces 
this conclusion [64] (Table 1.1). 
An additional component of this study focused on the role cTnISer43/45 plays during 
PKC activation by the agonist, endothelin-1 (ET-1, Ch. 2).  If PKC targets cTnISer43/45 in 
response to activation by ET-1, the accelerated relaxation rate attributed to cTnI phosphorylation 
during this response should be absent [78, 86].  While the re-lengthening rate, measured as 
TTR50%, is significantly slowed with cTnISer43/45Ala compared to controls during ET-1 
treatment, a more indirect process also may explain this experimental outcome. This conclusion 
is based on the accelerated basal re-lengthening produced by cTnISer43/45Ala as well as 
evidence phospho-mimetic cTnISer43/45Asp slows re-lengthening (Ch. 2 and Ch. 3). Taken 
together, the observations made in the present study could indicate cTnISer43/45Ala prevents 
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PKC from phosphorylating other cTnI residues and/or blocks the phosphorylation-induced thin 
filament transduction necessary for the ET-1-mediated acceleration of re-lengthening.  The 
altered basal and ET-1-induced contractile function observed with cTnISer43/45Ala suggests the 
Ser residues in this cluster play an essential role in defining the 3-dimensional orientation or 
structure of cTnI under basal conditions and in response to neurohormonal PKC activation.  Due 
to the chemical properties of Ala, the current studies with cTnISer43/45Ala are unable to 
definitively demonstrate the contribution of this cluster to neurohormonal modulation by PKC in 
myocytes.  
 While the Ala substitutions produced unanticipated changes in contractile function, the 
reduced rate and amplitude of peak shortening as well as the rightward shift in Ca2+ sensitivity 
observed with Asp substitutions at cTnISer43/45 are in agreement with the consensus ideas 
derived from biochemical studies about the functional impact of PKC-mediated phosphorylation 
this residue cluster (Ch. 3).   Previous studies demonstrated reconstitution of exhaustively 
phosphorylated cTnI into myofibrils reduced Ca2+ sensitivity and maximum actomyosin ATPase 
activity, and cTnISer43/45 phosphorylation levels strongly correlated with the functional 
response relative to the levels of cTnI phosphorylation at Ser23/24 and Thr144 [68] [51] [60, 
61].  Further work established phospho-mimetic Asp or Glu substitutions at Ser43/45 reduced 
cross-bridge cycling rate and actomyosin Ca2+ sensitivity [49, 68]. To date, only the impact on 
maximum isometric tension observed in the current studies differs from published work with 
cTnISer43/45Glu, which reduces peak isometric tension [68].  A smaller number of attached 
cross-bridges was proposed as a likely reason to explain the differential influence of Glu versus 
Asp in chapter 3, which could result from a subtle change in tropomyosin (Tm) positioning to 
prevent complete myofilament activation.  In keeping with this idea, peak tension and thin 
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filament conformation also differ slightly in the presence of rigor versus cycling cross-bridges 
[130].  Besides the difference in maximum tension, the present studies are consistent with earlier 
work on PKC-mediated cTnI phosphorylation and studies with phospho-mimetic substitutions at 
Ser43/45 in cTnI [49, 61 204, 62, 67, 68].  In addition, the current work adds to this research area 
by showing there is a length-dependent component to the influence of cTnISer43/45Asp on 
myofilament Ca2+ sensitivity of tension (Ch. 3).  Collectively, studies with cTnISer43/45Asp 
indicate phosphorylation of this cluster acts as a modulatory brake on function, and the length-
dependent response observed with cTnISer45Asp suggests the greatest influence of 
phosphorylation in this cluster should be observed with increased preload. 
Myocyte studies provide insight into the divergent functions attributed to cTnI 
phosphorylation  
My work in isolated myocytes provides insight into the often divergent conclusions 
reached in myofilament and genetic animal model studies.  Thus, this approach helped to resolve 
controversies about the modulatory role of cTnISer43/45 phosphorylation on function, which are 
due in large part to divergent functions observed when phospho-null Ala is substituted for 
Ser/Thr at PKC-targeted residues [47, 64].  Overall, the functional changes produced by 
cTnISer43/45Ala expression in this work are consistent with the majority of myofilament studies 
on cTnISer43/45 phosphorylation and/or work with cTnISer43/45Ala in myofilaments and 
transgenic (tg) animals [45, 72].  The diminished function observed after more extensive 
replacement with cTnISer43/45Ala in the present study also is in agreement with basal myocyte 
function measured in the cTnIAla5nb mouse model [64].  Endogenous cTnI is completely 
replaced by cTnI containing Ala at all 5 PKC-targeted residues (i.e. Ser23/24, Ser43/45 and 
Thr144) in this mouse model [47, 64].  The present studies show cTnISer43/45Ala caused a 
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decrease in myofilament Ca2+ sensitivity, which is also evident in cTnIAla5nb myocytes [64].  
The controversy arising from the cTnIAla5nb study is primarily caused by the interpretation of 
cTnISer43/45 function in this mouse model, with important contributing factors being the 
absence of in vivo cardiac function measurements, failure of the authors to discuss the 
physiological significance of the rightward shift in Ca2+ sensitivity in cTnIAla5nb myocytes and 
lack of consideration given to alternative data interpretations [64].   
My studies show the cTnISer43/45Ala substitution is not functionally conservative and 
could therefore cause cardiac dysfunction, which is a significant consideration for the cTnIAla5nb 
studies [47] [45, 64].   This functional change also impacts the interpretation of results obtained 
with ET-1 activation of PKC in cTnIAla5nb myocytes. In functional studies with wild-type and 
cTnIAla5nb myocytes, ET-1 increased myofilament Ca2+ sensitivity and slowed re-lengthening 
rate in wild-type myocytes in the presence of a phosphatase inhibitor, and this response is 
attenuated in cTnIAla5nb myocytes [64].  The authors concluded their results are explained by 
PKC phosphorylation of cTnI and proposed this phosphorylation produced an increase rather 
than a decrease in myofilament Ca2+ sensitivity [47, 64].  The findings suggest the observed 
response may not be an accurate measure of PKC signaling in myocytes and could result from 
impaired responses to environmental conditions and/or confounding factors such as 
cTnISer43/45Ala-induced changes in conformational positioning of Tn in the myofilament.  The 
current work with cTnISer43/45 substitutions shows there is a delicate balance between kinase 
and phosphatase activity (Chs. 2-4).  Different functional responses should be expected with the 
addition of a phosphatase inhibitor and/or when baseline function changes, as is observed in 
cTnIAla5nb myocytes [64].  Higher doses of ET-1 produce a similar functional response as 
phosphatase inhibition using low ET-1 doses, and high ET-1 produces a significant cellular 
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alkalosis and sensitizes cTnI to Ca2+ [86] [77, 92].  Thus, it remains possible functional 
responses attributed to ET-1-induced cTnI phosphorylation are instead due to alterations in the 
pH sensitivity of cTnIAla5nb in the myofilament. Moreover, pharmacological levels of PKC 
activation are known to increase myofilament Ca2+ sensitivity of tension independent from 
changes in cTnISer43/45 phosphorylation and are mediated by myosin light chain kinase 
(MLCK) phosphorylation of myosin light chain 2 (MLC2) [97].  In studies with cTnIAla5nb 
myocytes, there is also some evidence of compromised MLCK signaling [15, 47].  In addition, 
the Ca2+ transient response to ET-1 is elevated in intact cTnIAla5nb myocytes compared to wild-
type controls, and this mouse develops a dilated cardiomyopathy [64].  Collectively, the current 
work provides insights into the ability of Ala substitution at cTnISer43/45 to directly alter 
function and the potential for adaptive signaling to develop in cardiac myocytes.   Thus, the 
presence of both direct and adaptive mechanisms should be considered when interpreting the 
roles(s) played by PKC-mediated cTnI phosphorylation on the modulation of contraction.   
Direct role of cTnISer43/45 to modulate cardiac contractile function  
Overall, the current work with cTnISer43/45Asp substitutions provided significant 
insight into the role this cluster plays in modulating contractile function.  In previous work, 
cTnISer43/45 phosphorylation and/or phospho-mimetic substitution reduced cross-bridge 
cycling and myofilament Ca2+ sensitivity [45] [51, 68].  Thus, diminished peak shortening 
amplitude and accelerated cellular re-lengthening were anticipated in adult myocytes expressing 
cTnISer43/45Asp. The expected decrease in peak shortening is observed, but there is also a 
slowing of shortening rate. Fura-2AM-loaded myocytes also exhibits a slowing of re-lengthening 
rate compared to controls (Ch. 3). The slowed shortening rate is consistent with slowing of 
pressure development in multiple genetic animal models containing phospho-mimetic 
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substitutions at cTnISer43/45 [49, 62].  These studies also demonstrate cTnISer43Asp and 
cTnISer45Asp independently modulate function, exerting a brake-like effect on myocyte 
contraction. Both cTnI Ser23 and Ser24 phosphorylation are required to modulate cardiac 
relaxation, but these results demonstrate this is not true for cTnISer43/45 [40, 41].  In addition, 
cTnISer45Asp expression has a greater influence on cardiac myocyte contractile function based 
on the larger decrease in peak shortening and the slowed shortening and re-lengthening rates 
with comparable levels of cTnISer43Asp and cTnISer45Asp expression (Ch. 3).  Moreover, the 
absence of diminished peak shortening in myocytes expressing cTnISer43/45Asp indicates the 
individual residues may counterbalance one another at low levels of replacement, and there is 
evidence of communication between cTnISer23/24 and cTnISer43/45.   
The potential molecular mechanisms responsible for Asp substitutions at cTnISer43 
and/or Ser45 to function as a brake are discussed in chapter 3.  The most likely mechanisms 
include a reduction in Ca2+ binding to cTnC and a slowed cross-bridge detachment rate (Figs. 
5.1A, B). The slowing of Ca2+ binding is consistent with the diminished myofilament Ca2+ 
sensitivity in permeabilized myocytes as well as the reduced amplitude and rate of shortening in 
intact myocytes (Fig. 5.1A).  Recent biochemical studies also provide evidence modifications at 
cTnISer45 reduce the Ca2+ binding rate to cTnC, which may be mediated via functionally 
relevant interactions identified between this residue and the N- and/or C-lobes of cTnC [49, 70, 
71] [67].   The cTnISer43 residue resides on a different face of the -helix than Ser45, and while 
relevant Ser43 interactions are not yet known, this residue is in close proximity to upstream cTnI 
residues adjacent to the regulatory cTnC Ca2+ binding site in the cTn structural model [25].   It 
remains possible the reduced Ca2+ sensitivity produced by cTnISer43/45 also results from 
inhibited signal transduction following Ca2+ binding to the regulatory site in cTnC.  The 
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molecular changes responsible for this possibility likely depend on changes in the flexibility of 
the I-T arm within cTn and/or an overall conformational change to re-position the inhibitory 
peptide (IP) and H3/H4 helical domains, which form a significant component of the molecular 
switch and transmit the Ca2+ signal within cTn (Fig. 1.2A) [25, 119].    
The reduced Ca2+ binding rate and/or signal transduction mechanism is unable to explain 
the slowing of re-lengthening rate, which became more apparent with Ca2+ buffering in Fura2-
AM-loaded myocytes (Ch. 3 and Ch. 4).  This observation suggests cTnISer43/45 works to 
reduce cross-bridge detachment rates, which also may depend on conformational changes within 
the cTn I-T arm and/or the domains responsible for the switching mechanism in cTnI (e.g. IP and 
H3/H4 helices) (Fig. 5.1B).  This possibility is difficult to explain based on the current 3 state-
model of thin filament activation [22].  A slowing of cross-bridge detachment rate should also 
translate into faster cross-bridge attachment.  If so, the kinetics of this process should counteract 
the influence of cTnISer43/45 on Ca2+ binding, and there should be no change in shortening or 
pressure development rates. However, a 4-state model of thin filament activation has been 
recently proposed to explain hysteresis mediated by the thin filament to differentially influence 
cross-bridge attachment and detachment rates [131].  Further evidence to support this new model 
and experimental proof for slowed cross-bridge detachment in response to cTnI Ser43/45 
phosphorylation will need to be addressed in future studies.    
 The independent influence of cTnISer43Asp or cTnISer45Asp on myocyte shortening 
also suggests cTnISer43 and cTnISer45 exert their effects through separate mechanisms. As 
discussed above, cTnISer43 and cTnISer45 likely interact with different components of cTnC 
and/or cTnI to modulate function [119] [25].  If future experiments validate this idea, additional 
studies are needed to test whether the separate cTnISer43- and cTnISer45-mediated mechanisms 
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could prevent the overall conformational change needed to diminish peak shortening in myocytes 
with limited expression of cTnISer43/45Asp. The ability of cTnISer43 and cTnISer45 to counter 
the other residue after extensive replacement with cTnISer43/45Asp appears to be more subtle 
by day 4, when only a faster TTP is observed between the individual substitutions and is absent 
with cTnISer43/45Asp.  The diminished function produced by extensive cTnISer43/45Asp 
replacement is intriguing, and this effect could be explained if a threshold level of cTnISer45Asp 
exerts a dominant influence on either Ca2+ binding to cTnC or induces an overall conformational 
change in the thin filament, reducing myofilament Ca2+ sensitivity.  The later idea is possible if 
extensive replacement with cTnISer43/45Asp allows neighboring functional units to adopt the 
necessary conformational change to reduce overall myofilament Ca2+ sensitivity [3] [22].  The 
comparable functional influence of cTnISer43/45Asp and cTnISer45Asp on day 4 supports this 
idea.  Increased phospho-mimetic replacement at either cTnISer43 or cTnISer45 also could 
increase phosphorylation of the other residue, mimicking the effect of cTnISer43/45Asp. 
However, this scenario is unlikely because the individual residues produce slightly different 
effects on cardiomyocyte contraction with low and high levels of replacement at each site. 
Moreover, if phosphorylation increases at the neighboring residues after individual replacement, 
comparable contractile responses should have been observed with the individual substitutions 
and cTnISer43/45Asp, which is not the case (Ch. 3).     
 Augmented phosphorylation at cTnISer23/24 in myocytes expressing cTnISer43/45Asp 
substitutions raised the question of whether neighboring, but spatially distinct, Ser clusters 
communicate to modulate contractile function (Ch. 3 and Ch. 4). To test this idea, function was 
measured in myocytes expressing cTnIAspQuad, and the functional outcome was expected to be 
comparable to function observed with cTnISer43/45Asp replacement.  Instead, slightly different 
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functional responses are observed with each construct, providing important insight about 
communication between these Ser clusters.  One significant difference was the ability of limited 
cTnIAspQuad expression (e.g. <50%) to reduce function, which remained unchanged from 
controls at comparable cTnISer43/45Asp expression levels (Ch. 4). The continued slowing of 
myocyte re-lengthening rate after more extensive cTnIAspQuad replacement, but not 
cTnISer43/45Asp expression, also was not anticipated given cTnISer23/24 phosphorylation 
accelerates relaxation [40, 43, 70, 71, 78].  This conclusion is based on cTnISer23/24 
phosphorylation having little effect on Ca2+ association with the N-lobe of TnC but having a 
significant influence on promoting Ca2+ release from TnC [42]. These results suggest either 
cTnISer23/24Asp stabilizes the cTnISer43/45Asp structural response when present in the same 
cTnI and/or is necessary for cTnISer43/45 to reduce peak shortening amplitude and accelerate 
re-lengthening. Recent studies also showed two substitutions in the same myofilament protein 
can produce contradictory effects on Ca2+ binding and Ca2+ dissociation [105].  Thus, this data 
support the idea communication occurs between individual residues within a single cluster and 
between neighboring residue clusters within the same protein.  This work also shows 
myofilament communication is dynamic and able to influence phosphorylation at other sites in 
the same protein.    
Communication between the N-terminal residues cTnISer23/24 and cTnISer43/45 as well 
as the distal cTnIThr144 could have a significant impact on contractile function, but the 
consequences of this communication are not yet defined. Thr144 is specific to the cardiac 
isoform of TnI and is positioned in the inhibitory peptide domain adjacent to the H3 and H4 
domains, and all 3 domains act as “molecular switch” peptides. The positioning of cTnIThr144 
within cTnI suggests phosphorylation is an important mechanism for regulating the ability of the 
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switch peptide to transition between actin and TnC [25, 119] [3, 78]. If this is true, cTnIThr144 
phosphorylation could position the IP region to favor either myofilament activation or 
deactivation. The physiological importance of this residue seems obvious, and yet the functional 
role of cTnIThr144 phosphorylation remains controversial. In early in vitro work, phospho-
mimetic replacement at cTnIThr144 failed to influence maximal isometric tension or thin 
filament sliding speed in reconstituted myofibrils, indicating this residue was not functionally 
relevant [68]. In contrast, reduced maximum tension and slowed cross-bridge cycling developed 
in skinned myofibrils treated with Src-activated PKC , which phosphorylates cTnI Thr144 [59, 
78, 86]. Therefore, it is reasonable to predict cTnIThr144 phosphorylation positions cTnI to 
interact with actin. Moreover, Thr144 may position cTnI to enhance the functional influence of 
cTnISer23/24 phosphorylation on Ca2+ dissociation [116] [49]. Further work is needed to 
determine if cTnIThr144 phosphorylation also influences cTnISer43/45-dependent function.  
cTnISer43/45 substitutions produce adaptive signaling in isolated myocytes 
Another major outcome from the current work is the idea adaptive and dynamic 
myofilament signaling, produced by chronic cTnI phosphorylation at residues such as Ser43/45, 
plays an important role in modulating contractile function.  Functional adaptations were first 
identified in cTnI with phospho-mimetic Asp substitutions at Ser43 and/or Ser45 (Ch. 3).  More 
extensive studies demonstrated the presence of adaptations in cellular protein phosphorylation 
and Ca2+ handling, consistent with an adaptive functional response (Ch. 3 and Ch. 4). Although 
several potential target proteins were investigated here, additional proteins should be examined 
in the future.  Interestingly, I also found different phospho-mimetic substitutions produced 
specific adaptations within cardiac myocytes (Ch.4).  For example, cTnISer43/45Asp enhanced 
phosphorylation of cTnISer23/24 and cMyBP-CSer282 while cTnIAspQuad increased 
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phosphorylation at cTnIThr144, cMyBP-CSer273 and cMyBP-CSer282.  As discussed in chapter 
4, these adaptive differences may be due to the distribution of the adaptive response along the 
myofilament and/or to phosphorylation turnover within an individual protein. The preliminary 
evidence suggests PKD targeting to cTnISer23/24 is up-regulated while phosphatase activity is 
diminished in myocytes expressing Asp substitutions at cTnISer43/45 (Ch. 3). In addition, the 
specific compensatory response observed with cTnISer43/45Asp compared to cTnIAspQuad, 
along with some in vivo data, suggests there may be an organized layering to the adaptive 
response. This organized layering could be spatially or temporally regulated and/or dependent on 
other environmental factors.  Further work will be necessary to identify the signaling pathways 
and mechanism responsible for the adaptive responses.  
 Additional modifications within cTnI and cMyBP-C cannot be precluded from 
contributing to the adaptive response. Within cTnI, 14 residues, including 6 novel sites, have 
been identified by improved mass spectroscopy techniques (Table 5.1)[27]. Many of the novel 
sites identified are located in the N and C terminal domains of cTnI and could be important for 
coordinating the influence of cTnISer43/45 on either Ca2+ binding or cross-bridge dissociation. 
For example, the AMP-activated protein kinase (AMPK)-targeted residue cTnISer150 produces 
a leftward shift in myofilament Ca2+ sensitivity, which may counter the slowed Ca2+ binding to 
TnC with cTnISer43/45Asp substitutions (Ch.3 and Ch.4) [132]. Additionally, 14 candidate sites 
phosphorylated by AGC and/or Ca2+/Calmodulin-dependent (CaMK) kinases were identified as 
in vivo targets for rat cMyBP-C, and many are located in the functionally relevant N-terminus 
(Table 5.1)[125, 133]. However, analysis of site-specific phosphorylation at these residues is 
limited by a lack of commercially available phospho-antibodies. Overall, it will be critical to 
identify the signaling pathways responsible for mediating phosphorylation at each of the sites 
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targeted during the adaptive signaling response.  Eventually, studies to investigate adaptive 
signaling in vivo will be needed after a more comprehensive understanding of the adaptations, 
signaling pathways and conditions contributing to compensation is achieved in a less complex 
model, such as the cardiac myocyte.   
Dynamic signaling is likely not limited to the changes identified in cTnI and cMyBP-C in 
the present study.  Multiple sarcomeric and Ca2+ handling proteins are phosphorylated by the 
AGC and CaMK families of kinases, and work to modulate contractile function and Ca2+ cycling 
(Table 5.1, Fig. 5.2)[134]. For example, myosin light chain (MLC) phosphorylation in the thick 
filament accelerates cross-bridge detachment from the myofilament and could counteract the 
slowed cross-bridge detachment proposed to explain results with cTnISer43/45Asp [15]. 
Alternatively, phosphorylation at troponin T (TnT) may be elevated in myocytes expressing 
cTnIAspQuad. Augmented cTnT diminishes cross-bridge cycling, mitigating the probability 
phosphorylation increases when cTnISer43/45Asp is expressed [135]. However, increased TnT 
phosphorylation also could counteract the accelerated TTP at day 2 in myocytes expressing 
cTnIAspQuad (Ch. 4). Moreover, augmented PLB phosphorylation can contribute to the 
accelerated Ca2+ decay in these studies, but the lack of statistical significance indicates other 
Ca2+ handling proteins may also be involved in the adaptive response. Increased expression of 
the Na+-Ca2+ exchanger (NCX) and enhanced Ca2+ expulsion from the cytosol is also possible, 
but further work is necessary to confirm this hypothesis [136, 137].  
 The current studies also indicate it will be important to identify the kinases and 
phosphatases contributing to the adaptive response.  Myofilament phosphorylation is coordinated 
by a large regulatory network, and multiple Ser/Thr kinases phosphorylate cTnI (Figs. 5.2A-C).  
Preliminary experiments addressed potential mechanisms underlying adaptive cTnISer23/24 
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phosphorylation (Ch. 3). Protein kinase A (PKA), activated via -AR signaling, phosphorylates 
cTnI (Ser23/24), cMyBP-C (Ser273, Ser282, and Ser302), and PLB (Ser16) [5, 32, 104, 113, 
138]. I investigated whether phospho-mimetic substitution at cTnISer43/45 enhanced PKA-
mediated phosphorylation at cTnISer23/24, but PKA inhibition in preliminary work did not 
mitigate the adaptive cTnISer23/24 phosphorylation (Fig. 3.10).  PKA also inhibits protein 
phosphatase 1 (PP1) activity and could increase cTnI phosphorylation via this indirect 
mechanism (Fig. 5.2A) [5]. However, other kinases could contribute to this adaptive response.   
Recently, PKD emerged as an important mediator of stress-activated signaling in cardiac 
myocytes and is capable of phosphorylating cTnISer23/24 and cMyBP-CSer302 (Fig. 5.2C) [93, 
139] [94, 111, 140]. Preliminary analysis showed protein kinase D (PKD) inhibition also 
partially restored cTnISer23/24 phosphorylation to control levels with increased cTnISer43/45 
phospho-mimetic replacement (Figs. 3.7, 3.10). Moreover, the preliminary work is consistent 
with PKD activating a phosphatase, as phosphorylation at cTnISer23/24 increased in all groups 
following PKD inhibition (Fig. 3.10). Currently, PKD-mediated regulation of phosphatase 
activity has not yet been reported in a cardiac myocyte [5, 141]. Direct and indirect modulation 
by PKD suggests this kinase may participate in bifurcated signaling, whereby a single stimulus 
activates kinase and phosphatase activity which serves to amplify a signal [114, 120, 121]. A 
bifurcated mechanism would explain altered phosphorylation at both cTnISer23/24 and cMyBP-
CSer273/282, since these cMyBP-C residues are not directly phosphorylated by PKD [93, 94, 
114]. Alternatively, protein kinase G (PKG), a cyclic-GMP activated kinase, also phosphorylates 
(cTnI Ser23/24) and cMyBP-C (Ser273) in response to oxidative stress [95, 96] [142-144](Table 
5.1; Figure 5.2C). PKG may play a prominent role in the adaptive response observed in the 
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current studies, but further work with pharmacological inhibitors are needed to confirm this 
hypothesis [95, 96].  
Protein kinase C (PKC) is another possible kinase which could play a critical role in 
modulating cTnI and cMyBP-C phosphorylation, but the role of this kinase was not 
experimentally addressed here. Classical and novel PKCs are the primary isoforms present in the 
heart, and the activity of these isoforms is up-regulated during cardiac dysfunction [57, 58] [56, 
65].  The novel class kinases are thought to directly phosphorylate myofilament proteins, 
including both cTnI and cMyBP-C (Fig. 5.2B) [56-58] [60, 61, 145]. Both in vitro and in vivo 
studies show novel class PKCs phosphorylate cTnI Ser43/45 and Thr144, with PKC  favoring 
cTnISer23/24, as well as cMyBP-C at Ser273 and Ser302 [60] [59, 61, 146] [147, 148]. 
Conversely, classical PKC isoforms coordinate kinase/phosphatase targeting to the myofilament 
and do not necessarily execute their functional effects via direct phosphorylation of myofilament 
targets.  Instead, they are proposed to function as a mini-processor to modulate multiple 
pathways within a cardiac myocyte (Fig. 5.2B) [50] [102, 114, 141, 149, 150].  Hwang et al. 
proposed PKC II activates a bifurcative pathway by simultaneously activating PKD and 
phosphatases [114, 141]. Aside from the ability of PKA to target sarcomeric proteins and reduce 
phosphatase activity, the contribution of other kinases to the complex phosphorylation pattern 
observed with cTnISer43/45 phospho-mimetic expression is not yet determined. However, 
amplification of the adaptive signal by a “processor” kinase such as PKC could work to produce 
a sustained adaptive response.  If so, this pathway could provide the basis for a central 
mechanism underlying the adaptive signaling identified in the present studies.  
In the present model, enhanced cTnISer23/24 phosphorylation was predicted to result 
from increased kinase activity (Fig. 3.7). However, preliminary analysis utilizing the 
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phosphatase inhibitor calyculin A (Cal A) indicated phosphatase activity may be reduced in 
myocytes expressing cTnISer43/45 substitutions (Fig. 3.10). Cyclic regulation, or turnover, of 
phosphorylation is as equally important for normal cardiac function as the phosphorylation state.  
Phosphatases serve as a critical regulatory mechanism to produce phosphorylation turnover (Fig. 
5.2) [114, 121]. In the heart, the Ser/Thr phosphatase protein phosphatase 1 (PP1) and protein 
phosphatase 2A (PP2A) are active and target a large array of cardiac proteins [5, 128, 129]. 
Three isoforms of PP1’s catalytic subunit are expressed in cardiac tissue including PP1 , 
PP1 / , and PP1 , and the catalytic subunit associates with a diverse network of regulatory 
subunits to provide either substrate specificity or regulation of enzyme activity [129]. One well 
characterized regulatory protein for PP1 is inhibitor-1 (I-1), and its post-translational 
modification by both kinases and phosphatases regulate the ability of I-1 to inhibit PP1 activity 
[5, 129]. PKA-mediated phosphorylation at Ser35 on I-1 causes increased association between I-
1 and PP1, and reduces phosphatase activity in order to maintain the positive inotropic response 
induced by PKA activation.  Conversely, PKC  phosphorylates I-1 at Ser67, which inhibits I-1 
interactions with PP1, and results in elevated phosphatase activity [5, 141].  
Protein phosphatase 2A also targets many myofilament proteins including cTnI, and in 
vitro phosphorylation assays indicate PP2A uniformly dephosphorylates the protein [151]. 
Unlike PP1, PP2A forms a heterotrimeric protein consisting of a catalytic subunit (PP2A-C) 
dimerized with a scaffolding subunit (PP2A-A), but not an inhibitory subunit [128, 129]. Instead, 
phosphorylation at tyrosine 307 (Tyr307) on the catalytic subunit inactivates the phosphatase 
[128, 151]. In contrast, increased methylation at leucine 309 (Leu309) in the catalytic subunit 
actives PP2A, which enhances heterotrimer formation with a scaffolding subunit [128] [152]. 
There are 4 families of regulatory proteins, and many function within the heart, although their 
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expression is species and chamber-specific [128, 129]. Among these regulatory subunits, B56  
directs PP2A targeting to myofilament proteins [128, 129, 151, 153]. Collectively, the data 
shows increased replacement at cTnISer43/45 with Asp substitutions produces adaptive signaling 
with preliminary indication there may be increased kinase and reduced phosphatase activity. 
However, additional studies are needed to obtain adequate statistical power. This work also did 
not directly address the underlying mechanism for the altered kinase/phosphatase balance. 
Further studies are necessary to determine whether a similar change in kinase and phosphatase 
activity is produced by cTnIAspQuad. Moreover, it will be important to determine if the adaptive 
response originates from a structural change within cTnI or a reduction in phosphorylation 
turnover introduced by a phospho-mimetic substitution.  
The cTnIAspQuad and cTnISer43/45Asp constructs were expected to produce functionally 
similar outcomes due to the adaptive cTnISer23/24 phosphorylation arising from extensive 
cTnISer43/45Asp expression. However, the individual responses produced by the two constructs 
suggest there are different mechanisms contributing to the overall function response, which 
could be attributed to differences within a single cTnI versus across the myofilament and/or to a 
loss of phosphorylation turnover at cTnISer23/24 (Ch. 4). While the current work is unable to 
distinguish between these possibilities, the results provide evidence for a multi-layered signaling 
mechanism utilizing a distinct pattern of local, regional and/or distal adaptive responses. When 
one component of the signaling pathway is removed, the pathway is able to modify other protein 
targets to maintain cellular function.  For example, when cTnISer23/24 is no longer available for 
phosphorylation in cTnIAspQuad, phosphorylation increases in other local and regional targets, 
such as cTnIThr144 and cMyBP-C, while decreasing at more distal targets, such as PLB.  
Changes in kinase and phosphatase distribution throughout the cell may underlie this change. 
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Movement of a phosphatase away from the myofilament and towards PLB would explain the 
phosphorylation pattern produced by cTnIAspQuad. Conversely, a kinase may be recruited to cTnI 
and cMyBP-C to enhance phosphorylation at a target residue, such as cTnIThr144. 
Physiological and pathophysiological role of cTnISer43/45 on contractile function 
The distinct phosphorylation pattern produced by the cTnI phospho-mimetics indicates 
there are specific signaling mechanisms in play to respond to changes in the cellular 
environment, which may be mediated via both spatial and temporal regulation. For example, 
localization of signaling components could change in response to neurohormonal input to the 
cell. In agreement with this prediction, the PP2A regulatory protein B56  moved away from the 
myofilament in ventricular myocytes following treatment with the PKA agonist isoproterenol.  
The same protein remained associated with the myofilament after treatment with the PKC-
agonist ET-1 [154]. This spatio-temporal localization also may be important during the 
progression of heart failure.  Global phosphatase activity increases in end-stage heart failure, and 
more recent work suggested enhanced activity may be localized to specific subdomains within 
the cell [129, 153] [5, 127]. Additionally, temporal regulation of signaling also appears to be 
important for responding to cellular changes. In the heart, up-regulation of PKA develops during 
the early stages of cardiac stress, and as cardiac dysfunction progresses, PKA activity is reduced 
and phosphatase activity increases [5, 32, 124, 127, 153]. The present studies suggest adaptive 
signaling is an important part of maintaining physiological function in the heart.  Signaling 
adaptations are modulated by environmental factors, such as the physiological state of the heart, 
and loss of adaptive modulation is expected to accelerate the transition to heart failure. 
Therefore, dissecting out the precise signaling mechanism(s) contributing to the adaptive 
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response in cellular and in vivo models is essential for identifying the role adaptive signaling 
plays in both cardiac physiology and pathophysiology. 
A significant portion of the current work focused on the ability of cTnISer43 and 
cTnISer45 to act as a modulatory brake on cardiac function. However, changes in the 
myocardium during cardiac stress may alter compensatory signaling so cTnISer43/45 
phosphorylation becomes maladaptive. In a healthy heart, the ability of cTnISer43/45 to function 
as a brake is postulated to be important for short-term regulation (e.g. beat to beat; Fig.5.3A). 
Sudden changes in hemodynamic load could activate PKC signaling [155, 156]. Transiently, 
increased PKC activity is predicted to directly target the myofilament, and phosphorylate 
proteins, such as cTnISer43/45, to reduce ATPase activity, unloaded shortening velocity and 
pressure development in an effort to preserve cardiac energy stores and/or reduce arterial 
pressure [51, 64, 68, 73, 74, 114]. The resulting reduction in myocyte contraction could shorten 
the ejection phase of the cell cycle to reduce stroke volume, decrease cardiac output, and restore 
arterial pressure back toward previous steady-state levels [1]. Short-term functional regulation by 
cTnISer43/45 phosphorylation is not expected to stimulate adaptive signaling, but 
neurohormonal inputs released by mechanical stretch and sustained hypertension, such as 
angiotensin II, could activate multiple signaling pathways, including PKC, to produce a different 
response [155, 157]. The data are consistent with adaptive signaling playing a more prominent 
role during chronic cTnISer43/45 phosphorylation, which could develop during compensated 
cardiac dysfunction. 
The effects of cTnISer43Asp/Ser45Asp on contractile function closely match the cellular 
alterations produced by short-term acidosis, an early and critical element of myocardial ischemia 
[9, 158 372].  Therefore, it is reasonable the observations made in the present study could 
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provide insight into the mechanism activated during an early, compensatory stage of cardiac 
dysfunction (Fig.5.3B) [9, 158 372]. Chronic -AR signaling in the heart helps maintain cardiac 
pump function in the compensatory state [32] [124].  While this response may be initially 
beneficial for preserving contractile function, it depletes cardiac ATP levels [47, 159] [79]. As in 
healthy hearts, increased cTnISer43/45 phosphorylation could act as a brake to reduce the 
enhanced cross-bridge cycling produced by -AR activation in an effort to preserve cardiac 
energy stores (Ch. 3 and Ch. 4) [159, 160] [79]. Increased cTnISer43/45 phosphorylation is 
expected to reduce cardiac ejection of blood, but the data also suggest the adaptive increases in 
cTnI, cMyBP-C, and PLB phosphorylation observed with cTnISer43/45Asp and in acidotic 
hearts are part of a compensatory signaling mechanism designed to maintain systolic and 
diastolic function [79, 158, 159].   
Over time, metabolic demands may compete against and dominate over these adaptive, 
compensatory responses.  At this transition point, the heart progresses into decompensatory heart 
failure characterized by diminished force production and contractile function (Fig. 5.3C) [122, 
124]. PKC expression and activity are persistently elevated in failing hearts while PKA activity 
decreases during end-stage heart failure [5, 30, 56, 65].  In addition, PKD and PKG are known 
stress-activated kinases which may further contribute to the transition into a decompensatory 
state [142, 161]. Dysregulation of phosphatase activity also is gaining recognition as a prominent 
contributor to the development of heart failure [5, 127-129, 153]. Increased phosphatase activity 
could result from sustained activation by classical PKC isoforms and/or other kinases along with 
a loss in PP1 inactivation by PKA (Ch.3) [5, 127, 141]. However, PP2A activity is reduced in 
failing hearts with ischemic cardiomyopathy, supporting the idea specific environmental factors 
may produce spatio-temporal differences in the overall phosphorylation state [128]. Indeed, 
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samples from patients in end-stage heart failure exhibit increased phosphatase activity and 
reductions in both cTnI and cMyBP-C phosphorylation [125-128, 153]. However, cTnISer43/45 
phosphorylation remains elevated in human and animal models of heart failure [27, 30, 31] [65]. 
Based on the present findings, the loss of phosphorylation turnover at cTnISer43/45 may 
eliminate the ability of this cluster to function as a modulatory brake, and could eventually 
contribute to contractile dysfunction if and when adaptive mechanisms are lost and/or no longer 
functional. Thus, loss of signaling modulation within the heart could result in cTnISer43/45 
phosphorylation-mediated reductions in both systolic and diastolic dysfunction, which would 
accelerate the progression to end-stage heart failure [49, 62] [24, 42, 68, 105].  
Current in vivo models of PKC-mediated cTnI phosphorylation highlight the importance 
of maintaining the balance between kinase and phosphatase activity.  In addition, disruption of 
this balance is expected to impact the phenotypes observed in animal models with phospho-
mimetic substitutions at the PKC sites.  Mice expressing cTnIPKC-P exhibited compromised 
systolic function and diastolic function, similar to those anticipated in end-stage heart failure 
[62].   These results are puzzling given the severe cardiac phenotype observed with minimal 
expression and the lack of compensatory adaptations detected in this mouse.  In contrast to the 
cTnIPKC-P mouse, the preservation of peak pressure in the cTnIAllP mouse suggests compensatory 
adaptations are present in this model [49]. Future work is needed to identify the role adaptive 
signaling plays in producing the phenotypic differences between the cTnIPKC-P and cTnIAllP 
mouse models, though compensatory signaling was not detected in cTnIAllP mice [49]. However, 
Ca2+ handling and cMyBP-C phosphorylation were not evaluated in the cTnIAllP model, and 
treatment with the PKA agonist, dobutamine, produced a heightened acceleration of relaxation, 
arguing for the presence of adaptive signaling in these mice [49]. Loss of cTnISer23/24 
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phosphorylation turnover and altered adaptive signaling in the cTnIAllP model could mean this 
mouse is more susceptible to heart failure in response to stressors such as myocardial ischemia 



















Chemical properties and substitutions at cTnISer43/45 influence contractile function 
The cTnISer43/45Ala results indicate future work is needed to gain insight into the key 
interactions between Ser43/45 and other residues within cTnI and/or cTnC, their influence on 
thin filament function under basal conditions and their influence in response to PKC activation. 
Ala replacement at cTnISer43/45 is predicted to disrupt polar interactions with TnC and cause 
the functional changes observed with cTnISer43/45Ala expression.  Thus, gene transfer of cTnI 
containing a more polar residue such as asparagine (Asn) should either produce no change and/or 
the opposite influence on function compared to Ala.  At the biophysical level, studies with 
FRET-labeled cTnC also are needed to evaluate the impact of cTnISer43/45 Ala versus Asn 
substitutions on ionic interactions between cTnI and the N- and C-lobes of cTnC in reconstituted 
myofilaments.  Another focus for molecular studies would include efforts to distinguish between 
cTnISer43 versus cTnISer45 phosphorylation during PKC activation.  Currently, it is often 
difficult to distinguish between these residues by mass spectrometry, and efforts to generate 
phospho-specific antibodies by a number of investigators have been unsuccessful [30] [27, 162].  
The cTnISer43 site conforms to the most popular consensus sequence for phosphorylation by 
PKC while the sequences flanking cTnISer45 form a less recognized motif [163].  The 
identification of the most likely residue targeted for phosphorylation will require continued 
improvements and advances in mass spectrometry approaches.   The knowledge gained from the 
proposed biophysical and cellular studies is expected to be important for the development of 
small molecule therapeutics if in vivo work proposed later in this chapter demonstrates 
cTnISer43/45 phosphorylation plays a significant role in producing contractile dysfunction 
during heart failure.        
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The controversies arising from studies performed with the cTnIAla5nb mouse point to the 
need for additional work in this animal model.  Studies are needed to determine in vivo cardiac 
function, the nature of adaptive signaling, and the progression to heart failure produced by 
expression of cTnIAla5nb.  Results from this work could lead to studies focused on gaining 
further insight into adaptive signaling patterns and determining if cTnIAla5nb hearts are more 
susceptible to heart failure induced by other environmental stressors such as myocardial ischemia 
and/or hypertension.  In addition, cellular gene transfer studies with the same construct should 
mimic the responses observed in myocytes from the genetic animal model.  Direct versus 
adaptive influences of cTnIAla5nb on function could be uncovered in the event divergent 
outcomes are observed between cellular and in vivo studies. 
Direct role of cTnISer43/45 in the modulation of contractile function 
Important gaps remain in our understanding of cTnI inter-domain interactions and 
cTnC/cTnT interactions with the region around cTnISer43/45. Understanding the molecular 
structural changes within cTnI and neighboring Tn subunits will be important to investigate 
using substitutions at cTnISer43 and cTnISer45, which produce diverse functional responses.  
Further work utilizing molecular modeling techniques and biochemical approaches also is 
necessary to predict potential residue contacts between cTnISer43/45 and additional cTn 
subunits [25, 119]. Less is known about the molecular contacts between cTnISer43 and other 
cTn domains, and molecular modeling could help to predict the most likely proximal residues for 
interaction within the cTn core. Additional modeling also could predict how interactions could 
modify the response to cTnISer43 phosphorylation. The relevance of the predicted interactions 
should then be evaluated using biochemical approaches such as actomyosin MgATPase activity 
and FRET-measurements of Ca2+ association/ dissociation with cTnC [42, 67, 70, 105]. 
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Phosphorylation at cTnISer43Asp also could increase IT arm rigidity and diminish interactions 
with TnC, reducing both MgATPase activity and Ca2+association with TnC.  These molecular 
approaches are less complex and more efficient for testing prior to the transition to cellular or in 
vivo models. However, the increased phosphorylation of cTnISer43/45 under pathological 
conditions indicates these ideas also need further analysis in more complex models.   
Adaptive signaling by cTnISer43/45 substitutions  
My results also demonstrate changes within the cTnI backbone can modify function and 
adaptive signaling in response to amino acid substitutions at cTnISer43/45 with and without 
substitutions at cTnISer23/24 (e.g. cTnIAspQuad vs. cTnISer43/45Asp). However, the influence 
of structural positioning on function caused by multi-residue replacement within cTnI or the loss 
of turnover at cTnISer23/24 has led to controversies. Previous molecular modeling studies 
revealed the cTnI-specific, N-terminal extension interacts with the N-lobe of TnC, and this 
interaction is reduced by phosphorylation or phospho-mimetic substitution at Ser23/24 [117] 
[118]. Phosphorylation at cTnISer43/45 is predicted to increase I-T arm rigidity, and the 
combined Ser23/24 modification in the same cTnI (e.g. cTnIAspQuad) may target multiple 
molecular changes within cTn as well as kinase and phosphatase targeting of residues within a 
single cTnI.  Conformation changes along the myofilament also could contribute to altered 
kinase and phosphatase activity throughout the sarcomere and/or could amplify the functional 
and signaling responses caused by the structural changes induced by cTnISer23/24 and 
cTnISer43/45 modifications. Molecular modeling techniques, especially 3D reconstruction, 
along with biochemical studies will be important approaches needed to study and prove this idea 
[164]. Moreover, modeling the interaction between the N-terminal domain of cTnI and kinases 
and/or phosphatases via molecular dynamics could allow a more accurate prediction signaling 
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components which interact with Tn. Immunoprecipitation, in vitro binding assays, and 
myofilament FRET assays to evaluate Ca2+ binding are relevant approaches for confirming the 
modeling results. These approaches also may help identify additional molecular players 
contributing to compensatory signaling as well as the structural alterations responsible for 
modulating cellular communication.  
The mechanism underlying individual adaptive responses produced by cTnISer43/45Asp 
compared to cTnIAspQuad could also be addressed in physiologically relevant cellular and animal 
models.  If the adaptive response is modulated by negative charge distribution along the 
myofilament, dual gene transfer of cTnISer23/24Asp and cTnISer43/45Asp cTnI constructs into 
isolated cardiac myocytes should produce a functional response similar to cTnISer43/45Asp (e.g. 
increased cMyBP-CSer282). However, if loss of phosphorylation turnover determines the 
adaptive response, the adaptations and function measured in these myocytes is expected to 
resemble the functional response produced by cTnIAspQuad (e.g. enhanced cTnIThr144 and 
cMyBP-CSer302 phosphorylation). Phosphatase inhibition with Cal A also would be a direct 
approach for identifying the role of altered phosphorylation turnover. An additional approach, 
such as siRNA-mediated inhibition of a specific phosphatase, could be used to identify the 
precise cellular components participating in the adaptive response.  A set of in vivo experiments 
should also be performed to determine whether loss of functional modulation at specific PKC-
targeted residues within cTnI changes compensatory phosphorylation and/or if global disruption 
of phosphorylation turnover is sufficient to produce this response.  In addition, a comparison of 
adaptations observed in the cTnIPP and cTnIAllP mice could further address the importance 
cTnISer43/45 phosphorylation in stimulating compensatory signaling in vivo. Dynamic 
modulation of myofilament phosphorylation is a requirement for maintaining normal 
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physiological function. Significant alterations to cTnISer23/24 phosphorylation and 
kinase/phosphates activity occur during cardiac stress, and the proposed experiments in animal 
models could identify therapeutic targets to prevent or ameliorate the progression to cardiac 
dysfunction [27, 56, 65, 127] [29, 31].  
Though preliminary studies provided some candidate signaling components important in 
the cTnISer43/45Asp-induced adaptation, further clarification of the kinases and phosphatases is 
necessary to gain mechanistic insight.  The putative alterations in kinase/phosphatase activity in 
response to cTnISer43/45 phospho-mimetic replacement are illustrated in the lower panel of Fig. 
5.4.  Based on preliminary studies, increased PKD activity and diminished phosphatase 
activation are expected to result in the observed augmentation of cTnISer23/24 phosphorylation 
with cTnISer43 and/or cTnISer45 containing Asp substitutions (Fig. 5.4). However, the inability 
of PKD inhibition to completely restore cTnISer23/24 phosphorylation to control levels warrants 
additional investigation into the role of other kinases, such as PKG and PKC. The use of dual 
gene transfer of a dominant negative PKC isoform with cTnISer43Asp and/or cTnISer45Asp into 
isolated myocytes is one potential approach.  Based on previous work, this approach will require 
extensive controls to demonstrate the expression and activation of other PKC isoforms are not 
influenced by this change [102].  If PKC directly targets cTnISer23/24 in myocytes expressing 
these Asp substituted cTnIs and dominant negative PKC, reduced phosphorylation is expected, 
which could be detected by Western blot. Alternatively, PKC could modulate a phosphatase, and 
PKC inhibition would reduce phosphatase activity, resulting in enhanced cTnISer23/24 
phosphorylation. Another candidate kinase is protein kinase G (PKG), which is activated in 
response to oxidative stress and nitric oxide production in the heart [142] [95, 96]. Myocytes 
could be treated with a commercially available PKG inhibitor, KT5823, prior to evaluating the 
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phosphorylation level of target residues with site-specific phospho-antibodies via Western blot.  
Cells treated with individual inhibitors targeting a range of kinases also could be used to 
determine whether these kinases participate in the adaptive response.  For example, treatment 
with the PKC inhibitor bisindolylmalemide (Bis-I) or kb-Nb-142-70 (PKD) could each attenuate 
adaptive cTnISer23/24 phosphorylation if PKC is working upstream of PKD. However, if both 
inhibitors need to be added together to obtain restoration of cTnISer23/24 phosphorylation to 
control values, it would indicate the target kinases are working through separate signaling 
pathways. Because PKC, PKD, and PKG also are associated with a cardiac dysfunction, this 
work may provide insight into whether a specific stress signal works through a single pathway or 
if multiple signaling cascades can be activated by an individual change within the myofilament. 
The present studies investigating the adaptive communication pathway fail to identify the 
phosphatase contributing to cellular communication (Fig. 5.4). Further studies will be needed to 
investigate if PP2A activity is reduced by phospho-mimetic replacement in cTnI. PP2A is 
inactivated in ischemic human heart failure suggesting PP2A is important for regulating cardiac 
function [128]. Western blot analysis using site-specific antibodies for methylation of the 
activation site Leu309 and phosphorylation of the deactivation site Tyr307 could be used to 
monitor phosphatase activation states [128]. If cTnISer43/45 replacement diminishes 
phosphatase activity, Tyr307 phosphorylation should increase and/or Leu309 methylation should 
decrease [128]. Co-immunoprecipitation assays employing PP2A-specific antibodies can also be 
used to test whether cTnI phospho-mimetic replacement inhibits physical coupling between 
PP2A and the myofilament. Defining the contributions of kinase and phosphatase activity to the 
adaptive signaling response initiated by phospho-mimetic substitution at cTnISer43/45 and the 
potential for this signaling mechanism to be a common cellular response to other environmental 
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changes (e.g. cellular pH, energy availability, or reactive oxygen species) are expected to provide 
insight into the physiological importance of adaptive communication.  In addition, studies 
focused on kinase/phosphatase may be able to determine whether this communication becomes 
altered during the process of cardiac dysfunction and/or end-stage heart failure.  Insights into 
adaptive communication gained from cellular work are expected to be critical for identifying 
signaling components as therapeutic targets.  
Acute Asp replacement at cTnISer23/24 and cTnISer43/45 generates compensatory 
Thr144 phosphorylation, and yet the modulatory role of Thr144 in silico, in isolated myocytes 
and in vivo was not explored here. Molecular modeling could predict the effects of Thr144 
phosphorylation on cTn structure. If the increased phosphorylation at cTnISer43/45 exerts its 
functional effects through rotation of the I-T arm, there should be evidence to show cTnT and/or 
Tm hold the myofilament in the blocked state. Increased phosphorylation at cTnIThr144 could 
alternatively influence myofilament activation by modulating the position and/or anchoring of 
the cTnI H4 helix and/or carboxy-terminal mobile domain on the actin filament to effect the cTn-
Tm position. Maximum MgATPase activity assays in reconstituted thin filaments using 
cTnIThr144Asp alone or in combination with cTnISer23/24Asp or cTnISer43/45Asp could be 
compared to the functional effects predicted by modeling.  Additionally, the effects of Thr144 
phosphorylation on Ca2+ binding to TnC should be evaluated due to the proximity of cTnIThr144 
to the N-lobe of cTnC in the apo state [25]. A cTnIThr144Asp construct also could be utilized to 
evaluate the physiological effects of phosphorylation at this residue on sarcomere incorporation 
of cTnI and myofilament function. Studies in isolated myocytes using approaches similar to the 
ones utilized for the current work could be used for the initial studies. Based on cellular studies 
with the cTnIThr144Pro construct, increased replacement with Thr144Asp is expected to 
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accelerate re-lengthening without altering Ca2+ handling [78, 86]. A genetic mouse model with 
this substitution would provide insight into the more chronic effect of Asp replacement at 
cTnIThr144 on contractile function and allow the effects of cTnIThr144Asp on whole heart 
function to be evaluated. As in the cellular studies, relaxation is expected to be affected under 
basal conditions compared to non-transgenic controls. These studies will provide insight into the 
importance of cTnIThr144 phosphorylation in biophysical, cellular, and whole heart function.  
Physiological and pathophysiological role of cTnISer43/45 on contractile function 
The present results indicate adaptive signaling and/or phosphorylation turnover are 
important mechanisms for maintaining normal physiological function (Ch. 3 and Ch. 4).   
However, I did not explore whether the compensatory signaling mechanism identified in present 
study is a common response to environmental changes produced by cardiac stress, such as 
ischemia. To test whether the compensatory signaling mechanism identified in present study is a 
common response to cardiac stress, preliminary studies were performed in myocytes incubated 
with a transient acidosis similar to the pH change produced by acute myocardial ischemia after 
30min (Fig. 5.5)[9, 158 372]. These studies indicate treatment with an ischemic mimetic restored 
phosphorylation in myocytes expressing cTnISer43/45 substitutions toward control values, 
similar to the effects of PKD and phosphatase inhibition (Fig. 5.5A, Ch.3). While these results 
provide evidence adaptive signaling is stimulated by a cellular acidosis stressor, myofilament 
protein phosphorylation patterns in human patients or in animal models of ischemic injury may 
be more complex than the results obtained in isolated cells due to divergent alterations in kinase 
and phosphatase activity which may be specific for the disease state (Fig. 5.5B) [27, 29-31, 153] 
[56, 128].  
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Therefore, it seems reasonable to address the response to ischemic injury in a genetic 
mouse model expressing cTnISer43/45Asp. Under basal conditions, cardiac morphometry, 
morphology, histochemistry, and function are not expected to differ from non-transgenic 
controls. Myocytes isolated from these hearts can be compared to the results from the gene-
transfer studies presented in this body of work to determine whether additional compensatory 
mechanisms are present in the animal model. However, mice expressing cTnISer43/45Asp are 
expected to transition into end-stage heart failure more quickly than non-transgenic controls in 
response to cardiac injury, such as myocardial infarction. The reason for this prediction is the 
slowed cross-bridge cycling predicted for cTnISer43/45 phosphorylation becomes energetically 
unfavorable at an earlier time point. However, a compensatory period should be observed in 
cTnISer43/45Asp mice because cTnISer23/24 is still able to be modified. Alternatively, the 
adaptive phosphorylation occurring in these mice prior to injury may serve a protective role in 
response to cardiac stress similar to the effects of ischemic pre-conditioning [79, 159]. The more 
intriguing studies would involve comparing the effects of ischemia on cTnISer43/45Asp mouse 
model to the cTnIAllP mice [49]. Because cTnISer23/24 can no longer be adaptively 
phosphorylated in the cTnIAllP model, these mice are expected to have an even higher mortality 
rate in response to stress, such as MI. However, an improved response to myocardial ischemia 
and prolonged survival observed in cTnIAllP mice, this result would suggest the presence of a 
sustained negative charge at cTnISer23/24, cTnISer43/45, or cTnIThr144 is sufficient to 
maintain cardiac pump performance.   In summary, the current experiments provided significant 
insight into the functional contribution and adaptive response produced by Ser43/45 
phosphorylation in cTnI.  These studies also provided ideas for future molecular, cellular and in 
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vivo studies to provide more insight and a greater understanding of the role played by post-
translational modifications in the sarcomere. 
 
 






RSK1 S23172, S24172, S7827,37 None identified
S6K None identified
CaMKII Family 
PKD None identified S302139
AMPK None identified     




Table 5.1.  Documented and predicted phosphorylation of rat Tn, cMyBP-C and MLC2 by signaling kinases.  
Phosphorylation is predicted based on the presence of consensus phosphorylation motifs for each kinase.  
phosphorylation sites (S for Ser, T for Thr, Y for Tyr) targeted by each kinase are underlined.  Sites known to be 
phosphorylated without proof the specified kinase targets this residue are shown in bold.  Predicted, but non-
verified sites (probability >0.50) are not bolded or underlined.  Sites are consistently predicted by multiple tools 
including NetPhosK, Scansite, and NetPhorest [168-170].   
^ Note: For cMyBP-C only, mouse numbering is used for phosphorylation sites. All other residues listed in the table 
are rat sequence.  *T181 in human sequence, not present in rat sequence; **S14 only present in rodent MLC2.   
The references for this table include: [15, 26, 27, 35, 38, 51, 61, 94, 115, 127, 134, 135, 140, 141, 165, 171-182] 
S2334, S2434, S40168, S167168,
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Fig. 5.1. Predicted mechanisms for contractile function modulation by cTnISer23/24 and 
cTnISer43/45 phosphorylation A. Illustration of Ca2+ (blue) association with troponin C (TnC; 
orange) after cTnI (green) phosphorylation (yellow) at cTnISer23/24 (left panel) and 
cTnISer43/45 (right panel). The N-lobe contains the regulatory Ca2+ binding site in TnC. The 
illustration of cTnI depicts the N-terminus (residues 1-32) and the beginning of the amino-
terminal H1 helix residues (residues 33-50) to indicate the location of cTnISer23/24 and 
cTnISer43/45, respectively.  Arrows in the figure show the direction of Ca2+ movement relative 
to the Ca2+ binding site within the N-lobe of TnC. Phosphorylation at cTnISer23/24 accelerates 
Ca2+ release while cTnISer43/45 phosphorylation is predicted to slow Ca2+ binding to TnC. B. 
Illustration of one cycle of interactions between thick and thin filaments during a single cross-
bridge cycle. Components of the thick and thin filament are shown including the myosin cross-
bridge (purple), actin (blue), troponin (green), and tropomyosin (black). In addition, the cycling 
and cleavage of ATP into ADP and Pi by the cross-bridge is shown for each step.  Arrows 
between steps indicate the proposed transitions through each step of myofilament activation (Fig. 
1.2C), as proposed for the 3-state model. A “yield” sign indicates a possible step in cross-bridge 
detachment from the thin filament which could be slowed by cTnISer43/45 phosphorylation and 






























Fig. 5.2 Signaling cascades targeting sarcomeric cardiac troponin I (cTnI) and cardiac 
myosin binding protein C (cMyBP-C) A magnified portion of thick and thin filament proteins 
in the sarcomere is shown for each illustration. Signaling modulation targeting cTnI and cMyBP-
C were chosen as representative proteins targeted by multiple kinases and phosphatases in 
myocytes. A. Illustration of β-adrenergic receptor (light green) activation of cAMP production 
(light green) and downstream PKA (dark green) activation, which targets cTnI and cMyBP-C for 
phosphorylation. PKA also inhibits PP1 (purple) activity, and both PP1 and PP2A (orange) are 
capable of de-phosphorylating cTnI and cMyBP-C. B. Illustration of the PKC signaling pathway. 
Multiple sarcolemmal receptors activate PKC, as indicated by the ET-1, α-adrenergic receptor 
(α-AR) and angiotensin II (AngII) receptors shown in pink. The activation of PKC directly and 
indirectly modulates cTnI and cMyBP-C phosphorylation by direct phosphorylation (blue 
arrows) and by activating PP1 (purple). C. Illustration of PKD (red) and PKG (peach)-mediated 
phosphorylation of cTnI and cMyBP-C. PKD can be directly activated by α-adrenergic receptor 
(α-AR) (pink) activation or activated by PKC (blue). Preliminary results indicate PKD may up-
regulate phosphatase activity (dotted red) in myocytes expressing cTnISer43/45Asp. PKG 
(peach) is activated by the natriuretic peptide receptor A/B (NPR-A/B; grey/purple), which 
stimulates a receptor guanylate cyclase (rGC) to produce cGMP followed by PKG (peach 































































Fig. 5.3 Predicted physiological and pathophysiological effects of cTnISer43/45 
phosphorylation. Predicted changes in tension generation in isolated myocytes (left) and 
pressure development of whole hearts (right) with increased cTnISer43/45 phosphorylation. 
Isometric tension (P) is measured over a range of Ca2+ concentrations (-log[Ca2+] = pCa). The 
myofilament Ca2+ sensitivity (amount of Ca2+ required to generate 50% of the maximum tension 
[Po]) and Po are measured in permeabilized myocytes. Note: the adaptive response is not 
expected to influence tension measurements due to the loss of the cellular environment. Pressure 
is measured by in vivo hemodynamic measurements in the left ventricle over time. The rate of 
systolic pressure development (dP/dtmax), relaxation rate (dP/dtmin), and peak pressure (Po) are 
























Fig. 5.4 Potential pathways for adaptive cTnISer23/24 phosphorylation. Upper panel. An 
illustration of the cTnI structure showing the PKC-targeted residue clusters. The amino and 
carboxy termini are labeled. The cardiac-specific N-terminal extension (residues 1-32) is shown 
in green and contains cTnISer23/24. The amino terminus containing the cTnISer43/45 residues 
(residues 33-80), regulatory domain (residues 147-167), and carboxyl terminus (residues 168-
211) are shown in blue. The inhibitory peptide (IP; orange) contains cTnIThr144. PKA (dark 
green), PKD (red), PKC (blue), and PKG (peach) are candidate kinases for being part of the 
compensatory signaling cascade activated by cTnISer43Asp/Ser45Asp. Preliminary studies 
suggest PKA is not responsible for adaptive cTnISer23/24 phosphorylation (red X). PP1 (purple) 
and PP2A (orange) can also modulate cTnISer23/24 phosphorylation. Lower panel. The 
increased phosphorylation suggests the balance between kinase and phosphatase activity 



















































Fig. 5.5 Acidosis mimetic produces a similar adaptive response to cTnISer43/45Asp. A. 
Representative Western blot analysis of cTnISer23/24 phosphorylation in myocytes treated with 
M199 at physiological pH (pH 7.4; left columns; top row) and in response to cellular acidosis 
(pH 6.8; right columns; top row). Myocytes were treated with M199 alone. A section of sypro-
stained blot illustrates protein loading in each lane. B. Potential mechanism(s) for ischemia-
induced alterations to cTnISer23/24 phosphorylation. Kinase (red) activity may be up-regulated 
or phosphatase activity reduced following cellular acidosis. Both alterations would increase 
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